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ABSTRACT OF DISSERTATION

FUNCTIONAL PROPERTIES OF L-GLUTAMATE REGULATION IN
ANESTHETIZED AND FREELY MOVING MICE
L-glutamate (Glu) is the predominant excitatory neurotransmitter in the
mammalian central nervous system with involvement encompassing learning and
memory, cognition, plasticity, and motor movement. Dysregulation of the
glutamatergic system is implicated in several neurological disorders including
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and amyotrophic
lateral sclerosis. The mechanisms underlying these neurological disorders are
not clear, but evidence suggests that abnormal Glu neurotransmission plays a
role. Elevated levels of Glu in the synaptic cleft overstimulate the N-methyl-Daspartate receptor leading to excitotoxicity, which causes neuronal loss in
chronic neurological diseases. What is less understood is the source for the
elevated Glu levels. One hypothesis involves alterations in either activity or
concentration of Glu metabolizing enzymes. To study this, two transgenic mouse
models were developed that increase levels of Glu pyruvate transaminase
(GPT), responsible for Glu degradation, and Glu dehydrogenase (GLUD1),
responsible for Glu synthesis. Our laboratory is interested in studying stimulusevoked Glu release and re-uptake dynamics in these mice using an enzymebased multisite microelectrode array (MEA) capable of subsecond
measurements with low detection limits. Our main finding indicates that GLUD1
mice have increased release of Glu. The GLUD1 mice show spontaneous motor
neuron degeneration of the hind limbs that could be correlated to an excitotoxic
effect from the increased release of Glu. We wanted to study these GLUD1,
motor deficient mice without the affects of anesthesia. First, we needed to
modify the current MEAs for use in the awake, freely moving mouse. In these
studies we measured resting Glu levels as well as MEA viability with local
application of 1 mM Glu in both the striatum and prefrontal cortex of C57BL/6
mice. No change in MEA sensitivity for Glu was observed on days 3 through 7
post-implantation. Resting Glu levels are examined in the striatum of the freely
moving mouse by locally applying an uptake inhibitor or a sodium-channel
blocker. Our studies indicate the resting Glu levels are partially neuronally
derived and not from reversal of the high-affinity transporters. This

characterization has laid the foundation to study behavioral alterations of Glu in
the GLUD1 mice.
Keywords: Amperometry, Microelectrode, Sensor, Neurotransmitter,
Neurodegeneration
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Chapter One: Introduction
Intracranial Electrode Applications
The idea behind merging technology with the human brain for improving
quality of life is not a new concept. In fact, the first documented human cortical
stimulation was conducted over a century ago (Barthlow, 1874). When human
stereotactic devices were developed in the later 1940s, neurosurgeons were able
to investigate the effects of stimulating deeper brain structures (Spiegel et al.,
1947). The concept of treating neurological disorders with chronic stimulation
emerged in the 1960’s, but this was used mainly to pinpoint surgical lesions
(Perlmutter and Mink, 2006). Sterotaxic thalatomy and pallidotomy were popular
neurosurgical techniques for treating disabling tremor until levodopa therapy
emerged in the 1970s. Unfortunately, researchers discovered that prolonged
levodopa therapy resulted in drug related complications for advancing the very
symptoms the drug was intended to treat. At this same time, it was discovered
that chronic stimulation could be used for treating pain (Hosobuchi et al., 1973),
movement disorders, or epilepsy (Cooper, 1973). In an effort to find alternative
therapies for levodopa, pacemaker technology was merged with chronically
implanted deep brain electrodes for long-term deep brain stimulation (DBS)
(Benabid, et al., 1991, 1996). Researchers discovered that a high-frequency
electrical current can have the same affects as a lesion without the need for
destroying brain tissue. Since this time, DBS has been used to treat a variety of
neurological disorders including essential tremor, Parkinson disease (PD),
dystonias, tourette syndrome, pain, and obsessive compulsive disorder
(Perlmutter and Mink, 2006). Technology has emerged to not only treat patients
with electrical stimulation, but rather create brain-machine interfaces (BMIs) that
can translate the electrical activity of neuronal populations and perform the
desired motor movement. This would essentially return motor control to severely
disabled patients suffering from amyotrophic lateral sclerosis (ALS), spinal cord
injury, stroke, cerebral palsy, and amputees (Lebedev and Nicolelis, 2006).
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Clearly, intracranial electrode applications such as DBS and BMI hold a
great deal of promise but much more research is needed to fully understand how
these devices effect chemical signaling within and between neuronal subregions.
Neuroscientists have become interested in coupling these techniques with the
ability to monitor specific neurotransmitters. Since neurotransmitters such as
dopamine

(DA),

L-glutamate

(Glu),

γ-aminobutyric

acid

(GABA),

and

acetylcholine (to name a few) are the key chemicals for neuronal signaling
(Cooper, Bloom, and Roth, 2003) techniques have developed to better
understand their role in neuronal communication.

The most widely used

technique for studying neurotransmitters, microdialysis, has several limitations as
discussed below. Our laboratory has spent the past 15 years developing an
enzyme-based microelectrode array (MEA) that is capable of recording specific
neurochemicals. These devices have been routinely used in rats, mice, and
monkeys (both anesthetized and freely moving) to better understand the
glutamatergic system in relation to various neurological disorders including, but
not limited to, PD and epilepsy. The goal is to move this technology into the
operating room, either by itself or coupled with DBS and BMI, to further enhance
the quality of life for patients suffering from movement disorders.
An Overview of L-Glutamate Neurotransmission in the Mammalian Central
Nervous System
Glu is the predominant excitatory neurotransmitter in the mammalian
central nervous system (CNS) existing in all main afferent fibers ascending to the
brain cortex and in excitatory nerves (Boksha, 2004). Glu is involved in most
aspects of normal brain function including cognition, memory and learning,
plasticity, and motor movement.

As a neurotransmitter, Glu is found in

glutamatergic neurons, which are defined by the presence of vesicular glutamate
transporters (VGLUT). This protein is responsible for loading Glu into synaptic
vesicles through a proton-dependent electrochemical gradient across the vesicle
membrane that is created by a vacuolar-type ATPase (Takamori, 2006). When
these vesicles dock with the pre-synaptic plasma membrane and release Glu into
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the synaptic cleft there are two different classes of receptors that Glu can
activate; (a) ionotropic and (b) metabotropic. Their localizations are shown in
figure 1.1.
Ionotropic Glu receptors (iGluRs) contain three major types, all named
after the agonists that were originally used to selectively activate them; N-methylD-aspartate

(NMDA),

α-amino-3-hydroxy-5-methyl-4-isoazolepropionic

acid

(AMPA), and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (Kainate; KA).
Table 1.1 outlines some of the agonists and antagonist for NMDA, AMPA, and
KA receptors.

All three iGluRs are ligand-gated ion channels that are

predominantly associated with modulating postsynaptic excitability and plasticity
(Kew and Kemp, 2005; Swanson et al., 2005).

They are also found pre-

synaptically to modulate the release of Glu and other neurotransmitters
(Engelman and MacDermott, 2004; Galvan et al., 2006).

AMPA and KA

receptors are believed to be responsible for fast, excitatory neurotransmission
(Greene and Greenamyre, 1996). Upon Glu binding, both AMPA and KA
receptors change conformation to allow sodium influx into the post-synaptic
neuron and depolarize the membrane. The NMDA receptor is unique in that it
binds two ligands (Glu and the coagonist glycine) as well as being a
voltage-sensitive ion channel. At resting membrane potential, the ion channel is
blocked by extracellular magnesium which prevents calcium influx irregardless of
agonist binding.

Since this blockade is voltage-dependent, post-synaptic

depolarization facilitates NMDA receptor activation. Upon Glu binding to AMPA
or KA receptors, sodium enters the post-synaptic neuron leading to membrane
depolarization. This removes the magnesium block found in the NMDA channel.
Upon Glu and glycine binding to the NMDA receptor, the pore opens allowing an
influx of calcium (Swanson et al., 2005; Gardoni and Di Luca, 2006).

This

mechanism for receptor activation underlies the fundamental physiological
function of learning and memory; however, it is also the means by which
excitotoxicity occurs; in both acute and chronic neurodegeneration (Albin and
Greenamyre, 1992; Beal, 1992; Greene and Greenamyre, 1996).

3

Figure 1.1: Glutamate Synapse Schematic
Schematic representation of a typical glutamatergic synapse.

Glu is loaded into vesicle by

vGluTs and upon depolarization, the vesicles fuse and release the neurotransmitter into the
synaptic cleft. Once in the synaptic cleft, Glu can induce downstream signaling by postsynaptic
neurons through mGluRs and iGluRs. Sodium-dependent, high-affinity transporters located on
both glia and neurons are responsible for uptake of Glu with the majority of Glu transported into
glia and astrocytes. Gamma aminobutyric acid (GABA) neurons can also be regulated by mGluR
Groups II and III, which can affect downstream glutamatergic signaling. Adapted from Schoepp
et al., 2001.
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Table 1.1: Ionotropic Glutamate Receptors
Ionotropic Receptors (iGluRs)
NMDA

AMPA

Kainate

Receptor

NR1, NR2A, NR2B NR2C,

GluR1, GluR2, GluR3,

GluR5, GluR6

Subunits

NR2D NR3A, NR3B

GluR4

GluR7, KA-1 KA-2

Ca2+, Na+

Na+ (Ca2+)

Na+ (Ca2+)

NMDA, Quinolinate

AMPA, ACPA

Homocysteate

L-Quisqualic acid

Signal
Transduction
Agonists

Allosteric
Potentiators

Antagonists

Kainic Acid, ATPA
SYM2081
LY339434

CX516, CX546, CX614

Glycine, D-Serine

Cyclothiazide, IDRA-

D-Cycloserine, Spermine,

21, PEPA, LY404187

Spermidine

Concanavillin A

LY392098, LY503430

CGS 19755, PEAQX PPDA,

NBQX, YM872

LY382884,

D-AP5

ZK200775

UBP296

Dizocilpine, Ifenprodil

GYKI 52466

Memantine, Ro 25-698
Allosteric

(+)-CP-101,606

Antagonists

Ro 63-1908

(R)-LY303070
(R)-LY300164
CP-465,022

Benzimidazole

CP-526,427

Benzamidines
Channel

Phencyclidine

Blockers

Dizocilpine, Ketamine

NS3763

Jorospider toxin

N/A

(R,S)-2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)propionic
acid
(ACPA);
5-tert-butyl-4isoxazolepropionic acid (ATPA); (2S,4R) 4-methyl glutamic acid (SYM2081); (2S,4R,6E)-2amino-4-carboxy-7-(2-naphthyl)hept-6-enoic acid (LY339434); (±)-cis-4-phosphonomethyl-2piperidine carboxylic acid (CGS 19755); (2S*,3R*)-1-(phenanthrene-2-carbonyl)piperazine-2,3dicarboxylic acid (PPDA); (R)-2-amino-5-phosphonopentanoate (D-AP5); 2,3-dihydroxy-6-nitro-7sulfamoyl-benzo(F)quinoxaline
(NBQX);
[2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4tetrahydro-1-quinoxalinyl]-acetic acid (YM872); [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6(trifluoromethyl)quinoxalin-1-yl]
methylphosphonate
(ZK200775);
(3S,4aR,6S,8aR)-6-(4carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroxyisoquinoline-3-carboxylate (LY382884);
(R,S)-3-(2-carboxybenzyl)willardiine (UBP296); 5-carboxyl-2,4-di-benzamido-benzoic acid
(NS3763); (R-(R*,S*)-α-(4-hydroxyphenyl)-β -methyl-4-(phenylmethyl)-1-piperidine propanol (Ro
25-6981); 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908/Co
101244/PD 174494); 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine
(GYKI
52466);
(R)-1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-4,5-dihydro-3methylcarbomyl-2,3-benzodiazepine (GYKI 53784/LY303070); (R)-7-acetyl-5-(4-aminophenyl)-
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Table 1.1: (continued)
8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h) (2,3) benzodiazepine (GYKI 53773/LY300164); 3-(2Chloro-phenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one
(CP-465,022);
2-{2-[3-(2-Chloro-phenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}nicotinonitrile (CP-526,427); 1-(quinoxalin-6-ylcarbonyl)-piperidine (CX516); 5-carboxyl-2,4-dibenzoamido-benzoic acid, (NS3763) 1-(1,4-benzothiadiazine 1,1-dioxide (CX546); 2H,3H,6aHpyrrolidino[2”,1”-3’2’]1,3-oxazino[6’5’-5,4]benzo[e]1,4-dioxan-10-one (CX614); 7-chloro-3-methyl3,4-dihydro-2H-1,2,4-benzothiadiazine
1,1-dioxide
(IDRA-21);
(4-[2(phenylsulphonylamino)ethylthio]-2,6-difluorophenoxyacetamide
(PEPA);
(R,S)-N-2-(4-(3thienyl)phenyl)propyl-2-propanesulfonamide (LY392098); N-2-[4-(4-cyanophenyl)phenyl]propyl 2propanesulphonamide
(LY404187);
(R)-4-[1-fluoro-1-methyl-2-(propane-2-sulphonylamino)ethyl]-biphenyl-4-carboxylic acid methylamide (LY503430)
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Metabotropic Glu receptors (mGluRs) are G-protein coupled receptors that
regulate Glu release and modify postsynaptic excitability to Glu, high-affinity Glu
transporters, and vGluTs (Swanson et al., 2005). Since mGluRs rely on second
messenger responses, they are generally slower than iGluRs. These receptors
contain seven alpha-helical transmembrane domains with a ligand binding site
located on the extracellular N-terminus (Kew and Kemp, 2005). mGluRs are
classified into three groups. Group I (mGlu1 and mGlu5) are excitatory receptors
localized on glial and post-synaptic, glutamatergic neurons. Group II (mGlu2 and
mGlu3) receptors are inhibitory.

mGlu2 is located primarily on pre-synaptic

glutamatergic terminals, while mGlu3 is expressed on both glial and pre- and
post-synaptic glutamatergic neurons. Finally, Group III (mGlu4, mGlu6, mGlu7
and mGlu8) are also inhibitory receptors, but they are not as specific for
glutamatergic neurons. mGlu4 and mGlu7 receptors are located both pre- and
post-synaptically on both glutamatergic and other neurotransmitter synapses.
mGlu8 is

localized

primarily

on

pre-synaptic

glutamatergic

and

other

neurotransmitter terminals, while mGlu6 expression is only confirmed on retinal
cells. (Refer to Table 1.2 for further information regarding mGluRs).
Proper

activation

of

Glu

receptors

requires

that

extracellular

concentrations of Glu be kept low for a high signal-to-noise ratio in synaptic
transmission, thus allowing for stimulation with low levels of neurotransmitter
release. No extracellular enzymes for Glu metabolism have been identified, so
Glu clearance from the extracellular space is achieved by means of sodiumdependent, high-affinity transporters located primarily on glial cells.

These

transporters are more commonly known as excitatory amino acid transporters
(EAATs).

The uptake process is electrogenic and is therefore stimulated by a

negative membrane potential, which is maintained by the sodium/potassium
adenosine triphosphatase (Na+/K+ ATPase). Sodium is required for Glu binding
while potassium is required for net transport of Glu through the EAATs. To be
precise, for every 1 molecule of Glu transported into the cell, 3 sodium ions and 1
hydrogen ion are cotransported, while one potassium ion is transported out of the
cell (Takahashi et al., 1997; Danbolt, 2001; Kanai and Hediger, 2004; Grewer
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Table 1.2: Metabotropic Glutamate Receptors

Group II

Group I

Receptor
mGluR1
mGluR5

mGluR2
mGluR3

G-Protein
Gq;
increase
PLC

Go;
decrease
AC

Group III

mGluR4
mGluR6
mGluR7
mGluR8

Go; Gi
decrease
AC

Glutamatergic Localization
and Functions
Post-synaptic; activation
enhances excitability
Post-synaptic; also found in
glia; indicated in synaptic
plasticity
Pre-synaptic; linked to LTD
Pre- and post-synaptic; found
on glia where it is linked to
neurotropin release

Agonist
DHPG
ACPD
quisqualate
DHPG
quisqualate
CHPG
DCG-IV
APDC
ACPD
LY354740
LY379268

Pre- and post-synaptic; linked
to motor learning

L-SOP
ACPT-1
L-AP4

Expression localized to retinal
tissue
Pre- and post-synaptic;
autoreceptor

L-SOP
L-AP4

Pre-synaptic; regulation of
lateral perforant path

L-SOP
L-AP4
DCPG

Antagonist
LY393675
LY367385
MPEP

EGLU
LY404039
LY341495
MSOP
MAP4
CPPG

MSOP
MAP4

3,5-dihydroxyphenylglycine, DHPG; (1S,3S)-1-aminocyclopentane-1,3-dicarboxylic acid, ACPD;
2-(S)-amino-2-(3-cis-carboxycyclobutyl)-3-(9H-thioxanthen-9-yl) propionic acid, LY393675; [(+)-2methyl-4-carboxyphenylglycine], LY367385; (RS)-2-chloro-5-hydroxyphenylglycine, CHPG; 2methyl-6-(phenylethylnyl)-pyridine, MPEP; (2S, 2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine,
DCG-IV;
2R,4R-4-aminopyrrolidine-2,4-dicarboxylic
acid,
APCD;
(1S,2S,5R,6S)-2aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate, LY354740; (-)-2-oxa-4aminobicyclo[3.1.0]hexane-4,6-dicarboxylate, LY379268; (S)-α-ethylglutamic acid, EGLU; (-)(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid, LY404039; L(+)-2amino-4-phosphonobutyric acid, LY341495; S-serine-O-phosphate, L-SOP; (1S,3R,4S)-1aminocyclo-pentane-1,3,4-tricarboxylic acid, ACPT-1; L(+)-2-amino-4-phosphonobutyric acid, LAP4, (RS)-alpha-methylserine-O-phoshate, MSOP; (S)-2-amino-2-methyl-4-phosphonobutanoic
acid/alpha-methyl,
MAP4;
(RS)-4-phosphonophenyl
glycine,
CPPG;
(S)-3,4dicarboxyphenylglycine, DCPG
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and Rauen, 2005).

To date, five Glu transporters have been cloned and

numbered EAAT1-5. EAAT1 (Glu-Aspartate Transporter (GLAST) in rodents)
and EAAT2 (Glu Transporter (GLT-1) in rodents) are responsible for the majority
of Glu uptake in the mammalian CNS and both are located exclusively on glial
cells. Glu transporters differ in brain localization; EAAT1 predominates in the
cerebellum, while EAAT2 is the major Glu transporter of the forebrain. EAAT3
(Excitatory Amino Acid Carrier (EAAC1) in rodents) is expressed in the lowest
concentration compared to the others and thought to account for a small
percentage of Glu uptake. It has a wide expression throughout the mammalian
brain, located primarily on neurons. EAAT4 is found in Purkinje cells of the
cerebellar molecular layer, while EAAT5 is found in the retina.

For a

comprehensive review on Glu transporters, refer to Danbolt, 2001.
Excitotoxicity
While Glu normally functions as a neurotransmitter; excessive stimulation
of Glu receptors can cause neuronal degeneration by a mechanism termed
excitotoxicity (Olney, 1978). Olney and colleagues defined this process as “a
phenomenon whereby the excitatory action of Glu and related excitatory amino
acids becomes transformed into a neuropathological process that can rapidly kill
CNS neurons.”

Excitotoxic cell death involves prolonged depolarization of

neurons, changes in intracellular calcium concentrations, and the activation of
enzymatic and nuclear mechanisms of cell death (Doble, 1999). In the classical
model of excitotoxicity, post-synaptic depolarization is initiated by activation of
AMPA receptors and voltage-dependent sodium channels, leading to sodium
entry and further depolarization.

To maintain ionic equilibrium, chloride ions

enter the cell along with water that is following the osmotic gradient. Entry of
water causes osmotic swelling of the cell, but the process is reversible and
therefore is not the final mechanism of excitotoxicity (Choi, 1987). Instead, the
calcium-dependent part of the cascade seems essential for toxicity and cellular
death.

Depolarization of the membrane by sodium leads to opening of voltage-

sensitive calcium channels as well as removal of the magnesium block on the
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NMDA receptor. These are the two primary sources for calcium entry into the
cell. This appears to be the irreversible step and the ability of the neuron to
survive this calcium influx may depend on intracellular organelles, such as the
mitochondria or endoplasmic reticulum, to buffer the influx of calcium (Doble,
1999). If the neuron is unable to buffer the large quantities of calcium entering
the cell, calcium can overstimulate proteases, protein kinases, and nitric oxide
synthetases. This leads to production of free radicals or apoptotic mechanisms
and eventually cell death (Nicholls and Budd 2000; Sattler and Tymianski, 2000).
During the time course of excitotoxicity, the extracellular concentrations of
Glu rise for three main reasons. First, influx of calcium leads to vesicular release
of Glu from pre-synaptic neurons. Second, more Glu is being released into the
extracellular space due to cell lysis. Finally, since Glu transport is electrogenic,
membrane depolarization can slow down or even reverse these transporters
keeping Glu in the extracellular space for prolonged periods of time (Doble,
1999). This increase in extracellular Glu can diffuse to nearby neurons, thus
propagating and amplifying cell death.
The above process is most commonly seen in stroke, ischemia, and
traumatic brain injury and referred to as acute excitotoxicity. Evidence exists for
a slower, indirect form of excitotoxicity involved with chronic neurodegenerative
diseases. In this form of excitotoxicity, mitochondria become damaged leading to
energy impairment and subsequent decrease in intracellular ATP levels (Beal,
1992; Greene and Greenamyre, 1996; Doble, 1999). As ATP levels decrease,
the Na+/K+ ATPase, responsible for maintaining the resting membrane potential
slows down leading to depolarization. This can relieve the magnesium block on
NMDA channels as well as open voltage-gated calcium channels.

With the

magnesium block removed, the NMDA receptor is more susceptible to activation
by ambient or even slightly elevated levels of extracellular Glu (Beal, 1992;
Greene and Greenamyre, 1996; Doble, 1999). Over prolonged periods of time
(years) this process becomes similar to what is seen in acute excitotoxicity. For
this reason, it has been postulated that slow, indirect excitotoxicity is partly
responsible for the neuronal loss seen in several neurodegenerative disorders
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including amyotrophic lateral sclerosis (ALS).

ALS is characterized by

progressive muscular weakness leading to paralysis and eventual death due to
respiratory failure (Williams and Windebank, 1991).

This neurodegenerative

disease has the largest body of evidence supporting excitotoxicity contributes to
the progression of symptoms (Doble, 1999). Several studies have suggested
that there is a defect in Glu metabolism (Heath and Shaw, 2002; Rao and Weiss,
2004) causing elevated levels of the neurotransmitter Glu in the cerebrospinal
fluid (Rothstein et al., 1990; Shaw et al., 1995; Spreux-Varoquaux et al., 2002) of
ALS patients compared to control patients. The failure to properly metabolize
Glu may result in raised extracellular Glu levels that overtime could contribute to
excitotoxic and motorneuron degeneration described above.
L-Glutamate Metabolism
Metabolic compartmentation in the brain was first demonstrated by Lajtha
and colleagues (1959) when they injected [14C] Glu into the rat brain and found
that glutamine was the predominant molecule containing the isotope.

They

interpreted this data as glutamine was formed exclusively from a “small” pool of
Glu that rapidly accumulates Glu and synthesizes glutamine (Hertz, 2004).
Computer simulation studies over the next decade by Van den Berg and
Garfinkel (1971) showed the flow of Glu from a “large” compartment where it was
degraded to glutamine in a “small” compartment and an identical flow of
glutamine in the opposite direction.

This process became known as the

Glutamate-glutamine cycle (Benjamin and Quastel, 1975). But, it wasn’t until the
selective localization of glutamine synthetase that the “small” pool was
determined to be astrocytes (Norenberg and Martinez-Hernandez, 1979). Since
glutamine synthetase is absent in neurons, this meant all neuronal constituents
constitute the “large compartment.”
Today, the Glutamate-glutamine cycle is a well understood mechanism.
Upon depolarization and vesicular release of Glu, it is taken up into astrocytes by
high affinity transporters (Danbolt, 2001).

Once in the astrocytes, Glu is

aminated into glutamine by glutamine synthetase that is localized only in
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astrocytes.

Glutamine is not neurotoxic and therefore it can be safely

transported out of the astrocytes through System N located on astroglial cells. In
the extracellular space, glutamine is transported into neurons through System A
(Bak et al., 2006). When returned to the neuron, glutamine is converted back
into Glu by posphate-activated glutaminase (PAG), which is located on the inner
mitochondrial membrane (Kvamme et al., 2000). The Glu formed is returned to
the cytosol and subsequently packaged into vesicles for future neurotransmitter
signaling.
Since neurons are incapable of net synthesis of Glu from glucose
(Waagepetersen et al., 2005), the Glutamate-glutamine cycle was previously
thought to provide neurons with all the Glu necessary for neurotransmitter
signaling. Because of this theory, the Glutamate-glutamine cycle was originally
thought to operate in a stoichiometric one-to-one ratio. For every Glu released,
one glutamine was transported into neurons to replenish the neurotransmitter
pool of Glu. However, recent evidence suggests this process is oversimplified
and other enzymes must be responsible for replenishing the neurotransmitter
pool of Glu (Fonnum, 1993; Peng et al., 1993; Broman et al., 2000;
Waagepetersen et al., 2000; Danbolt, 2001; Waagepetersen et al., 2005). It is
now known that Glu is metabolically closely related to the tricarboxylic acid (TCA)
cycle (Waagepetersen et al., 2005). For example, when Glu is transported into
astrocytes, it can be metabolized into glutamine by glutamine synthetase or
transaminated into α-ketoglutarate. Alpha-ketoglutarate can then enter the TCA
cycle where it is eventually metabolized into malate, and malate can be
decarboxylated into pyruvate and reduced to lactate. Lactate can be transported
out of astrocytes and into neurons by monocarboxylate transporters (Gladden,
2004; Pierre and Pellerin, 2005). Once in the neurons, lactate can be oxidized to
pyruvate and either re-enter the TCA cycle or it can be transaminated back into
Glu for neurotransmitter packaging and signaling. (Please refer to Figure 1.2).
This example highlights one of the many possible fates of Glu and is used to
show the complicated competition for Glu between cellular energy demands and
neurotransmitter

signaling.

Furthermore,
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Hassel

and

Bråthe

(2000)

Figure 1.2: The Glutamate-Glutamine Cycle Revisited
Schematic representation of Glu synthesis between astrocytes and neurons.

The classic

Glu/glutamine cycle is highlighted in the purple, dashed box. All enzymes are shown in RED,
while dashed arrows indicate multiple metabolic steps that are not shown due to size limitations.
The terms “mito” and “cyt” indicate either mitochondrial or cytoplasmic localization, respectively.
Figure modified from Waagepetersen et al., 2000.
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demonstrated that it is possible to obtain Glu formation independent of glutamine.
This implies that enzymes other than PAG and glutamine synthetase are
responsible for de novo synthesis or degradation of Glu.

Two such Glu

metabolizing enzymes found in neurons are glutamate pyruvate transaminase
(GPT) and glutamate dehydrogenase (GLUD1).
Glutamate Pyruvate Transaminase
GPT exists as a dimer with a molecular mass of approximately 100 kDa in
most species (Saier and Jenkins, 1967). The enzyme catalyzes a reversible
transaminase reaction using pyruvate as a co-substrate to form alanine and αketoglutarate (Figure 1.3A). Biochemical studies show GPT activity in both the
cytosol and mitochondria of astrocytes and neurons (Balazs and Haslam, 1965;
Erecińska et al., 1994), but the greatest activity is found in astrocytes of the
cerebral cortex (Westergaard et al., 1993). It is debated throughout the literature
whether GPT favors Glu degradation (Saier Jr. and Jenkins, 1967; Ruščák et al.,
1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993; Schousboe et
al.,

2003).

This

process

most

likely

depends

on

the

amount

of

substrates/products available. However, Matthews and colleagues (2000, 2003)
demonstrated that GPT is an active Glu degrading enzyme that acts as an
effective neuroprotectant in cell culture models of exogenous and endogenous
Glu excitotoxicity. Unfortunately, GPT does not exist in the extracellular space
and, due to its large size, is unable to cross the blood-brain barrier. This makes
it an unsuitable candidate for excitotoxicity thereapeutics; nevertheless these
studies demonstrate the propensity for GPT to metabolize Glu.
Glutamate Dehydrogenase
Similar to GPT, GLUD1 catalyzes a reversible reaction; however, this
reaction favors Glu formation from ammonia and α-ketoglutarate, using NAD(P)+
as co-factors as shown in figure 1.3B (Yudkoff et al., 1991; Kanamori and Ross,
1995; Bak et al., 2006). GLUD1 is composed of six identical subunits, each with
a molecular mass of 56 kDa (Mastorodemos et al., 2005).
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Biochemical and

Figure 1.3: Glutamate Metabolic Pathways
A) Glu metabolism by Glutamate Pyruvate Transaminase.
Dehydrogenase.
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B) Glu synthesis by Glutamate

histochemical studies show GLUD1 is localized to the inner mitochondrial
membrane of neurons (Toledano et al., 1979; Rothe et al., 1990; McKenna et al.,
2000), while immunohistochemical studies show astrocytic localization (Kaneko
et al., 1987).

This suggests that GLUD1 is ubiquitously expressed in

mitochondria throughout the mammalian brain (Madl et al., 1988).

Recently,

however, two isoforms of Glu dehydrogenase (GLUD1 and GLUD2 have been
identified in humans and primates (Burki and Kaessmann, 2004), which may
account for the discrepancies in localization.

GLUD1 is considered a

housekeeping gene ubiquitously expressed throughout mammals while GLUD2
is a brain-specific isotype found in primates and humans (Plaitakis and Zaganas,
2001; Burki and Kaessmann, 2004; Mastorodemos et al., 2005; Kanavouras et
al., 2007). Burki and Kaessmann (2004) demonstrated that GLUD2 formed by
retroposition of GLUD1 to the X chromosome in primates 23 million years ago
and may be indicative of higher thought processes.

In humans, these two

isoforms are homologous differing in only 16 amino acids (Kanavouras et al.,
2007). Because the retroposition occurred in primates, rodents only have the
GLUD1 copy.
GLUD1 is thought to be controlled by cellular energy demands since it is
allosterically stimulated by ADP and inhibited by ATP (Smith, 1979; Plaitakis and
Zaganas, 2001). This indicates that the activity of the enzyme can operate in the
direction of oxidative deamination when cellular supplies of ATP are low. By
converting Glu to α-ketoglutarate the mitochondria is provided with essential
reducing equivalents, through NAD(P)H, for synthesis of ATP. In addition, the αketoglutarate formed can be metabolized in the TCA cycle for further production
of ATP. This has been supported by studies examining pancreatic beta cells and
modulation of GLUD1 to regulate insulin release (Gylfe, 1976; Stanley et al.,
1998).
Several studies examining post-mortem CNS tissue have determined that
increases in GLUD1 activity are associated with several different neurological
disorders.

Malessa and colleagues (1991) found that GLUD1 activity was
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significantly increased in the ventral white matter and in the dorsal horn of the
spinal cord in ALS patients compared to control. It is well documented that Glu
levels are increased in the CSF of ALS patients (Rothstein et. al, 1990; Doble,
1999; Heath and Shaw, 2002; Spreux-Varoquaux et al., 2002).

Since the

GLUD1 reaction favors Glu formation, this finding by Malessa and colleagues,
suggests a causative relation for the increased levels of Glu. These CSF Glu
levels may be high enough to cause excitotoxicity and damage the lower motor
neurons—a hallmark of ALS. Burbaeva and colleagues (2005) determined that
GLUD1 was increased in brain tissue homogenate from the prefrontal cortex
(PFC) of Alzheimer’s disease (AD) patients compared to control patients.
Additionally, the same group (Burbaeva et al., 2003, 2007) determined that
GLUD1 activity was increased in the PFC of schizophrenic patients compared to
control patients.

In both studies this group concludes that alterations in Glu

metabolizing enzymes may be responsible for changes in the extracellular
concentration of Glu. The results of all of these independent studies strongly
suggests that increased GLUD1 activity is involved in three different neurological
disease states.
Techniques for Measuring L-glutamate: Microdialysis
Microdialysis is a technique that utilizes semipermeable membranes to
restrict the diffusion of extracellular molecules or neurotransmitters along their
concentration gradients. (Ungerstedt, 1984; Di Chiara et al., 1996). A
microdialysis probe consists of a cylindrical dialysis membrane with inlet and
outlet tubes. These probes have a diameter of 150-400 µm with an average
length of 1-4 mm (Kennedy et al., 2002). Dialysis probes are stereotaxically
compatible and therefore have been used in both anesthetized and awake
animal models. Once implanted, dialysate samples are collected every 5 to 20
minutes and experiments can last from hours up to 3 or 4 days (Westerink,
1995).

Collected fractions are generally analyzed using analytical chemistry

techniques.

High

performance

liquid

chromatography

coupled

with

electrochemical or fluorescence detection is often used due to their sensitivity
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and ability to handle small sample sizes (< 10 µl) (Westerink, 1995). The high
sensitivity of the analytical techniques allows for detection of low concentration of
analytes in the femtomolar range (Kennedy et al., 2002). Another advantage of
microdialysis is the ability to measure multiple analytes simultaneously thus
allowing the researcher to study several neurotransmitter systems at once.
Despite how commonplace the technique has become in the laboratory, there
are several large disadvantages that make microdialysis unsuitable for
measuring Glu.
Due to the high-affinity transporters, Glu neurotransmission lasts on the
order of milliseconds to seconds (Kinney et al., 1997). Since dialysate samples
are collected over minutes, Glu release and re-uptake is often missed or grouped
together into larger pools within the samples, which makes it exceptionally
difficult to study behavioral paradigms. Recent advances in the collection and
analyzing methods have increased the time resolution into the range of seconds.
Lada and colleagues (1997) showed that using capillary electrophoresis coupled
with laser-induced fluorescence detection resulted in sample collection every 12
seconds. That same year, Tucci and colleagues (1997) demonstrated a similar
method with samples collected every 6 seconds. However, the fastest collection
time published was by Rossell and colleagues (2003) that demonstrated a 1second collection method. For these methods, dialysate samples are collected in
a tube and this tube is cut into specific lengths corresponding to the desired
collection time (Kennedy et al., 2002). This is a controversial method because
diffusion through the tubing (band broadening) can affect concentration values in
different time intervals, if the tubing is not cut immediately (Rossell et al., 2003).
Also, the flow rates and dead volume can drastically change the temporal
response, which suggests band broadening is responsible for a sluggish
response to analyte in the fractions collected (Lada et al., 1997). In this paper,
Lada goes onto explain that band broadening within the dialysis probe or tubing
prevents this method from achieving faster than a 10 second temporal response.
This brings into question the validity of the Rossell study claiming 1 second
response times.
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The large size of the microdialysis probe causes substantial short- and
long-term trauma, which is evidenced by histological, physiological, and
biochemical changes in nearby CNS tissue (Bungay et al., 2003). During the first
hours after implantation the blood-brain barrier is disrupted, blood flow to the
tissue surrounding the probe is decreased and release of neurotransmitters is
altered (Westerink, 1995). Positron emission tomography (PET) imaging has
revealed that glucose metabolism is drastically and irreversibly altered by chronic
implantation of a microdialysis cannula/probe (Schiffer et al., 2006). Three days
after implantation a glial barrier is observed and may account for probe blockage
(Benveniste and Diemer, 1987).

This glial barrier is markedly increased if

nonfunctional microdialysis probes are removed and functional probes are
reinserted in an attempt to continue freely moving studies within the same animal
(Georgieva et al., 1992). Clapp-Lilly and colleagues (1999) demonstrated that
ultrastructural damage occurs up to 1.4 mm away from a microdialysis probe
implant site. In addition, perfusion and removal of material by the probe may
produce concentration gradients that can further damage tissue up to several
millimeters away from the implant site (Bungay et al., 1990). The implantation
damage caused by microdialysis probes has drastic effects on local
neurotransmitter

dynamics.

Carbon

fiber

microelectrodes

coupled

with

voltammetric techniques were used to demonstrate that evoked dopamine
release is attenuated up to 220-250 µm from the microdialysis probe implant site
(Yang et al., 1998; Borland et al., 2005). If this probe-induced trauma along with
glial barrier formation is not taken into account for microdialysis analysis, the
estimation of extracellular concentrations and clearance of neurotransmitters
such as DA and Glu can be underestimated (Lu et al., 1998; Yang et al., 1998;
Bungay et al., 2003).
demonstrated

that

rats

Furthermore, Frumberg and colleagues (2007)
implanted

with

microdialysis

probes

performed

significantly worse in object recognition tasks despite no change in locomotor
activity. These studies demonstrate the excessive damage caused by a dialysis
probe as well as question the physiological validity of dialysis samples.
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Finally, previous microdialysis studies indicate that resting Glu levels are
virtually

tetrodotoxin

(TTX)

and

calcium-independent

(Timmerman

and

Westerink, 1997). This does not fulfill the classical criteria for excytotoxic release
thus raising doubt as to the vesicular origin of Glu. Several laboratories have
also demonstrated that increases in neurotransmitters due to stress are largely
TTX-independent as well. These studies indicate that physiological release of
Glu, whether it be resting or stimulated, is from non-neuronal sources such as
reversal of the high-affinity transporters (Kanai and Hediger, 2004). However,
little data supports this hypothesis. Instead, since Glu released from neuronal
pools is rapidly cleared and has limited diffusion, it has been hypothesized that
microdialysis fails to reliably sample synaptic pools of Glu (Drew et al., 2004).
Drew and colleagues claim that the current microdialysis probes sample from too
large of an area to reliably measure changes close to the synapse. For this
reason, the relevance of using microdialysis to study Glu neurotransmission is
uncertain.
Techniques for Measuring L-glutamate: Amperometric Detection with
Microelectrode Arrays
The poor temporal and spatial resolution as well as the severe damage on
CNS tissue due to implantation has warranted more reliable techniques that are
less invasive for the study of Glu. Within the past decade several groups have
developed Glu selective microelectrodes to address the above inconsistencies
with microdialysis studies on glutamatergic physiology (Hu et al., 1994; Rahman
et al., 2005) and some studies utilizing these microelectrodes have shown that
Glu is TTX-dependent (Kulagina et al., 1999; Day et al., 2006; Oldenziel et al.,
2006). Our laboratory has developed an enzyme-based multisite microelectrode
array (MEA) that uses amperometric recording techniques with subsecond
measurements (Burmeister et al., 2000; Burmeister and Gerhardt, 2001;
Burmeister et al., 2002; Nickell, et al., 2004; Day et al., 2006; Nickell et al., 2007).
These MEAs have 4 platinum (Pt) recording sites each measuring 333 X 15 µm,
and because of the small size, the MEAs have been shown to cause minimal
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damage to surrounding CNS tissue and are viable for at least one week postimplantation (Rutherford et al., 2007). Furthermore, through a specific coating
technique that is referred to as self-referencing, our laboratory is able to
selectively measure resting Glu levels and consistently demonstrate that resting
Glu levels are TTX-sensitive (Day et al., 2006).

For a thorough explanation

regarding the MEAs and self-referencing, please refer to Chapter Two: Materials
and Methods.
Mouse Models
The mouse model has many advantages as an experimental animal
model. They have a unique adaptation and ability to survive inbreeding (Joyner
and Sedivy, 2000), they have a short generation turnover and low maintenance
cost for breeding, housing, and drug administration (Cryan and Holmes 2005;
Jacobson and Cryan, 2007). More importantly, mouse and humans share close
metabolic and anatomical similarities.

Genes between the two species are

greater than 99% conserved (Consortium, 2002). This provides the researcher
with a model system to study human diseases including diabetes, cancer,
immunological, and neurological disorders.
Inbred mice strains offer several additional advantages to those already
mentioned including genetic and phenotypic uniformity. This uniformity reduces
the number of animals needed for experiments, because variability is limited to
extragenetic or varying controllable environmental factors.

In particular, the

inbred mouse is a valuable tool for studying the aforementioned human diseases.
Since inbred strains trace back to a common ancestor, they are considered
isogenic and homozygous at all loci. (Beck et al., 2002), which indicates that
differences between mouse strains as well as genetically modified mice and
wildtype (WT) littermates is a function of the change in genotype (Crabbe et al.,
2002; Lesch, 2004; Festing, 2004).
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Thesis Outline
The present studies address the use of these MEAs to study Glu
dynamics in both anesthetized and awake, freely moving mice.

For our

anesthetized studies, we studied the importance of GPT and GLUD1 on the
neurotransmitter pool of Glu. Since no specific modulators for either of these
enzymes exist, we used transgenic mouse models that were developed at the
University of Kansas by Dr. Elias K. Michaelis’s group. The remainder of the
work addresses the adaptation and validation of the MEAs for use in awake,
freely moving mice. It serves to develop and characterize a new technique as
well as expand upon the current knowledge regarding resting Glu levels in the
freely moving mouse. The long-term goal is to incorporate the freely moving
technology with the GPT and GLUD1 transgenic mouse models, so we can
determine if altering Glu metabolizing enzymes has any effect on behavior.
In Chapter Three, we investigated how upregulation of GLUD1 affects
stimulus-evoked Glu release and uptake as well as exogenously applied Glu in
the striatum (Str) of two inbred mouse strains: C57BL/6 and BALB/C.

We

examined two different mouse strains due to histochemical data acquired at the
University of Kansas that revealed C57BL/6 mice have endogenously higher
levels of GLUD1 protein compared to BALB/C mice. Local application of 70 mM
KCl resulted in a significant increase in Glu release in both strains of GLUD1
transgenic mice compared to WT littermates. Furthermore, uptake of 70 mM
KCl-evoked Glu release as well as clearance of 5 mM Glu was similar for the
GLUD1 transgenic mice compared to WT littermates in both mouse strains. At
16 months of age, the C57BL/6 GLUD1 transgenic mice developed lower limb
atrophy that resulted in severe gait disorders and righting problems. Histological
data conducted at the University of Kansas revealed severe atrophy of Betz cells
within the motor cortex and atrophy of lower motor neurons in the spinal cord. To
our knowledge, this is the first animal model that displays a late onset
neurodegeneration, similar to what is observed in patients suffering from ALS.
In Chapter Four we examined how upregulation as well as knockout (KO)
of the GPT gene affects Glu neurotransmission in C57BL/6 mice. Similar to
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studies in Chapter Three, we investigated stimulus-evoked Glu release and
uptake as well as clearance of exogenously applied Glu in the Str. In the GPT
transgenic mice, we did not observe any differences in stimulus-evoked Glu
release, but did observe significantly slower uptake dynamics of both stimulusevoked Glu and exogenously applied Glu. In the GPT KO mice, homozygous
mice released significantly more Glu compared to WT littermates.

We also

observed that GPT homozygous KO mice cleared exogenously applied Glu
slower compared to WT. Despite these differences, we have not observed any
noticeable phenotypic or behavioral alterations due to upregulation or KO of the
GPT gene.
In Chapter Five we wanted to study the GLUD1 motor deficient mice in an
awake, freely moving mouse model. Before we could do this, we had to develop
and characterize our current freely moving technology for a mouse model. We
adapted our current technology for freely moving rats to make the recording
apparatus smaller and lighter weight for recordings in the awake mouse. Using
our self-referencing MEAs that were selective for Glu measures, we reliably
measured Glu for 7 days post-implantation in both the Str and PFC of the
C57BL/6 mouse.

Through an attached guide cannula we locally applied a

solution of 1 mM Glu and saw no loss in MEA sensitivity on days 3 through 7
post-implantation. However, we did observe changes in both uptake rate and
time for 80 percent of the Glu signal decay (t80) over days. Uptake rate became
slower, while the t80’s became longer over days in both the Str and PFC. With
our self-referencing MEAs we were able to measure resting Glu levels in both
brain areas and found that the Str had elevated resting Glu levels compared to
the PFC. Through the attached guide cannula we locally applied DL-threo-βhydroxyaspartate (THA), a non-selective Glu transport blocker and tetrodotoxin
(TTX), a potent sodium-channel blocker to pharmacologically alter resting Glu
levels. We found that local application of THA increased resting Glu levels since
the uptake was blocked, while TTX decreased resting Glu levels because
neuronal depolarization and subsequent vesicular release of Glu was prevented.
These two studies indicate that the source of resting Glu levels in the Str is at
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least partially neuronally derived and not from reversal of the high-affinity
transporters. Finally, we measured Glu changes due to a stressor. Introduction
of a fox urine soaked cotton ball into the recording chamber resulted in an
increase in Glu levels throughout the duration of the stressor. Glu levels returned
to baseline 15 minutes after the stressor was removed. The ability to monitor Glu
without anesthesia allowed us to study Glu dynamics for at least 7 days postimplantation. When we couple this finding with our changes in Glu from a
stressor such as fox urine we can design behavioral paradigms to better
understand physiological release and uptake of Glu and apply this technique to
better understand the role of Glu metabolizing enzymes on the neurotransmitter
pool of Glu
Copyright © Kevin Nicholas Hascup
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Chapter Two: Materials and Methods
Principles of In Vivo Electrochemistry
In vivo electrochemistry utilizes microelectrodes that were implanted into
the mammalian CNS providing a means to record chemical signaling of neurons.
The microelectrode’s recording surface, or working electrode (normally an inert
metal such as Pt or carbon, could oxidize or reduce compounds of interest. A
potential was applied versus a reference electrode, normally a Ag/AgCl reference
electrode that was in ionic contact with the working microelectrode. Low noise
headstages, which include potentiostats, apply this potential and were computercontrolled

with

multiple

inputs

to

simultaneously

record

from

several

microelectrodes or several recording surfaces on a single MEA. If the potential
at the microelectrode surface was sufficient, molecules directly at the recording
surface of the working electrode were either oxidized or reduced depending upon
their intrinsic electrochemical properties.

Oxidized molecules donate one or

more electrons to the recording surface while reduced molecules receive
electrons from the recording surface.

The currents generated from those

Faradaic reactions were linear with respect to concentration of the electroactive
molecule(s) in the tissue surrounding the microelectrode. This basic principle
allows for in vitro calibration methods for in vivo studies.
One of the simplest electrochemical techniques was amperometry and
involves the measurement of current at a constant fixed potential. The current
was continuously monitored, thus, events were measured as quickly as ≤ 1 ms.
Since the voltage was applied continuously to the working electrode, the nonFaradaic background current recorded from the microelectrode was low and
allowed for sensitive measurements of electrochemically active molecules.
Several neurochemicals reside in the extracellular space of the CNS that
were electrochemically active on Pt recording surfaces at low or high oxidation
potentials including ascorbic acid (AA), dopamine (DA), norepinephrine (NE),
serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA),
nitric oxide (NO), uric acid, and 3,4-dihydroxyphenylacetic acid (DOPAC). In
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addition, enzymes were applied to the recording surface to produce an
electrochemically active reporter molecule, such as hydrogen peroxide (H2O2), to
allow measurements of molecules that were not inherently electrochemically
active. When a potential of +0.7 V versus a Ag/AgCl reference was applied to
the Pt recording sites, the newly formed H2O2 oxidizes and the resulting change
in current from the transfer of electrons to the Pt recording surface was detected.
While O2 was required as a cofactor for oxidase enzymes, the oxidation of the
reporter molecule, H2O2, generates a portion of the O2 for continued reactions.
This did not, however, allow measures using oxidase enzymes in zero O2
environments.
An important and often forgotten aspect of microelectrodes was that
analytes from only a small area (microns) of tissue surrounding the recording
surface were detected. This was useful for studying small or layered structures
in the brain or the spinal cord.

Additionally, microelectrodes with multiple

recordings surfaces could be geometrically arranged to measure analyte
concentrations from two or more distinct brain regions. Since microelectrodes
coupled with amperometric techniques measured analytes of interest on rapid
time scales (1-1000 ms), uptake and release kinetics of faster neurotransmitters,
such as Glu, were easily studied.
Microelectrode Array Fabrication
Enzyme-based
photolithographic

multisite

methods

MEAs

(Methods

were
and

mass

Materials

fabricated
in

using

Microelectronic

Technology, 1984; Wire Bond, 1998; Photolithography, 2001). For a detailed
account regarding MEA design and use, refer to Hascup et al., 2006.

An

advantage of photolithography allowed routine production of reproducible
recording surfaces as small as 5-10 μm. In addition multiple microelectrodes
were patterned onto a single fabrication substrate (usually 2.5 cm x 2.5 cm)
allowing for increased fabrication numbers at a decreased cost.

Finally,

photolithographic methods were used to manufacture numerous MEA designs
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with multiple recordings sites in well-defined, highly reproducible, geometrical
configurations.
Our multisite MEAs were constructed in conjunction with Thin Films
Technology, Inc., (Buellton, California). Initially, MEA photographic masks were
designed on a computer aided design program where arrays of 4-16 recording
sites were arranged on templates. A 2.5 cm x 2.5 cm x 125 μm thick ceramic
wafer (alumina, Al2O3, Coors Ceramic, Coors Superstrate 996) served as a
common substrate for the MEAs. Ceramic reduced the cross-talk from adjacent
connecting lines.

Additionally, ceramic was strong and rigid, which aided in

precise stereotaxic placement into tissues with minimal flexing or breaking. The
ceramic substrate was polished or lapped down to achieve MEAs as thin as 37.5
microns.
Following cleaning, photoresist was spun onto the ceramic wafer.

To

transfer the MEA image onto the wafer, collimated light was passed through a
photomask of the MEA design, thus exposing the design onto the photoresist.
Spaces for the recording sites, connecting lines and bonding pads were not
exposed to light. Solvents were used to remove unexposed photoresist from the
wafer.

Many 1 cm long MEAs (34-64) were patterned onto the wafer

simultaneously to facilitate production and increase the number of MEAs that
were made from the ceramic substrate (figure 2.1). Patterning could also be
performed on the reverse side of the ceramic wafer to increase recording site
density for future generations of MEA designs.
Next, an adhesion layer of Titanium (Ti) was used to allow Pt adhere to
the ceramic substrate. Ti (500 Ǻ thick) was sputtered onto the developed
photoresist-covered-ceramic wafer.

Following the adhesion layer, the active

recording metal layer, Pt, for most of our work, was sputtered onto the substrate
(~1.5 μm thick). Solvents were used to remove the developed photoresist and
unwanted metals left on the recording pads, connecting lines, and connecting
pads.
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Figure 2.1: Ceramic Wafer
Photograph of a ceramic wafer containing 34 microelectrodes with Pt bonding pads, connecting
lines and recording sites (not visible) were patterned onto the 2.5 cm x 2.5 cm, 125 μm thick
substrate.
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Once the Pt recording sites, connecting lines, and bonding pads were in
place, the connecting lines were coated with an insulator using another
photolithographic step. The connecting lines act as wires to connect the bonding
pads to the recording sites and must be insulated from aqueous environments.
To accomplish this, the MEAs were again coated with photoresist. A second
photomask was used to define the areas where polyimide was placed. Polyimide
acts as an insulator to define the recording site active area and the bonding pads
as well as reducing the cross talk between the connecting lines.

After the

photoresist was developed, polyimide was spun onto the wafer (2-4 μm thick).
Once the insulating layer was applied, only the recording sites and bonding pads
were exposed. The photoresist and excess polyimide were removed and the
remaining polyimide was cured at 200oC. The complete fabrication process is
depicted in figure 2.2.
After the formation of the MEA on the ceramic wafer, a diamond saw was
used to form or “cut out” the individual MEAs. A major advantage of the diamond
saw was that it produced highly polished edges for reduced tissue damage
during implantation. The ceramic wafer with Pt recording sites was attached to a
printed circuit board (PCB) holder for easier handling and connection to recording
equipment. To connect the ceramic wafer to the PCB holder, each bonding pad
was wire bonded to an individual Pt recording site on the ceramic wafer. The tips
were epoxied onto the paddle for stability and insulation of the wire bonds.
Cutting and assembly was performed in conjunction with Hybrid Circuits, Inc.,
(Sunnyvale, CA).

The PCB holder and fully constructed multisite MEA for

anesthetized measurements are shown in figures 2.3A and 2.3B, respectively.
Figure 2.3C is a version of the MEA for awake animal recordings.
Due to the flexibility of the fabrication process, our MEAs were
manufactured with different recording site geometric configurations. An S2 MEA
was used for both anesthetized and freely moving experiments. The ceramic tip
of an S2 (figure 2.3D) has 4 Pt recording sites (333 µm X 15 µm) in a side-byside configuration. This configuration allows for dual detection in a similar brain
region.
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Ceramic Substrate
Photo Resist 1

Level 1 Pattern
Titanium Film
Platinum Film

Titanium/Platinum
Liftoff
Photo Resist 2

Level 2 Pattern

Spin or Sputter
Polyimide
Polyimide Liftoff
Cross Sectional
View After Diamond
Saw Cutting
Figure 2.2: Microelectrode Array Fabrication Process
Schematic of the fabrication sequence for the ceramic wafers with Pt recording sites.
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A

C

1

3 4 2

B

D

1 3 4 2

Figure 2.3: Microelectrode Array Photographs
Photograph of the MEA PCB with and without the attached ceramic tip. A.) Close-up view of the
PCB. Numbers beneath the pin holes indicate the specific Pt recording site connection. B.) Fully
assembled MEA. Black epoxy was used to insulate the wire bonding from the ceramic tip to the
PCB as well as to provide stability. Pins were soldered into place for MEA attachment into a dual
inline pin (DIP) socket.

Pins placed in the upper left and right of the PCB provided added

stability. C.) Fully assembled MEA for recordings in freely moving animals. D.) Photomicrograph
of an S2 ceramic tip containing 4 Pt recording sites in a side-by-side configuration.
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Potentiostat
Our headstage/potentiostat was referred to as the Fast Analytical Sensing
Technology (FAST) 16 Mark II system (Quanteon L.L.C, Nicholasville, KY). The
purpose of the potentiostat was to create a constant potential difference between
the Ag/AgCl reference electrode and the MEA to force a non-spontaneous redox
reaction to occur. The potentiostat held a constant potential at the reference
electrode so that the applied potential at the working electrode was known. In
other words, the potential applied at the working electrode was measured against
the standard potential of the reference electrode. The FAST 16 Mark II system
amplified and digitized the electrical current generated by oxidation or reduction
reactions. For our Glu experiments, the amplification resulted in a gain scaling
factor of 200 pA/V. Figure 2.4 shows an illustration of the flow of current through
our FAST 16 Mark II recording system from a GluOx coated MEA.
Our Windows™ based FAST 16 Mark II system software created and
recorded second-by-second (1 Hz), or faster data files. The software was written
for eight simultaneous channel recordings, which could increase as the number
of Pt recording sites increases in future generations of MEAs. The FAST 16 Mark
II software displayed amperometric or chronoamperometric recordings at display
rates of up to 40 Hz (nominal 1-10 Hz). Recorded files were exported to other
Windows™ based applications, such as Excel™, for easier data processing; or
processed directly through the data analysis software package on the FAST 16
Mark II system software.

The low noise design and software oversampling

allowed the FAST 16 Mark II recording system to be used for bench top
experimentation without the need of a Faraday cage.

However, greater

performance was achieved with the use of a Faraday cage or appropriate
shielding for most applications.
Microelectrode Array Cleaning Procedures
MEAs received from Hybrid Circuits underwent a cleaning procedure to
remove any particulate matter or residue from the Pt recording sites that were
deposited during the manufacturing process. New MEAs were placed into a
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Figure 2.4: FAST 16 Mark II Potentiostat Diagram
The above diagram outlines the flow of electrons through our FAST 16 Mark II recording system.
The potentiostat held a constant potential of -0.7 V to our Ag/AgCl reference electrode which
created an applied potential of +0.7 V at our working electrode. In the case of an MEA coated
with GluOx; when Glu came into contact with GluOx, it was metabolized into α-ketoglutarate and
H2O2. The H2O2 diffused through the exclusion layer that was used to repel interferents such as
AA and DOPAC. When the H2O2 came into contact with a Pt recording surface at an applied
potential of +0.7 V, it was oxidized and the transfer of two electrons to the Pt recording sites were
detected on the recording system.

To keep the reaction thermodynamically stable, the two

electrons traveled to the Ag/AgCl reference electrode where two chloride ions were released.
The half reactions are written beneath their respective reference and working electrodes.
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stirred solution of Fisherbrand Citrisolv™ (Fisher Scientific, Catalog #22- 143975) for five minutes followed by a five minute rinse in ddH2O. After the chemical
cleaning procedure, a thin film can develop on the Pt recording sites, so a
Kimwipe® (Kimberly-Clark Professional) was delicately swiped across the tip of
the MEAs to remove this film and any excess ddH2O. MEAs were then dried for
fifteen minutes in an oven at 105 – 115 ºC prior to coating.
An advantage of these MEAs was the ability to reuse them for multiple
experiments. Any applied enzyme layers (described below) need to be removed
from the Pt recording surfaces.

A slightly different cleaning procedure was

employed for MEAs that were previously coated with an enzyme layer. The MEA
tip was placed into a stirred solution of ddH2O at 80°C to soften the protein matrix
on the Pt recording sites. Following 30 minutes of soaking, the MEAs were
cleaned as described in the preceding paragraph and tested for response to
H2O2 to ensure good sensitivity of the Pt recording surfaces.
Exclusion Layers
Exclusion layer coatings were applied after successful cleaning of the
MEAs and were used to alter their recording properties. Exclusion layers were
applied to block or minimize undesirable electrochemically active compounds
found in high concentrations in the CNS such as AA (250-500 μM) or DOPAC
(25-40 µM).

By blocking these undesired electrochemically active molecules

from the Pt recording sites, the MEA had better selectivity for the analyte of
interest. The planar geometry of the multisite MEAs often affected how materials
adhered to the recording surfaces.

Exclusion and enzyme layer coatings

retarded compounds from diffusing to the MEA surface by creating a diffusion
barrier, thus limiting the response time of the MEA. For this reason, coating
parametrics were performed to determine optimal coating procedures for both
exclusion layer and enzyme layer coatings.
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Nafion® Exclusion Layer
Nafion®, an anionic Teflon® derivative, is one of the most widely used
methods for improving the selectivity of voltammetric recordings in CNS tissue.
Historically, Nafion® is used on the surface of carbon fiber microelectrodes for the
detection of catecholamines (Gerhardt et al., 1984; Rice et al., 1985; Rose et al.,
1985; Kuhr and Wightman, 1986; Rose et al., 1986; Gerhardt and Hoffman,
2001). The negatively charged sulfonic acid groups substituted into the polymer
matrix of Nafion® repeled anions from the Pt recording surfaces. If these anions
were not blocked, they caused high background signals that interfered with
reliable recordings.

At the same time, the negatively charged sulfonic acid

groups on Nafion® concentrated cationic species such as DA, NE and 5-HT.
With the development of the multisite MEAs, Nafion® was a logical choice for an
exclusion layer and was used reliably in our studies of Glu (Nickell, et al., 2004;
Day et al., 2006; Nickell et al., 2006; Rutherford et al., 2007). However, since
Nafion® attracted catecholamines to the Pt recording surface, which were
oxidizable on Pt, other exclusion layers were used in CNS regions with high
catecholamine levels except in the freely moving mouse studies. Only Nafion®
coated MEAs were used for freely moving mouse studies due to its longevity in
vivo compared to other exclusion layers.
Nafion® (5%, Sigma-Aldrich, Catalog #27,470-4) was aliquoted into a 1 mL
brown glass vial. The MEA tip was then lowered half-way into the aliquot of
Nafion® and then rotated in a circle five times lasting approximately one second
per rotation. The tip was pulled straight out of the Nafion® solution. Next, MEAs
were placed into an oven at 165-175°C for four minutes to allow the Nafion® layer
to cure on the tip. In general, lower temperature curing produced thicker films
compared to higher temperature curing (Gerhardt and Hoffman, 2001). Also,
longer drying times at higher temperatures produced MEAs with lower responses
to both AA and to analytes such as Glu. MEAs coated with excessive Nafion®
showed little or no detectable response to electrochemically active molecules.
MEAs not coated with enough Nafion® recorded high levels of background AA
once inserted into the brain. After MEAs cured, they were allowed to cool to
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room temperature for 30 minutes before enzyme coating. An important concept
to remember was that once a prepared Nafion® coated MEA was placed into an
aqueous solution (either a beaker or the brain) the tip must remain wet or at the
very least, removed from solution for only a limited time. When Nafion® dried
after soaking, it cracked allowing areas where interferents passed through and
were oxidized on the Pt recording surfaces. If the Nafion® layer cracked, the
MEA was no longer selective for the analyte being measured.
1,3-phenylenediamine
The organic molecule 1,3-phenylenediamine (mPD) was another chemical
used to create an exclusion layer for Pt recording microelectrodes (Lowry et al.,
1998; McMahon and O’Neill, 2005; Kirwan et al., 2007). A potential was applied
to a solution of mPD causing mPD to electropolymerize on Pt recording surfaces.
Historically, mPD or its derivate 1,2-phenylenediamine (oPD), was used on
carbon fiber microelectrodes for selectivity and prevention of microelectrode
fouling; a process where oxidizable molecules such as serotonin adhered to the
carbon fiber surface thus preventing detection.

Electropolymerized mPD

selectivity was achieved by forming a size exclusion layer approximately 30 nm
in thickness (Murphy, 1998; Kirwan et al., 2007) that prevented larger molecules
such as AA, DA, and DOPAC from reaching the recording surface. Smaller
molecules, such as nitric oxide and H2O2, were still able to pass through the
matrix (Friedeman et al., 1996). Since H2O2 was a reporter molecule for oxidase
enzymes, this made mPD an ideal exclusion layer for our enzyme-based
multisite MEAs (Lowry et al.,1998; Kirwan et al., 2007).
The electropolymerizing procedure was completely different from Nafion®
coating but had four distinct advantages. 1) The matrix formed by mPD blocked
catecholamines such as DA, NE, and 5-HT from reaching the Pt recording sites.
This helped make the MEA more selective for measuring the analyte of interest,
Glu. 2) The mPD was electropolymerized onto the MEA after the MEA was
coated with an enzyme layer. mPD electropolymerized through the enzyme layer
and formed the matrix.

Since mPD was electropolymerized after enzyme
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coating, additional coatings of mPD could be applied to the MEA surface without
cleaning the MEA. If the matrix degraded during an experiment, the MEA could
be replated, recalibrated, and re-used to finish the experiment. 3) Because a
potential must be applied for mPD coating, individual Pt recording sites could
also be selectively coated with mPD. Removing the applied potential between a
Pt

recording

site

and

the

headstage

electropolymerized onto that site.

4)

prevented

mPD

from

being

Once mPD was successfully

electropolymerized onto the Pt recording sites, the solution did not have to
remain wet. Since mPD was hydrophilic (Murphy, 1998) our laboratory found
that aqueous solutions slowly degraded the matrix over time, which made it
unsuitable for chronic recordings in the freely moving mouse.

The

electropolymerization procedure is outlined below.
Our laboratory found that 1,3-phenylenediamine dihydrochloride, 99%
(Sigma-Aldrich, Catalog# 235903-25g) worked best for electroplating and matrix
formation on the Pt recording sites. First, a solution of 5 mM mPD was prepared
in a degassed solution of 0.05 M phosphate buffered saline (PBS). Degassing
was accomplished by bubbling nitrogen gas through the 0.05 M PBS solution for
20 minutes to remove oxygen before dissolving mPD. Once the 5 mM mPD was
dissolved in the degassed 0.05 M PBS, the mPD solution was stored in a brown
glass bottle to prevent oxidation from light. If the solution turned yellow, it had
oxidized and did not electropolymerize on the MEA recording surface. Even with
these storage methods, the 5 mM mPD solution oxidized after several hours so
we recommended using the solution immediately. When the mPD solution was
prepared, the MEA was connected to the FAST 16 Mark II recording system and
approximately 40 mL of the 5 mM mPD was poured into a 50 mL beaker. The
MEA tip was lowered half-way into the solution along with a glass, Ag/AgCl
reference electrode (Bioanalytical Systems, Inc. RE-5B, Catalog #MF-2079). A
fast-cyclic potential of +0.25 to +0.75 versus a Ag/AgCl reference electrode was
applied for fifteen minutes to allow the mPD to electropolymerize onto the Pt
recording sites. At fifteen minutes, the MEA tip was removed from the 5 mM
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mPD solution, rinsed with ddH2O, and stored at room temperature for 24 hours
prior to calibration.
Enzyme Layer Coatings
Enzymes provided a means to convert a molecule that was not inherently
electroactive, and thus not measurable, into a reporter molecule such as H2O2
that was oxidized at the Pt recording surfaces of the MEAs.

The current

measured from the oxidation of H2O2 generated during the enzymatic breakdown
was directly proportional to the analyte concentration. Table 2.1 provides a list of
available oxidase enzymes and their potential uses.

Oxidase enzymes that our

laboratory has used to measure neurochemicals are shown in BOLD and include
L-glutamate oxidase (GluOx) (Burmeister and Gerhardt, 2001; Burmeister et al.,
2002; Pomerleau et al., 2003; Nickell et al., 2005; Day et al., 2006; Rutherford et
al., 2007), choline oxidase (Burmeister et al., 2004; Parikh et al., 2005) L-lactate
oxidase (Burmeister et al., 2005) and L-glucose oxidase.

Furthermore,

acetylcholine esterase was used to measure acetylcholine (in conjunction with
choline oxidase) and catalase was used to prevent H2O2 detection.
As previously mentioned, the O2 dependence of oxidase enzyme-coated
MEAs is also a concern. It is widely known that O2 is required by the enzymes to
measure the analyte, but a portion is returned to the tissue by the oxidation of
H2O2 to O2 and H+ at the MEA surfaces. In our experience oxidase enzymecoated MEAs were relatively free from O2 dependence over a useful range in
vivo (Burmeister et al., 2003), but certain applications, such as those during
recordings of stroke episodes, require correction by use of an O2 sensing
microelectrode.
Immobilization of enzymes to the Pt recording surface helped stabilize the
enzymes and made them active for longer periods of time. Our laboratory has
immobilized several of the oxidase enzymes onto the Pt recording surfaces.
While the general procedure remains the same for crosslinking the enzymes to
the Pt recording sites, relative ratios of the enzyme to protein mixtures varies.
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Table 2.1: Enzymes Capable of Producing a Reporter Molecule

Enzyme

Substrate

Product

Measure

Acetylcholinesterase

Acetylcholine

Choline, Acetic Acid

Choline with
Choline oxidase

Alcohol oxidase

Alcohol, O2

H2O2, Aldehyde

Alcohols

D-amino acid oxidase

D-amino acids, O2

H2O2, NH4+, 2-oxo acid

D-amino acids

L-amino acid oxidase

L-amino acids, O2

H2O2, NH4+, 2-oxo acid

L-amino acids

Ascorbate oxidase

Ascorbate, O2

Dehydroascorbate

Remove
Ascorbate

Aspartate oxidase

Aspartate, O2

H2O2, NH4+
Oxaloacetate

Aspartate

Catalase

H2O2

O2

H2O2

Cholesterol esterase

Cholesteryl oleate,
or other Cholesterol
ester, Taurocholate

Cholesterol, Oleic acid,
or other corresponding
ketone

Cholesterol ester
with Cholesterol
oxidase

Cholesterol Oxidase

Cholesterol, O2

H2O2
4-cholesten-3-one

Cholesterol

Choline Oxidase

Choline, O2

H2O2, Betaine

Choline

Galactose oxidase

D-galactose, O2

H2O2
D-galacto-hexodialose

Galactose

Glucose oxidase

Glucose, O2

H2O2, Gluconic Acid

Glucose

L-glutamate oxidase

L-glutamate, O2

H2O2, α-ketoglutarate

L-glutamate

GABAase

GABA
α-ketoglutarate

NADPH, H+
L-glutamate

GABA with
L-glutamate
oxidase

Glutaminase

Glutamine

NH4+, L-glutamate

Glutamine with
L-glutamate
oxidase

Glycerol kinase

Glycerol, ATP

Glycerol-3-phosphate,
ADP

Glycerol with
Glycerol-3phosphate oxidase
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Table 2.1: (continued)

Enzyme

Substrate

Product

Measure

Glycerol-3-phosphate
oxidase

Glycerol-3phosphate, O2

H2O2
Dihydroxyacetone
phosphate

Glycerol

Hexokinase

ATP, Glucose

Glucose-6-phosphate,
ADP

ATP with
L-glutamate
oxidase

Horseradish peroxidase

H2O2

H2O, O2

Use as mediator
for H2O2 detection

Lactate oxidase

Lactate, O2

H2O2, Pyruvate

Lactate

Lysine oxidase

Lysine, O2

H2O2, NH4+
6-amino-2-oxohexanoic
acid

Lysine

Pyruvate oxidase

Pyruvate, O2,
Phosphate

H2O2, CO2,
acetyl phosphate

Pyruvate

Sarcosine oxidase

Sarcosine, O2

H2O2, Glycine,
Formaldehyde

Sarcosine

Xanthine oxidase

Xanthine, O2

H2O2, Uric acid

Xanthine

This table shows oxidase enzymes that can be immobilized onto the Pt recording surface of our
MEA. The enzymes that were used to measure analytes of interest by our laboratory are in
BOLD lettering.
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Our laboratory focuses on GluOx for the detection of Glu dynamics in the
mammalian CNS whose immobilization procedure is outlined in detail below.
L-Glutamate Oxidase
GluOx was purified from a wheat bran culture of Streptomyces sp. X-1196 and metabolized Glu with co-substrates O2 and H2O to form α-ketoglutarate,
H2O2, and ammonia (Kusakabe et al., 1984).

The enzyme had maximal

specificity at physiological pH (7.4) and temperature (37°C) (Kusakabe et al.,
1983). GluOx is specific for the L-enantiomer of Glu with a KM value of 0.21 mM
and shows no activity for D-Glutamate nor did this enantiomer block enzyme
activity (Kusakabe et al., 1983). L-aspartate was also oxidized, but to a lesser
extent (0.6%) and had a considerably higher KM value of 29 mM (Kusakabe et
al., 1983).

Our laboratory has shown that local application of 200 µM L-

aspartate in vivo does not elicit a response on the MEA (Pomerleau et al., 2003).
In addition, salt solutions such as potassium chloride, sodium chloride, nor
calcium chloride do not have an effect on the relative activity of the enzyme
(Kusakabe et al., 1983). This was further verified when local application of 0.9%
physiological saline, did not elicit a response on the MEA (Pomerleau et al.,
2003).
L-Glutamate Oxidase Coating Procedure
A stock solution of GluOx (Associates of Cape Cod, Seikagaku America,
Catalog #100645-1) was prepared by adding 50 μl of ddH2O to the lyophilized,
purified enzyme in a vial to make a final concentration of 1 UI/μl. All proteins and
enzymes were brought to room temperature and 0.010 g of bovine serum
albumin (BSA) Fraction V, 99% (Sigma-Aldrich, Catalog #A-3059) was dissolved
in a 1.5 mL microcentrifuge tube containing 985 μl ddH2O by manual agitation.
Once dissolved, 5 μl of glutaraldehyde (Glut) solution, Grade I, 25% (SigmaAldrich Catalog #G-6257) was added to the BSA mixture and manually mixed by
inversion five times. The solution was then set aside for five minutes until it
turned a faint yellow color. Glut crosslinked proteins that adhered to the MEA
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surface when cured. The BSA served as a matrix to protect the oxidase enzyme
activity during immobilization. Next, 9 μl of the BSA/Glut mixture was removed
and added to a 300 μl microcentrifuge tube and to this 1 μl of the GluOx stock
solution (1 UI/μl) was added and mixed by pipette agitation. This 10 μl solution
had a final concentration of 1% BSA, 0.125% Glut, and approximately 1% GluOx.
We have carried out an extensive series of parametric studies to determine this
optimized stoichiometry for enzyme immobilization.
All enzymes were applied to the Pt recording sites by hand. Solutions
were drawn up into a 10 μl Gastight® Hamilton microsyringe (Hamilton Co.
Catalog #80065) and slowly dispensed to form a small droplet of solution at the
tip of the microsyringe. Using a dissecting microscope (and a steady set of
hands), the droplet was briefly applied to the Pt recording sites. The solution
quickly dried, leaving behind a thin, translucent layer of enzyme that was visible
underneath a dissecting microscope.

Two additional coats of enzyme were

applied in the same manner with one minute dry times in between each coat.
This procedure was complete once a visible film remained following coating. The
advantage of using multisite MEAs was that a pair of recording sites was coated
with the enzyme mixture and the adjacent sites were coated with the inactive
protein matrix (BSA and Glut) in the same manner as applying the enzyme
mixture.

Our laboratory referred to this technique as “self-referencing”

(Burmeister and Gerhardt, 2002) and this approach had many advantages which
are discussed in more detail in the section entitled ‘Self-Referencing.”
Once the enzyme and/or inactive protein matrix was applied, MEAs were
stored at room temperature.

Enzyme-coated MEAs must cure at room

temperature for 48-72 hours prior to calibration and experimentation. Complete
curing

increased

enzyme

layer

adhesion

to

the

MEA

surface.

The

enzyme/protein layers on “uncured MEAs” dissolved when placed in solution. A
48-72 hour curing time provided better sensitivity to Glu as well as increased the
shelf-life of the MEAs. Optimal curing times varied depending on temperature,
humidity, and enzyme.

GluOx coated MEAs were optimal for at least three

weeks..
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Calibration
We often observed that the micro-fabricated MEAs have highly
reproducible Pt recording surfaces. However, manufacturing procedures only
investigated the geometric surface area of the MEAs. Since each Pt recording
site on a MEA responded differently to H2O2 and therefore Glu, they must be
calibrated in vitro prior to experimentation to determine standard curves. Thus,
calibrations were used to equate a change in current from the oxidation of H2O2
to a proportional change in analyte concentration from the Glu generating the
H2O2. A known concentration of analyte was added to 40 mL of 0.05 M PBS
solution at 37°C to generate a current in picoamperes (pA) that was measured by
the FAST 16 Mark II system. The FAST 16 Mark II system software recorded the
current for each addition of analyte, created a calibration curve for each Pt
recording site, and stored the slope (nA/µM) of this calibration. Also, known
interferents such as AA were added during the calibration to test the selectivity of
the recording sites to the analyte of interest versus interferents.

When the

experiment was performed, the calibration data was recalled and used to
determine the concentration of analyte measured from the current during
experiments in vivo.
Calibration Preparation
®

Nafion coated MEA tips were soaked in a solution of 0.05 M PBS at 37°C
for at least one hour prior to calibration. These MEAs can be placed in the PBS
solution overnight for calibration the next morning. The soaking time allowed for
better diffusion of analytes through the Nafion® layer as well as activation of the
enzyme layer. The mPD coated MEAs, on the other hand, did not require long
soaking times. The time period the MEA tip soaked in the calibration solution was
sufficient for proper enzyme activation without additional soaking.
All stock solutions for Glu calibrations were prepared in ddH2O and listed
below:
1.) 20 mM AA (Ascorbic acid powder, Fisher Scientific,
Catalog #A62)
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2.) 20 mM L-glutamic acid sodium salt hydrate, minimum 99%
(Sigma-Aldrich, Catalog #G1626)
3.) 2 mM DA (3-Hydroxytyramine hydrochloride, Sigma-Aldrich,
Catalog #H-8502)
4.) 8.8 mM H2O2 (Rite Aid, 3% H2O2 Topical Solution)
Solutions were stored at 4°C. AA and H2O2 were made fresh daily since they
oxidize in solution. Glu was made fresh on a weekly basis. DA was kept for a
month providing the stock solution contained 0.01 M perchloric acid.
Calibration Procedure
Forty milliliters of 0.05 M PBS was measured out with a graduated cylinder
and added to a 50 mL beaker. This beaker was placed in a recirculating water
bath (Quanteon, L.L.C.) set at 37°C resting upon a battery operated, portable
magnetic stir plate (Barnant Co., Model #700-0153). The calibration temperature
was maintained at 37°C to activate GluOx for physiologically relevant
temperatures. We used a battery operated stir plate to reduce potential AC (60
Hz) current that affected the recordings. A 10 x 3 mm stir bar was added to the
0.05 M PBS and the solution was slowly stirred to facilitate diffusion without
forming a vortex in the solution. A glass Ag/AgCl reference electrode was placed
in the buffer solution. Finally, the MEA tip was lowered halfway into the buffer
solution.
After initial system settings were completed on the FAST 16 software, the
FAST 16 Mark II recording system applied a potential of +0.7 V versus the
Ag/AgCl reference to the MEA recording surfaces. Once calibration started, the
current was allowed to reach a stable baseline (approximately 10-15 minutes, but
occasionally longer). When a stable baseline was achieved, the baseline was
marked. (When ‘marking’ a time point for an event, such as baseline, interferent,
or analyte addition, was recorded by the FAST 16 Mark II software. A series of
data points before the ‘mark’ were averaged and used in the calibration analysis).
Next, 500 μl of 20 mM AA (interferent) was added for a final beaker concentration
of 250 μM.

When a new stable baseline was reached, the interferent was
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marked. Next, three, 40 μl additions of 20 mM Glu were added for final buffer
concentrations of 20, 40, and 60 μM Glu. Analyte marks were recorded after
each addition to create the standard curve. After 3 additions of analyte, 40 μl of
2 mM DA (2 μM final beaker concentration) was added to the solution as a test
substance and marked. Finally, 40 μl of 8.8 mM H2O2 (8.8 μM final beaker
concentration) was added to the solution to confirm MEA sensitivity and the
addition was marked. The test substances were used to check selectivity. The
additions of test substances did not factor into calculating the standard curve for
the analyte of interest. All chemicals used in vivo were tested in vitro to ensure
that they were not electrochemically active on the Pt recording surface. It was
important to know whether a chemical was electrochemically active in vitro prior
to its local application near the Pt recording sites during experimentation. This
guaranteed that in vitro or in vivo analyte concentration changes were from the
analyte of interest rather than due to local application of drugs. Upon completion
of the calibration, the program was stopped, the data were saved, and the MEA
tip was removed from the buffer solution and stored appropriately.

Nafion®

coated MEAs were placed in 0.05 M PBS while mPD electroplated MEAs were
kept dry. Graphs of typical self-referencing Glu calibrations with either Nafion® or
mPD applied as exclusion layers are shown in figures 2.5A and 2.5B,
respectively.
Microelectrode Array Calibration Criteria
During calibration, the FAST 16 Mark II recording software automatically
calculated selectivity ratios for Glu over AA as well as the slope (MEA sensitivity
for Glu), limit of detection (LOD), and linearity (R2). What do all these numbers
mean and how did one know if they have a satisfactory Glu MEA? A poor R2 was
rarely seen with good MEAs. Since the MEA fabrication procedure was highly
reproducible, we have found that Glu responses were extremely linear and often
resulted in linear regression curve fits with R2 ≥ 0.99.
Slope or sensitivity of the MEA referred to how well the MEA measured
the change in Glu concentration. The number was used to equate a change
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Figure 2.5: Calibration Results From Nafion® and mPD Coated MEAs
A) The calibration of a Nafion® coated Glu self-referencing MEA. During calibration, solutions
were added to determine each recording site’s sensitivity to Glu, selectivity for Glu over AA,
lowest LOD, and responsiveness to other electroactive molecules (e.g. DA and H2O2). The
enzyme-coated Glu recording site responded well to Glu and some electroactive molecules. The
enzyme-free sentinel site did not respond to Glu but showed similar responses to the same
electroactive molecules. Final concentrations of each addition: 250 µM AA, 20, 40, and 60 µM
Glu, 2 µM DA, and 8.8 µM H2O2. B.) Calibration of an mPD coated Glu self-referencing MEA. All
calibration concentrations were the same as previously described. Note how mPD excluded the
DA response on both the GluOx and sentinel recording sites.
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in current to a change in Glu concentration. The slope was also used to calculate
LODs, which were the most important criteria for determining if a MEA was
satisfactory for use.

We use LODs to select MEAs because slopes were

misleading. LOD was defined as the analyte concentration that yielded an MEA
response that was equivalent to 3 times the background noise of the recording
system. This was a conservative calculation of the lowest detectable change in
analyte concentration that was not attributed to noise. Our MEA LODs range
from 0.2 to 1.0 μM, depending on the recording enzyme composition and stability
of the sites. Typically, for in vivo experiments MEAs with LODs ≤ 1 μM were
used since this was smaller than the response expected.
Selectivity referred to the ratio of the MEAs sensitivity to Glu over the
sensitivity to interferents such as AA. It was calculated by dividing the Glu slope
by the AA slope.

A MEA with a selectivity of 100:1 meant that a 100 μM

concentration increase of AA resulted in an apparent 1 μM concentration
increase in Glu.

With a selectivity of 100:1, the MEA was 99% effective at

blocking AA. Selectivity ratios of 100:1 or greater were ideal, but selectivity ratios
of 20:1 were used and effective at blocking interferents since this ratio was not a
linear correlation. In other words, a MEA with a selectivity of 50:1 was blocking
approximately 98% of the AA while a MEA with a selectivity of 20:1 was still
blocking approximately 95% of the AA signal.
Glass Micropipettes
After calibrations were completed, a glass micropipette was attached to
the PCB holder so the tip of the glass micropipette rested among the 4 Pt
recording sites.

Through this glass micropipette, drug solutions were locally

applied for pharmacological manipulations of the CNS.

We used a vertical

pipette puller (David Kopf Instruments, Model 700C, Catalog #730) to prepare
single barrel (1 mm o.d., 0.58 mm i.d., A-M Systems, Inc., Catalog #601500)
glass micropipettes.

Using an upright stereomicroscope, the tip of the

micropipette was bumped against a glass stir rod to create an internal diameter
of 12-15 μm. Next, modeling clay was attached to the PCB holder. The glass
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micropipette was attached to the modeling clay (used to hold the glass
micropipette steady while it was positioned among the recording sites). Once the
glass micropipette was properly positioned, it was held more firmly in place by
applying melted Sticky Wax (Kerr Corporation, Catalog #00625) onto the PCB
between the ceramic wafer and the modeling clay. The drying of the Sticky Wax
repositioned the glass micropipette relative to its placement amongst and above
the Pt recording sites. If necessary, the tip of a spatula was heated to help
remodel the Sticky Wax and thus reposition the glass micropipette. Figure 2.6A
shows a glass micropipette attached to the PCB with modeling clay and Sticky
Wax.

Figure 2.6B shows the tip of a glass micropipette positioned among the

recording sites for an S2 MEA. The tip of the glass micropipette did not touch the
ceramic surface. Rather it was positioned between 50-100 microns above the Pt
recording sites (as shown in figure 2.6C).

This distance allowed an optimal

amount of CNS tissue between the glass micropipette and MEA when it was
lowered into the brain. If the MEA was too close to the Pt recording sites,
pressure ejection of fluid caused a dilution artifact in vivo (an actual decrease in
analyte concentration due to the introduction of exogenous fluid in the area of the
Pt recording site). If positioned too far, the rapid diffusion and uptake of Glu into
glia limited its diffusion to the Pt recording sites on the MEA surface. For proper
positioning of the glass micropipette among the Pt recording sites, the MEA was
viewed at two angles underneath a dissecting microscope.
The glass micropipette was filled with solution using a 30-gauge, four inch
long hypodermic needle (Popper and Sons, Inc., Standard Female Luer Hub,
Catalog #7400). Glass micropipettes were always filled prior to implantation.
First, drug solutions were drawn into a 1 mL tuberculin tip syringe (BecktonDickinson, and Co., Catalog #309602), which was then attached to the intake
end of a μStar 0.22 μm sterile filter (Costar Corp, Catalog #8110). The other end
of the filter attached to a 30-gauge, four inch long, hypodermic needle. The
solution was dispensed through the filter and ultimately through the hypodermic
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Figure 2.6: Positioning of the Glass Micropipette
Photographs of a glass micropipette attached to a multisite MEA. A.) Photograph of the glass
micropipette held in place with modeling clay and Sticky Wax. B.) Photomicrograph of a glass
micropipette tip positioned among the four Pt recording sites on an S2 MEA. C.) Side view
photomicrograph of the glass micropipette tip held approximately 50 μm above the MEA tip.
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needle. The needle was inserted into the glass micropipette and filled from the
pulled tip up to the open end without creating air bubbles within the glass
micropipette.

Air bubbles prevented effective delivery of drugs by pressure

ejection and made it difficult to determine the volume of fluid dispensed.
Solutions were normally pressure ejected prior to MEA implantation into the brain
to determine that there was a smooth fluid flow out of the glass micropipette.
Solutions were removed from a glass micropipette by inserting the 30-gauge
filling needle with an attached tuberculin syringe to draw up the solution.
Ag/AgCl Reference Electrode
While larger glass Ag/AgCl reference electrodes were suitable for mPD
electropolymerization and MEA calibration, this reference electrode was too large
for many biological applications. For this reason, a smaller Ag/AgCl reference
electrode was made at the start of every experiment.

Miniature Ag/AgCl

reference electrodes were prepared by first stripping 0.25 inch of the Teflon®
coating from each end of a silver wire (0.008 inch bare, 0.011 inch coated; A-M
Systems, Inc., Catalog #786500). One of the stripped ends was soldered to a
wire crimp pin (Mill-Max Mfg. Corp., Part #3603) for connection to the FAST 16
Mark II headstage.

The other end was placed into a solution of 1 M HCl

saturated with NaCl. A Pt wire acted as the counter electrode and was also
placed into the solution. Our laboratory used a regulated power supply (Elenco
Precision, Model XP-620) that outputs 9 V. However, DC adapters ranging from
1.5 V to 9 V were acceptable.

The negative lead was attached to the Pt counter

electrode while the positive lead was connected to the Ag wire. With both wires
in solution, the applied potential attracts Cl- on the wire to form AgCl thus making
the Ag/AgCl reference. The plating potential was applied for approximately 1015 minutes. When properly connected, bubbles formed around the Pt counter
electrode. These miniature Ag/AgCl references were soaked in 3M NaCl prior to
use in vivo.

50

MEA Preparation for Awake, Freely Moving Mice
Refer to Rutherford et al., 2007 for a complete description on preparing
MEAs for chronic recordings. For our awake, freely moving recordings, we used
a smaller, lighter weight MEA, which is shown in figure 2.3C. Microelectrode
connecting wires were prepared by first stripping both ends of 30 American Wire
Gauge (AWG) varnished copper wire (RadioShack).

One end of the copper

connecting wire was soldered to a pin-hole on the row closest to the MEA tip.
Four copper wires were soldered to the PCB, each corresponding to one of the
Pt recording sites. Once all wires were soldered, the MEA tip was coated with
five minute epoxy, which protected the MEA connection from potential water or
other liquid damage during the remaining portion of the procedure. The MEA tip
was coated with Nafion® (we found this exclusion layer worked longer for chronic
implantations compared to mPD) and enzyme and inactive protein matrix
solutions as previously described.

The enzyme and inactive protein matrix

solutions were allowed to cure for 48-72 hours before the MEA modifications
were completed.
Once the enzyme cured, a gold-plated socket (Ginder Scientific Part #220S02) was attached to the other end of the copper wire (figure 2.7A). Also, a
miniature Ag/AgCl reference was prepared and attached to a gold socket. The
gold sockets of the reference and MEA wires were inserted into a miniature,
black connector (Ginder Scientific, 9-pin ABS Plug, Part #GS09PLG-220). Pliers
were used to push the gold sockets into the connector so that the gold sockets
were flush with the miniature, black connector. The copper wires were wrapped
around the connector and the MEA tip was positioned parallel to the connector.
Correct positioning of the MEA tip was essential for accurate stereotaxic
placement into the brain. Five minute epoxy was used to secure the MEA and
wires, making sure that all wires were covered with epoxy. The solder contacts
on the gold sockets were also covered with epoxy to ensure that moisture did not
penetrate the connector and disrupt the recording (figure 2.7B).
Similar to anesthetized experiments, drugs were locally applied close to
the Pt recording sites for pharmacological studies in freely moving mice. Instead
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Figure 2.7: Awake, Freely Moving MEA Preparation
Photographs of the assembly process for the awake, freely moving MEAs. A.) Four copper wires
were soldered to the MEA (one for each Pt recording site). Gold sockets were soldered to the
other end of each copper wire. B.) The gold sockets were inserted into a black connector along
with a miniature Ag/AgCl reference wire. The MEA was positioned parallel to the black connector
and was held in place using five minute epoxy. C.) A fully assembled MEA with attached guide
cannula was held in place with Sticky Wax. The guide cannula was held in place so an internal
cannula was positioned among the four Pt recording sites.
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of a glass micropipette, a 26-gauge stainless steel guide cannula (Plastics One
Inc., C315G Cannula Guide 26GA 38172, PO: 052604AA, SO: 41123-1) was
centered among the recording sites with sticky wax similar to the glass
micropipette as previously described. A 33 gauge stainless steel internal acute
cannula (Plastics One Inc., C315IA Cannula Internal Acute, PO: 121409, SO:
45203-1), slightly longer than the guide, was inserted into the guide cannula.
The internal acute cannula tip was positioned among the four Pt recording sites
of the MEA at a distance of approximately 70 μm above the MEA tip. To prevent
clogging of the guide cannula, a stainless steel dummy cannula (Plastics One
Inc., C315DC Cannula dummy, PO: 121409, SO: 45203-3) remained in the guide
cannula at all times, and was only removed when solutions were locally applied
through the internal acute cannula. An assembled MEA with attached guide
cannula is shown in figure 2.7C.
Freely Moving Recording Apparatus
The recording headstage was slightly different from those used for in vitro
and in vivo anesthetized animal recordings. This headstage screwed directly
onto the mouse MEA assembly connecting the chronically implanted MEA to the
FAST 16 Mark II recording system. The headstage consisted of a miniature
connector with five connector pins (one connecting each of the four channels and
one for the Ag/AgCl reference electrode). The connector pins led to the four
channel mini-amplifier, which was positioned as close as possible to the animal
in order to minimize noise artifacts. Shielded connecting wire, led to an electrical
swivel (Airflyte Electronics Co., P/N 1001460-012) at the top of the recording
chamber.

The headstage was connected at the top center of the recording

apparatus to the electrical swivel (commutator) that contained twelve electrical
contacts. The commutator allowed the animal to move freely to all areas of the
behavior chamber. Figure 2.8 diagrams the equipment used for freely moving
recordings.
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Figure 2.8: Diagram of the Freely Moving Recording Chamber
This diagram shows a mouse connected to the FAST 16 Mark II recording system for awake,
freely moving recordings. Briefly, once a mouse was introduced into the recording chamber it
was connected to the primary amplifier, which attached to the electrical swivel allowing the mouse
to move to all areas of the recording chamber. The electrical swivel was connected to the FAST
16 Mark II recording system where the signal was amplified and digitized on a PC workstation.
The bottom right inset is a photograph of the electrical swivel mounted to the top of the recording
chamber.
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Chronic Implantation Procedure
For chronic implantation surgeries, mice were anesthetized with isoflurane
and placed in a stereotaxic apparatus fitted with a mouse adapter (David Kopf
Instruments, Model 926) and mouse anesthesia mask (David Kopf Instruments,
Model 907). A constant flow of isoflurane was maintained using a SurgiVet Tec 4
Vaporizer. Mouse body temperature was maintained with an isothermal heating
pad at 37°C. The mouse’s eyes were coated with artificial tears (www.medivet.com, Catalog #11970) to help maintain fluid and prevent infection.

All

surgeries were performed in a Vertical Laminar Flow Workstation, (Microzone
Corp., VLF-2-4) with a High Efficiency Particulate Air (HEPA) filter.

Prior to

incision, excess fur on the head was shaved and the skin directly on top of the
mouse’s head (between the ears and from just behind the eyes to the neck) was
wiped with a proviodine solution to keep the incision area clean and prevent
infection. The skin on top of the head was reflected, making as small an incision
as necessary. The mouse underwent a craniotomy to remove a 2 mm x 2 mm
portion of the skull for MEA implantation. Additionally, three small holes (<0.5
mm) were drilled in the skull with a Dremel® engraving cutting bit (#105) for
placement of the reference electrode and two stainless steel skull screws (Small
Parts Inc., Part #MPX-080-02-M) that helped hold the assembly in place. Similar
to the anesthetized studies, a Ag/AgCl reference electrode was implanted
remotely from the recording site. For our freely moving mouse experiments,
MEAs were lowered into either the right PFC (AP: +1.5, ML: 0.3; DV: -2.4 vs
bregma) or right Str (AP: +0.9, ML: 1.5, DV: -3.85 vs bregma) according to the
atlas of Paxinos and Franklin (2004). Figure 2.9 shows a diagram of the mouse
skull with skull screws, Ag/AgCl reference wire, and MEA placement.

The

assembly was secured with approximately four layers of Ortho-Jet Powder (Lang
Dental Manufacturing Co., Inc. REF-1330) mixed with Jet Acrylic Liquid, (Lang
Dental Manufacturing Co., Inc., REF-1406), which the skull screws help anchor in
place. The dental acrylic covered as much of the MEA PCB holder as possible,
without adhering to the threads of the cannula or the MEA connector. The dental
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Figure 2.9: MEA Implantation Surgery
The above figure shows an overhead view of the mouse skull and the placement of the skull
screws, Ag/AgCl reference wire, and MEA implantation site.
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acrylic had a smooth texture to prevent the rodent from scratching the implanted
MEA. Following surgery, mice were placed on a heating pad to help maintain
body temperature until they recovered from the anesthesia. Three subcutaneous
injections, totaling 1 mL of Ringer’s Solution, Mammal (Fisher Scientific, Catalog
#S77939) were administered subcutaneously immediately following surgery.
Mice were given three days to recover prior to the start of a recording session.
On experiment days, the mouse was allowed to explore the behavior
chamber for 15-20 minutes before being connected to the FAST 16 Mark II
recording system. Usually, the first day of recordings involved local application of
an isotonic solution of 1 mM Glu (pH ~ 7.4) to determine the MEA response
before behavioral or pharmacological studies were conducted. Ejected solutions
were filtered and then delivered into the internal guide cannula with the aid of 28gauge tubing (Small Parts Inc.) fitted over a 10 μl Hamilton microsyringe. The
Hamilton syringe was inserted into a repeating dispenser (Hamilton, Co; PB6001) to provide accurate volume ejections of locally-applied chemicals.

The

microsyringe with repeating dispenser was placed on top of the recording
chamber while the tubing was lowered through the hole drilled out for the
commutator into the recording chamber. The dummy cannula was removed and
the fluid cannula was inserted in its place. The animals were not restrained to
insert the cannula as restraining the mouse altered behavioral studies by
stressing the rodent.
Self-Referencing
An advantage of photolithographic fabrication of MEA designs was the
precise control of the layout of the MEAs allowing for multiple recording sites
geometrically configured in a small area. Multiple recording sites on a single
MEA were used to remove chemical interferents that contributed to a portion of
the analyte signal (Burmeister and Gerhardt, 2001). Our laboratory referred to
this principle as ‘self-referencing’ and it was commonly used in our data analysis.
As mentioned in the coating section, the GluOx was applied to a pair of Pt
recording sites while the chemically inactive protein matrix (BSA and Glut) was
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applied to the adjacent pair of recording sites referred to as ‘sentinel sites’. A
schematic of the coating procedure with either Nafion® or mPD is shown in figure
2.10.
The GluOx coated Pt recording sites detected extracellular Glu
concentrations (the analyte) in addition to molecules that the inactive protein
matrix coated recording sites detected (interferents). These additional molecules
detected, included interferents such as AA and DOPAC as well as other
neurotransmitters such as DA, NE, 5-HT. (Refer to figures 2.5A and 2.5B that
show a typical Glu self-referencing calibration where the GluOx coated sites
responded to Glu while the inactive protein matrix coated sites did not.)
The purpose of the inactive protein matrix on the self-referencing, or
sentinel sites, was to make the response times of the sentinel sites similar to the
GluOx recording sites. As mentioned earlier, protein coats altered the diffusional
properties of molecules to the Pt recording surfaces. Without this inactive protein
matrix layer, the sentinel sites would respond faster to interferents than the
GluOx coated sites. Protein layers on both pairs of Pt recordings sites were
necessary to minimize differences between the temporal recording properties of
the different MEA surfaces.

Ideally, the sentinel vs. analyte recording sites

should be positioned side-by-side.

However, our current, manual enzyme

coating procedures precluded this arrangement.
Experimentally, self-referencing recordings were beneficial for providing
qualitative as well as quantitative assessment of the analyte of interest. During
an experiment, the FAST 16 Mark II recording software allowed the user to
simultaneously view changes in Glu concentration for all four recording sites. If a
peak was seen on the GluOx coated sites, but not the inactive protein matrix
coated sites, this provided a good qualitative assessment that Glu was being
measured. Figure 2.11 shows a screen capture of a Glu self-referencing MEA
during an in vivo experiment.
Quantitatively, the self-referencing method was even more powerful.
Since some of the response on the GluOx coated sites was attributed to
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Figure 2.10: Nafion® and mPD Self-Referencing MEA Schematic
Schematics and photomicrographs of an S2, Nafion® coated (A) and mPD coated (B), selfreferencing, Glu selective MEA. The left side of each schematic shows the bottom pair of Pt
recording sites coated with GluOx, BSA, and Glut. The Glu that came into contact with the GluOx
was converted to α-ketoglutarate and H2O2. The H2O2 readily diffused through the Nafion® or
mPD layer that blocked anionic substances such as AA and DOPAC. When the H2O2 came into
contact with the Pt recording sites at a potential of +0.7 V versus a Ag/AgCl reference, the H2O2
was oxidized and the resulting two electrons were transferred to the Pt recording site and the
change in current was measured by the FAST 16 Mark II system.

The right side of each

schematic shows the top pair of Pt recording sites coated with the inactive protein matrix of BSA
and Glut, also referred to as the sentinel sites. Since no GluOx was coated onto this pair of
recording sites, Glu was not converted to a reporter molecule and thus was not measured on the
Pt recording sites. Once again, the Nafion® or mPD acts on these sites based on charge or size
exclusion, respectively.
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Figure 2.11: Screen Capture of an In Vivo Glu Response on a Self-Referencing MEA
Screen capture of the FAST-16 Mark II system with a self-referencing Glu MEA. Stimulus-evoked
(70 mM KCl) Glu release was measured in the motor cortex of a rhesus monkey. Each colored
line corresponds to a different Pt recording site (1=white, 2=red, 3=green, 4=blue). Sites 1 and 2
are coated with GluOx and show a rapid, robust increase in extracellular Glu compared to the two
sentinel recording sites (Sites 3 and 4).
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interferents, the sentinel sites were used to record the interferents contributing to
the Glu response. If the recording sites’ measure of Faradaic responses to DA
and H2O2 are close (<10%) during calibration, the raw current data collected for a
sentinel recording site was subtracted from the raw current obtained from the
GluOx coated sites. This new raw current, once divided by the slope of the
corresponding GluOx recording site, provided the adjusted concentration of Glu
that was free of interferents. This unique feature of our MEAs allowed us to
study resting Glu levels (Day et al., 2006; Rutherford et al., 2007), which is
examined in more detail in chapter Five.
Besides removal of interferents that contributed to a portion of the analyte
signal, self-referencing recordings removed periodic or random noise (Burmeister
et al., 2002).

This was an obvious advantage because smaller changes in

current (lower detection limits) were achieved. Figure 2.12 illustrates removal of
noise using self-referencing recordings. The noisy upper trace was a response
from a GluOx coated recording site, while the middle trace was the resulting
sentinel site response. When the sentinel site raw current is subtracted from the
GluOx raw current and divided by the slope of the GluOx coated site, the signalto-noise ratio of the peaks was greatly improved as shown in the lower trace.
This dual-channel noise subtraction approach is widely used in other
methodologies such as electrophysiology and spectroscopy and is now used with
the our MEAs.
Signal Analysis
A Picospritzer® III (Parker Hannifan, Corp, General Valve Operation) or
related hardware was connected to the FAST 16 Mark II recording system, so
when solutions were pressure ejected through the glass micropipette, or
experimental events occurred, the software recorded these events. The FAST
16 Mark II recording system automatically saved amperometric data, time, and
pressure ejection marks (external events) for all four channels for a specified
time period.

All calculations were performed offline using a Microsoft Office

ExcelTM macro created by Jason J. Burmeister. As the FAST 16 Mark II recording
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Figure 2.12: Example of Self-Referencing Subtraction
Pressure ejection of 70 mM KCl (black arrowheads) caused a release of Glu in the Str of a
C57BL/6 mouse. Non-Faradaic current decreased the signal-to-noise ratio making it difficult to
distinguish between current fluctuations and low Glu responses. The noise occurred on both the
GluOx coated sites (top, black trace) and the sentinel recordings sites (middle, red trace). When
the raw current from the sentinel recording site was subtracted from the raw current on the GluOx
coated sites, the noise was removed creating a higher signal-to-noise ratio for Glu measurements
(lower, blue trace).
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software progressed, we analyzed individual peaks during the actual experiment.
However, for the purposes of this dissertation, all data calculations were
performed using the Microsoft Office ExcelTM macro.
Figure 2.13A shows a typical Glu current signal (blue) and the
corresponding self-referencing current (red) at 10 Hz.

For Glu analysis, the

absolute value of the self-referencing current was subtracted from the absolute
value of the GluOx current and divided by the slope.

This yielded the Glu

concentration trace free of interferents as shown in figure 2.13B. A
stereomicroscope mounted on a universal boom stand fitted with a reticule
monitored the amount of stimulus ejected from the glass micropipette (Friedmann
and Gerhardt, 1992). Pressure ejection of 70 mM KCl (70 mM KCl, 79 mM NaCl,
2.5 mM CaCl2, pH 7.4) caused a depolarization event and released Glu into the
extracellular space, causing a robust and reproducible rise in the Glu signal
compared to baseline.

The maximum change in concentration compared to

baseline was referred to as maximum amplitude or amplitude of the Glu signal.
This value was normally recorded in μM units. Next, the maximum amplitude of
the signal was divided by the amount of stimulus (i.e. volume pressure ejected
from the glass micropipette) necessary to elicit the Glu release.

Volume

displacement was calibrated according to the pipette inner diameter. (Note: the
single barrel glass micropipettes had a solution volume of approximately 250 nl
per mm of glass, but this varies with the inner diameter/total volume of the glass
micropipette. For this reason, we suggest using the type of glass micropipettes
from A-M Systems, Inc., Catalog #601500 as discussed earlier.) The volumes of
stimulus ejected were recorded in nanoliters, so this calculation was referred to
as amplitude per nanoliter with units μM/nl. Finally, the time period for the signal
to reach the maximum amplitude from baseline was recorded (in seconds) and
referred to as rise time (tr).
Signal decay referred to the point of maximum amplitude of the
signal to its return to baseline. The clearance of Glu was a result of the rapid
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Figure 2.13: Analysis Parameters
The top graph (A) shows the absolute value of the current from a GluOx coated site (blue) and a
self-referencing site (red).

The bottom graph (B) is a Glu trace after the absolute value of the

current from the self-referencing site was subtracted from the absolute value of the current from
the GluOx coated site and divided by the slope of the GluOx coated site obtained during
calibration. Additionally, this trace shows examples of resting Glu levels, maximum amplitude
(Max Amp), t80, and uptake rate. The diamonds on both graphs indicate local application of 0.5 µl
of 1 mM Glu.
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uptake of Glu into glial and neuronal transporters (Danbolt, 2001). Glu uptake
followed apparent first order decay rate. The decay of the Glu signal was fitted to
the slope of the linear regression of the natural log transformation of the data
over time and this was referred to as k-1 and had units of sec-1 (Parikh et al.,
2004).

When k-1 was multiplied by the maximum amplitude of the signal, the

uptake rate, or micromolar of Glu removed from the extracellular space per
second (μM/sec), was obtained. Finally, the decay of the signal was examined at
different percentages of decay. These often include t50, t80, and t100, and follow
the general format of tD (sec), where t refers to the time from maximum amplitude
for the signal to decay by D percent.
Development of Mouse Lines
All transgenic and knockout (KO) mice were developed at the University of
Kansas by Dr. Elias K. Michaelis’s laboratory. All transgenes were inserted into
the mouse genome under the control of the Neuronal specific enolase (NSE)
promoter. The NSE promoter has been shown to be expressed only in neurons
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997). Transgenic
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with
vectors containing cDNA of mouse GLUD1 or rat GPT placed under the control
of the NSE promoter. This promoter was excised from the pNSE-LacZ vector by
first digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm7Z. The NSE promoter was also excised and cloned into the modified pGEM-7Z.
Finally, either a GLUD1 or GPT open reading frame was cloned into the pNSEGEM-7Z to create the pNSE-GLUD1 or pNSE-GPT vector, respectively. This
vector was digested, the DNA recovered, and microinjected into the nucleus of
fertilized mouse ooctyes to generate either the GLUD1 or GPT transgenic mice.
Oocytes were transferred to surrogate C57BL/6 or BALB/C mice. Pups carrying
the transgene were identified by PCR and Southern Blot Analysis.
Copyright © Kevin Nicholas Hascup
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Chapter Three: Glutamate Dynamics in Glutamate Dehydrogenase
C57BL/6 and BALB/C Transgenic Mice
Introduction
Glu is the predominant excitatory neurotransmitter in the mammalian CNS
with an indirect excitotoxic role implicated in several neurodegenerative disorders
including PD, AD, and ALS (Doble, 1999). Evidence supports that mitochondrial
damage leads to energy impairment and a decrease in intracellular ATP levels
(Beal, 1992; Greene and Greenamyre, 1996; Doble, 1999).
+

As ATP levels

+

decrease, the Na /K ATPase, responsible for maintaining the resting membrane
potential slows down causing membrane depolarization. This can relieve the
magnesium block on NMDA channels as well as open voltage-gated calcium
channels.

With the magnesium block removed, the NMDA receptor is more

susceptible to activation by ambient or even slightly elevated levels of
extracellular Glu (Beal, 1992; Greene and Greenamyre, 1996; Doble, 1999).
Over prolonged periods of time (years) this process becomes similar to what is
seen in acute excitotoxicity. For this reason, it has been postulated that slow,
indirect excitotoxicity is partly responsible for the neuronal loss seen in several
neurodegenerative disorders. Over-activation of the iGluRs are responsible for
these excitotoxic effects (Gardoni and Di Luca, 2006) through the influx of
calcium into the neuron (Doble, 1999).

NMDA receptor antagonists have

beneficial effects on experimental models of PD (Nash et al., 2000; Loschmann
et al., 2004) as well as blocking the development of L-DOPA-induced dyskinesias
(Tahar et al., 2004; Wessell et al., 2004). Clinical trials with memantine, an
NMDA receptor antagonist, have shown functional improvement in AD patients
with severe dementia (Parsons et al., 1999; Winblad and Poritis, 1999; MiguelHidalgo et al., 2002). Memantine does not accumulate in the channel during
normal synaptic activity, which offers a novel approach for the treatment of AD.
This drug blocks high levels of Glu at the NMDA receptor, while allowing
activation by low levels of physiologically relevant neurotransmission. (Hynd et
al., 2004; Lipton, 2005). Finally, ALS is characterized by the selective loss of
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motor neurons that leads to the muscle weakening, paralysis, and eventual
respiratory failure (Williams and Windebank, 1991; Doble, 1999; Rao and Weiss,
2004). While no specific NMDA antagonist drugs have been identified for the
treatment of ALS, riluzole, a drug that inhibits neuronal release of Glu, increased
the lifespan of ALS patients by 3 months (McGreer and McGreer, 2005).
Few studies have examined the cause for these excessive levels of Glu in
neurodegenerative disorders such as ALS, which has the largest body of
evidence supporting that excitotoxicity contributes to the progression of
symptoms (Doble, 1999). In ALS, several parameters involving dysfunction of
glutamatergic neurotransmission have been identified including increased Glu
levels in the CSF, decreased Glu uptake, and elevated amounts of Glu
metabolizing enzymes (Heath and Shaw 2002). Plaitakis and Caroscio (1987)
showed increased fasting plasma levels of Glu in ALS patients, and others have
shown increased levels of Glu in the CSF of ALS patients (Rothstein et al., 1990;
Spreux-Varoquaux et al., 2002). Several studies have also reported contradictory
findings indicating decreases in Glu levels in various regions of post-mortem
CNS tissue in ALS patients compared to controls (Perry et al., 1987; Tsai et al.,
1990). Deficiencies in Glu transporters are also implicated for the reason behind
increased Glu levels in the CNS. Rothstein and colleagues (1992) were the first
to demonstrate decreased Glu transport using synaptosomes from affected brain
areas of ALS patients.

Furthermore, it has been shown that the EAAT2

transporter number is decreased in ALS patients compared to control (Rothstein
et al., 1995; Fray et al., 1998; Sasaki et al., 2000).
However, a study conducted by Malessa and colleagues (1991) showed
alterations in Glu metabolizing enzymes in ALS patients compared to control
patients. In particular, GLUD1 was upregulated in the ventral horn of the spinal
cord of ALS patients compared to controls (Malessa et al., 1991). This enzyme
was also upregulated in the PFC of AD patients (Burbaeva et al., 2005), as well
as schizophrenic patients (Burbaeva, 2003, 2007).

GLUD1 catalyzes a

reversible reaction that favors Glu formation from ammonia and α-ketoglutarate
(Yudkoff et al., 1991; Kanamori and Ross, 1995; Bak et al., 2006). Unfortunately,
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no specific modulators for this enzyme exist, which has prevented appropriate in
vivo study of the role this enzyme plays on glutamatergic neurotransmission. For
this reason, a mouse model was created that overexpresses neuronal GLUD1 in
both the C57BL/6 and BALB/C mouse strains to elucidate the role of GLUD1 on
the neuronal contribution of Glu.
In the present study we examined the differences in stimulus-evoked Glu
release and reuptake (using an isotonic solution of 70 mM KCl and 5 mM Glu; pH
7.4) in the Str of C57BL/6 and BALB/C GLUD1 mice compared to wildtype (WT)
littermates.

Stimulus-evoked Glu release provides an indication as to any

differences upregulation of GLUD1 causes in the amount of Glu available for
neuronal release. Examining reuptake of stimulus-evoked Glu release as well as
clearance of exogenously applied Glu provided information regarding Glu
transporter availability or function in the transgenic mice compared to WT
controls.
Methods
All transgenic mice were developed at the University of Kansas by Dr.
Elias K. Michaelis’s laboratory. The GLUD1 transgene was inserted into the
mouse genome under the control of the Neuronal specific enolase (NSE)
promoter. The NSE promoter has been shown to be expressed only in neurons
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997). Transgenic
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with
vectors containing cDNA of mouse GLUD1 placed under the control of the NSE
promoter.

This promoter was excised from the pNSE-LacZ vector by first

digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.
The NSE promoter was also excised and cloned into the modified pGEM-7Z.
Finally, a GLUD1 open reading frame was cloned into the pNSE-GEM-7Z to
create the pNSE-GLUD1 vector. This vector was digested, the DNA recovered,
and microinjected into the nucleus of fertilized mouse ooctyes to generate the
GLUD1 transgenic mice.
BALB/C mice.

Oocytes were transferred to surrogate C57BL/6 or

Pups carrying the transgene were identified by PCR and
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Southern Blot Analysis.

Progeny were eventually backcrossed into both a

C57BL/6 or BALB/C mouse strains. Our colleagues were interested in examining
the in vivo effects of this enzyme in two different strains of mice, because of
western blot studies that indicated exogenous expression of GLUD1 was
increased in C57BL/6 mice compared to BALB/C mice (figure 3.1). Gene copy
number was assayed by Southern Blot analysis and determined to be
upregulated three to four-fold in the transgenic mouse strains compared to WT
littermates through the first four generations of breeding.
GLUD1 transgenic and WT C57BL/6 and BALB/C mice were transported
to the University of Kentucky and housed as described in Chapter Two. Male
C57BL/6 and BALB/C mice between the ages of 8 and 12 months were used at
the time of recordings. Mice were given 3 i.p. injections of 12.5% urethane for a
total dose of 1.25 g/kg. All studies were conducted in the Str. Glu recordings
were conducted using enzyme-based MEAs with a sampling rate of 1 Hz. as
previously described in Chapter Two. At the time of our studies in the C57BL/6
GLUD1 transgenic mice, self-referencing techniques were not being utilized. As
our MEA technology progressed, self-referencing was routinely utilized including
the study with BALB/C GLUD1 transgenic mice. A craniotomy was performed
over both striatal hemispheres and MEAs were positioned using the coordinates
from Paxinos and Franklin (2004) (AP: +0.9 mm; ML ± 1.5, ±1.7 mm; DV: -2.35, 2.85, -3.35, -3.85 mm) in order to create a depth profile of the Str in transgenic
and WT mice. A glass micropipette with an internal diameter of 10-12 µm was
attached to the PCB and positioned among the 4 Pt recording sites, resting 50100 µm above the recording surface. Through this glass micropipette isotonic
solutions of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2; pH 7.4) or 5
mM Glu (in 0.9% saline; pH 7.4) were locally applied to the surrounding brain
tissue to study glutamatergic neurotransmission. Upon initial MEA implantation, a
stable baseline recording was obtained for at least 30 minutes prior to local
application of solutions. When self-referencing MEAs were used, resting Glu
levels were calculated at the end of this initial baseline time period. After the
initial baseline recording, solutions were locally applied at regular 30 second
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Figure 3.1: Western Blot Analysis of Exogenous GLUD1
C57BL/6 mice showed increased endogenous expression for the enzyme GLUD1 compared to
BALB/C mice.

BALB/C mice had approximately 55% the endogenous activity of GLUD1

compared to C57BL/6 levels. Data table and blots supplied by the University of Kansas.
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intervals (for a total of 20 signals; 10 signals from each Pt recording site) to
assess Glu dynamics at each dorsal ventral position. Due to the reproducibility
of Glu signals in vivo (figure 3.2), all signals for a particular depth were averaged
into a single data set for that depth. Data analysis involved a two-tailed student’s
t-test comparing GLUD1 transgenic to WT for each strain. All data is reported as
mean ± standard error of the mean and significance was defined as p < 0.05.
Results
The fact that α-ketoglutarate was a product of GluOx activity and a
substrate for GLUD1, we needed to determine the concentration of αketoglutarate that would significantly decrease our MEA response to Glu. To do
this we calibrated the same GluOx MEA in 0.05M PBS with varying
concentrations of α-ketoglutarate in the buffer.

We determined that

approximately 5 mM α-ketoglutarate was required before a significant (p<0.05)
drop in MEA sensitivity to Glu was observed (figure 3.3). MEA current values
after calibration in increasing buffer concentrations of α-ketoglutarate are shown
in table 3.1.

Dicarboxylate transporters were found on both astrocytes and

neurons indicating that α-ketoglutarate existed in the same location as our
recordings, the extracellular space. While no studies were found that determined
the relative KM values for these transporters with α-ketoglutarate, KM values for
similar TCA cycle substrates were found in the tens of micromolar range (Pajor,
2006). This was much less than the approximate 5 mM concentration needed to
significantly reduce MEA sensitivity to Glu.
In the C57BL/6 GLUD1 transgenic and WT mice, local application of 70
mM KCl resulted in robust, reproducible Glu signals compared to baseline.

We

also observed that the GLUD1 transgenic mice released more Glu upon
depolarization compared to WT littermates (Figure 3.4).

To quantitate this

finding, we volume matched the amount of stimulus locally applied to both mouse
groups. Only Glu signals that were elicited by 100 to 200 nl of 70 mM KCl were
used for this analysis, therefore, no significant difference in the amount of
stimulus used was observed between the GLUD1 transgenic (134 ± 8 nl) and WT
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Figure 3.2: Reproducibility of Glu Signals From 70 mM KCl Depolarization
The above trace demonstrated the reproducibility of Glu signals elicited due to stimulus-evoked
release by 70 mM KCl. Signals were from a GLUD1 transgenic BALB/C mouse and taken at
approximately 30 second intervals. The reproducibility of the Glu signals allowed us to average
the individual signals for a given depth into a single data set.
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Figure 3.3: Effects of α-Ketoglutarate on MEA Sensitivity
All four sites of a Glu selective MEA were coated with GluOx and its response to Glu was
determined in 0.05 M PBS with increasing concentrations of α-ketoglutarate. Concentrations of 5
mM α-ketoglutarate and higher significantly (*p<0.05; #p<0.001) decreased the MEA sensitivity to
Glu. Data was from a single MEA over four trials. A one-way analysis of variance (ANOVA) with
Tukey’s post hoc was used to determine significance.

73

Table 3.1: Amperometric Glu Current with Increasing Buffer Concentration of
α-Ketoglutarate
[α-KG]
(mM)
Current
(pA)

0

1

3

5

7

10

47.2 ± 3.2

44.1 ± 3.3

36.1 ± 3.5

32.9 ± 3.2

25.5 ± 2.7

23.3 ± 2.8

Data is averaged from a single MEA over four trials and shown as mean ± standard error of the
mean.
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Figure 3.4: 70 mM KCl-Evoked Glu Release Traces in the C57BL/6 Mouse
Series of amperometric Glu recordings showing differences in volume matched, stimulus-evoked
Glu release in WT (red) and GLUD1 (blue) transgenic C57BL/6 mice. Note the reproducibility of
the signal and the significantly increased release of Glu in the GLUD1 transgenic mice compared
to WT. Arrows indicate time points for local application of an isotonic solution of 70 mM KCl (pH
7.4).
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(140 ± 6 nl) mice (figure 3.5A). When the average maximal amplitude of Glu
release is quantitated, C57BL/6 GLUD1 transgenic mice (9.9 ± 1.4 µM) released
significantly more Glu (p < 0.05) compared to WT littermates (6.3 ± 0.7 µM)
(figure 3.5B). Using the same subset of signals, striatal, depth-related alterations
in stimulus-evoked Glu release were also examined (figure 3.6). The average
Glu release was calculated at each depth (DV -2.25 to -3.75 mm) and compared
amongst C57BL/6 GLUD1 transgenic and WT mice. No significant differences
were seen within groups of mice, however, a significant difference (p<0.05) in
Glu release was observed at depth -2.25 and -3.25 mm between GLUD1
transgenic (9.5 ± 1.4 µM and 12.7 ± 3.0 µM, respectively) and WT mice (5.4 ± 0.6
µM and 5.7 ± 0.8 µM, respectively).
Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics
(Nicholson, 1995) and was affected by the amount of available substrate, Glu
uptake was analyzed by selecting a subset of signals with maximum release
values were in the range of 3-13 µM. This range was chosen, because these
peak Glu values were easily obtainable in both groups. Within this subset of
signals, no significant difference in average maximum release of Glu was
observed in WT (6.3 ± 0.4 µM) and GLUD1 transgenic mice (7.8 ± 0.6 µM), nor
was a significant difference in the uptake rate of stimulus-evoked Glu release
observed between WT (1.8 ± 0.2 µM/sec) and GLUD1 transgenic mice (1.9 ± 0.3
µM/sec) (figure 3.7).
Because Glu transporters were electrogenic (Takahashi et al., 1997,
Doble, 1999) and the introduction of potassium ions and subsequent membrane
depolarization changed their function, we wanted to determine transporter
function without membrane depolarization.

To do this, we locally applied an

isotonic solution of 5 mM Glu (pH 7.4) and used a subset of Glu signals that were
in the same range as those used for our stimulus-evoked Glu uptake analysis, 313 µM.

There was no significant difference in the maximal amplitude of

exogenously applied 5 mM Glu in the C57BL/6 GLUD1 transgenic (7.7 ± 0.8 µM)
and WT (9.5 ± 0.4 µM) mice (figure 3.8A). Similar to the stimulus-evoked Glu
data, there was no significant difference in the clearance rate for locally applied
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Figure 3.5: Stimulus-Evoked Glu Release in C57BL/6 GLUD1 Transgenic Mice
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 100 and
200 nl were analyzed for the C57BL/6 GLUD1 transgenic (n=4) and WT (n=9) mice. Since the
volumes were matched, no significant difference in the amount of stimulus locally applied was
observed between WT (140 ± 6 nl) and transgenic mice (134 ± 8 nl). B) The average maximal
amplitude of Glu released after local application of 70 mM KCl was significantly increased
(*p < 0.05) in the GLUD1 transgenic (9.9 ± 1.4 µM) compared to WT littermates (6.3 ± 0.7 µM).
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Figure 3.6: Stimulus-Evoked Glu Release Depth Profile in the C57BL/6 Mouse
Average stimulus-evoked Glu release at different recording depths within the Str of C57BL/6
GLUD1 transgenic (n=4) and WT (n=9) mice. GLUD1 transgenic mice released significantly
(*p<0.05) more Glu compared to WT littermates at depths -2.25 and -3.25 mm. At recording
depths -2.75 and -3.75 mm there was no significant difference in the amount of Glu released
between the two mouse groups. (*p<0.05 based on a two-tailed t-test for comparing mouse
groups at individual recording depths).
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Figure 3.7: Stimulus-Evoked Glu Uptake in the C57BL/6 Mouse Groups
A) To properly study uptake kinetics, a subset of Glu signals were examined whose average
maximal amplitude fell in a range of 3-13 µM for both the C57BL/6 GLUD1 transgenic (n=4) and
WT (n=9) mice. No significant difference was observed between WT (6.3 ± 0.4 µM) and GLUD1
transgenic (7.8 ± 0.6 µM) mice. B) There was no significant difference in the uptake rate of
stimulus-evoked Glu between WT (1.8 ± 0.2 µM/sec) and GLUD1 transgenic mice (1.9 ± 0.3
µM/sec).
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Figure 3.8: Clearance of Exogenously Applied 5 mM Glu
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for both the C57BL/6 GLUD1 transgenic (n=4) and WT (n=9) mice.

No significant

difference was observed between WT (9.5 ± 0.4 µM) and GLUD1 transgenic (7.7 ± 0.8 µM) mice.
B) There was no significant difference in the rate of Glu clearance between WT (2.9 ± 0.2
µM/sec) and GLUD1 transgenic mice (2.5 ± 0.5 µM/sec).
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5 mM Glu in the WT (2.9 ± 0.2 µM/sec) and GLUD1 transgenic mice (2.5 ± 0.5
µM/sec) (figure 3.8B).
In the BALB/C GLUD1 transgenic and WT mice, local application of 70
mM KCl resulted in robust, reproducible Glu signals compared to baseline similar
to what was observed in the C57BL/6 mouse groups. From these traces we
noticed that the BALB/C GLUD1 transgenic mice released more Glu upon
depolarization compared to WT littermates (Figure 3.9).

To quantitate this

finding, we volume matched the amount of stimulus locally applied to both mouse
groups. Only Glu signals that were elicited by 50 to 150 nl of 70 mM KCl were
used for this analysis, therefore, no significant difference in the amount of
stimulus used was observed between the BALB/C GLUD1 transgenic (106 ± 4 nl)
and WT (98 ± 5 nl) mice (figure 3.10A). When the average maximal amplitude of
Glu release is quantitated, BALB/C GLUD1 transgenic mice (5.2 ± 0.4 µM)
released significantly more Glu (p < 0.05) compared to WT littermates (3.9 ± 0.4
µM) (figure 3.10B).

Using the same subset of signals, striatal, depth-related

alterations in stimulus-evoked Glu release were also examined (figure 3.11). The
average Glu release was calculated at each depth (DV -2.25 to -3.75 mm) and
compared amongst the BALB/C mouse groups. No significant differences were
seen within groups of mice, however, a significant difference (p<0.01) in Glu
release was observed at the ventral depth of -3.25 mm between GLUD1
transgenic (6.1 ± 0.7 µM) and WT mice (2.7 ± 0.4 µM).
Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics
(Nicholson, 1995) and was affected by the amount of available substrate, Glu
uptake was analyzed by selecting a subset of signals with maximum release
values were in the range of 3-13 µM. This range was chosen, because these
peak Glu values were easily obtainable in both groups. Within this subset of
signals, no significant difference in average maximum release of Glu was
observed in WT (5.2 ± 0.3 µM) and GLUD1 transgenic mice (5.4 ± 0.3 µM), nor
was a significant difference in the uptake rate of stimulus-evoked Glu release
seen between WT (1.3 ± 0.1 µM/sec) and GLUD1 transgenic mice (1.6 ± 0.2
µM/sec) (figure 3.12).
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Figure 3.9: 70 mM KCl-Evoked Glu Release Traces in the BALB/C Mouse
Series of amperometric Glu recordings showed differences in volume matched stimulus-evoked
Glu release in WT (red) and GLUD1 (blue) transgenic BALB/C mice. Note the reproducibility of
the signal and the significantly increased release of Glu in the GLUD1 transgenic mice compared
to WT. Arrows indicate time points for local application of an isotonic solution of 70 mM KCl (pH
7.4).
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Figure 3.10: Stimulus-Evoked Glu Release in BALB/C GLUD1 Transgenic Mice
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150
nl were analyzed for the BALB/C GLUD1 transgenic (n=4) and WT (n=5) mice.

Since the

volumes were matched, no significant difference in the amount of stimulus locally applied was
observed between WT (98 ± 5 nl) and transgenic mice (106 ± 4 nl). B) The average maximal
amplitude of Glu released after local application of 70 mM KCl was significantly increased (*p <
0.05) in the GLUD1 transgenic (5.2 ± 0.4 µM) mice compared to WT littermates (3.9 ± 0.4 µM).
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Figure 3.11: Stimulus-Evoked Glu Release Depth Profile in the BALB/C Transgenic Mice
Average stimulus-evoked Glu release at different recording depths within the Str of BALB/C
GLUD1 transgenic (n=4) and WT (n=5) mice. GLUD1 transgenic mice (6.1 ± 0.7 µM) released
significantly (**p<0.01) more Glu compared to WT littermates (2.7 ± 0.4 µM) at depth -3.25 mm.
At the other three recording depths, there was no significant difference in the amount of Glu
released between the two mouse groups.

(Significance based on a two-tailed t-test for

comparing mouse groups at individual recording depths).
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Figure 3.12: Stimulus-Evoked Glu Uptake in the BALB/C Mouse Groups
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for both the BALB/C GLUD1 transgenic (n=4) and WT (n=5) mice.

No significant

difference was observed between WT (5.2 ± 0.3 µM) and GLUD1 transgenic (5.4 ± 0.3 µM) mice.
B) There was no significant difference in the rate of stimulus-evoked Glu clearance between WT
(1.3 ± 0.1 µM/sec) and GLUD1 transgenic mice (1.6 ± 0.2 µM/sec).
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Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997;
Doble, 1999), we wanted to determine transporter function without membrane
depolarization. Do to this, we locally applied an isotonic solution of 5 mM Glu
(pH 7.4) and used a subset of Glu signals that were in the same range as those
used for our stimulus-evoked Glu uptake analysis (3-13 µM). There was no
significant difference in the maximal amplitude of exogenously applied 5 mM Glu
in the BALB/C GLUD1 transgenic (7.8 ± 0.3 µM) and WT (8.3 ± 0.3 µM) mice
(figure 3.13A). Similar to the stimulus-evoked Glu data, there was no significant
difference in the clearance rate for locally applied 5 mM Glu in the WT (2.5 ± 0.2
µM/sec) and GLUD1 transgenic mice (2.4 ± 0.5 µM/sec) (figure 3.13B).
Since self-referencing MEAs were used to study the BALB/C GLUD1
transgenic mice, we were able to determine resting Glu levels in the Str. Thirty
second baseline measures were taken prior to local application of 70 mM KCl at
each recording depth. Resting Glu levels were only measured when 70 mM KCl
was in the barrel of the glass micropipette. Possible diffusion of 5 mM Glu out of
the barrel could cause unphysiologically elevated resting Glu levels. Using our
self-referencing recording techniques, resting Glu levels were determined and
found to be similar in the Str of both WT (0.8 ± 0.1 µM) and GLUD1 transgenic
mice (0.8 ± 0.2 µM; figure 3.14A).

Additionally, a depth analysis profile revealed

resting Glu levels were similar at all recording depth within mouse groups and
across groups of mice at individual depths (figure 3.14B).
Because the immunohistochemical data obtained from the University of
Kansas revealed that endogenous expression of GLUD1 in the BALB/C mouse
strain was approximately 55 percent the C57BL/6 strain (figure 3.15A), we
wanted to compare maximal amplitude of stimulus-evoked Glu release in the WT
and GLUD1 transgenic mouse strains. When we compared the BALB/C WT
mice to the C57BL/6 WT mice we saw that the BALB/C WT mice released
significantly (p<0.01) less Glu upon stimulation compared to the C57BL/6 WT
mice (figure 3.15B). The average maximal values in the BALB/C WT mice were
approximately 62 percent of the C57BL/6 WT mice. The BALB/C GLUD1
transgenic mice released significantly (p<0.001) less Glu upon stimulation
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Figure 3.13: Clearance of Exogenously Applied 5 mM Glu in BALB/C Mice
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for both the BALB/C GLUD1 transgenic (n=3) and WT (n=3) mice.

No significant

difference was observed between WT (7.8 ± 0.3 µM) and GLUD1 transgenic (8.3 ± 0.3 µM) mice.
B) There was no significant difference in the rate of exogenously applied Glu clearance between
WT (2.5 ± 0.2 µM/sec) and GLUD1 transgenic mice (2.4 ± 0.2 µM/sec).
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Figure 3.14: Resting Glu Levels in the BALB/C GLUD1 Transgenic Mice
A) Averaged resting Glu levels were determined for the entire Str and no significant difference
was found between WT (0.8 ± 0.1 µM) and GLUD1 transgenic mice (0.8 ± 0.2 µM). B) Average
resting Glu levels were determined for each depth within the Str. No significant difference was
observed within mouse groups neither at different depths nor across mouse groups at each
recording depth.
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Figure 3.15: Endogenous GLUD1 Expression Correlates with Stimulus-Evoked Glu
Release
A) C57BL/6 mice showed increased endogenous expression for the enzyme GLUD1 compared to
BALB/C mice. BALB/C mice had approximately 55% endogenous activity of GLUD1 compared to
C57BL/6 levels (*p<0.05).

Data table and blots supplied by the University of Kansas.

B)

Comparison of stimulus-evoked Glu release between WT and GLUD1 transgenic mouse groups.
BALB/C WT mice released approximately 62% of the amount of Glu as compared to C57BL/6 WT
mice (**p<0.01) while BALB/C GLUD1 transgenic mice released approximately 53% of the
amount

of

Glu

compared

to

C57BL/6
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GLUD1

transgenic

mice

(***p<0.001).

compared to the C57BL/6 GLUD1 transgenic mice. The average maximal values
of Glu release in the BALB/C GLUD1 transgenic mice were approximately 53
percent of the C57BL/6 GLUD1 transgenic mice. This further supports that an
increase in gene copy number resulted in an increased stimulus-evoked Glu
release.
A microarray study was conducted at the University of Kansas to
determine any additional genes that were up or down regulated in the C57BL/6
mice due to the insertion of the pNSE-lacZ vector with the GLUD1 cDNA insert.
Several genes were upregulated two fold in the C57BL/6 GLUD1 transgenic mice
compared to C57BL/6 WT mice (Table 3.2). The ones related to glutamatergic
neurotransmission involved a mGluR (mGluR7), two different subunits for the
NMDA receptor (NMDA2A and NMDA2B), and a calcium binding protein
(Calbindin-28K).
Discussion
These were the first studies demonstrated by our laboratory that our
MEAs could be used to reliably study Glu in a mouse model. Local application of
70 mM KCl as well as 5 mM Glu resulted in Glu signals that were robust

and

reproducible in both the WT and GLUD1 transgenic mouse strains. We observed
important differences between these two groups of mice that were similar across
strains. First, local application of 70 mM KCl resulted in significantly (p<0.05)
increased release of Glu compared to WT littermates in both the BALB/C and
C57BL/6 mice.

When a depth profile of the Str was analyzed, there were

regional differences in the amount of stimulus-evoked Glu release. Next, we
determined that the rate of uptake for stimulus-evoked Glu release as well as
local application of 5 mM Glu was similar in both the WT and GLUD1 transgenic
mice for both mouse strains. As our MEA methodology advanced, we were able
to use self-referencing techniques to determine resting Glu levels in the BALB/C
mouse. There was no significant difference in resting Glu levels in the BALB/C
WT and GLUD1 transgenic mice. A DNA microarray study revealed that some
genes were upregulated 2 fold in the C57BL/6 GLUD1 transgenic mice compared
to the WT mice.
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Table 3.2: Microarray Comparison of Transgenic to WT GLUD1 C57BL/6 Mice
Gene

Protein

Transgenic/WT Gene Ratio

Grm7

mGluR7

2.092

Grin2a

NMDA2A

2.058

Grin2b

NMDA2B

2.058

Calb1

Calbindin-28K

2.056

A microarray study revealed that additional genes were upregulated two-fold in the GLUD1
transgenic C57BL/6 mouse group compared to WT littermates.
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GLUD1 catalyzes a reversible reaction that favors Glu formation from
ammonia and α-ketoglutarate (Yudkoff et al., 1991; Kanamori and Ross, 1995;
Bak et al., 2006). Unfortunately, no specific modulators for this enzyme exist,
which has prevented appropriate in vivo study of the role this enzyme plays on
glutamatergic neurotransmission.

For this reason, a mouse model was created

that overexpresses neuronal GLUD1 in both the C57BL/6 and BALB/C mouse
strains to elucidate the role of GLUD1 on the neuronal contribution of Glu. Local
application of 70 mM KCl resulted in significantly increased Glu release in the
GLUD1 transgenic mice compared to WT mice for both C57BL/6 and BALB/C
mouse strains. In addition, when a depth profile of the Str was conducted, there
were specific depths where Glu release was significantly increased in the GLUD1
transgenic mice compared to the WT mice. In the C57BL/6 GLUD1 transgenic
mice, depths -2.25 and -3.25 mm showed significantly increased Glu release
compared to the WT mice.

Only depth -3.25 mm in the BALB/C GLUD1

transgenic mice had significantly increased stimulus-evoked Glu release
compared to WT mice. Depth -2.25 mm was elevated in the BALB/C GLUD1
transgenic mice compared to WT mice, however, it was not significant. This
demonstrated the advantage of our recording capability to measure discrete
regions within a large brain structure. Other in vivo recording techniques, such
as microdialysis, are too large to perform this type of analysis. Because of this
advantage, we have shown that the Str is not a homogenous structure for Glu
release and regional differences exist. More importantly, this was the first study
that shows upregulation of a Glu metabolizing enzyme was responsible for
increased neuronal release of Glu.
The uptake rate for stimulus-evoked Glu release as well as the clearance
of exogenously applied Glu was determined for both mouse strains. There was
no significant difference in the stimulus-evoked Glu uptake rate or clearance of
exogenously applied Glu observed between GLUD1 transgenic and WT mice in
both strains.

However, we did observe that the uptake rate of exogenously

applied Glu was increased in both strains of the GLUD1 transgenic and WT mice
when compared to the uptake of stimulus-evoked Glu. Since Glu uptake was
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driven by electrochemical gradients across the cell membrane to produce a
negative

membrane

potential

(Takahashi

et

al.,

1997;

Doble,

1999),

depolarization of glial membranes by the local application of 70 mM KCl may be
responsible for the decreased stimulus-evoked Glu uptake compared to the
clearance rate of exogenously applied Glu. Despite this, both chemicals showed
the same trends, which indicated that Glu uptake was similar between the
GLUD1 transgenic and WT mice.

Even though the GLUD1 transgenic mice

released significantly more Glu compared to WT mice during chemical
stimulation, they removed this Glu from the extracellular space at the same rate
as WT mice. This meant that extracellular concentrations of Glu in the GLUD1
transgenic mice were elevated for longer periods of time upon stimulation
compared to WT mice. Over a prolonged period of time, these elevated levels
may lead to slow-indirect excitotoxicity.
Using our self-referencing recording techniques, we were able to record
resting Glu levels in the Str of BALB/C WT and GLUD1 transgenic mice. Resting
Glu levels were similar in the WT and GLUD1 transgenic BALB/C mice. This
indicated that ambient levels of Glu were not elevated in the GLUD1 transgenic
mice despite the fact that more Glu was released upon stimulation. One possible
explanation for this finding was that resting Glu levels were analyzed in
anesthetized mice. Anesthetics such as urethane, which was used in these
experiments,

exert

their

effects

by

enhancing

inhibitory

synaptic

neurotransmission as well as inhibiting excitatory neurotransmission (Hara and
Harris, 2002).

Our lab has also demonstrated that urethane significantly

decreased resting Glu levels by 58 percent (Rutherford et al., 2007). Because of
these two factors, anesthetized animal models may not provide accurate
measures of resting Glu and future experiments in awake, freely moving GLUD1
transgenic mice are needed to better determine unstimulated levels of Glu.
To determine additional genes that may have been up or down regulated
due to the introduction of the GLUD1 vector, a DNA microarray study was
conducted on the C57BL/6 mouse strain at the University of Kansas. This study
revealed that gene expression encoding several receptors for Glu signaling were
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increased two fold (table 3.2). The mGluR7 gene was increased. This is a Gprotein coupled inhibitory autoreceptor found on both pre- and post-synaptic
neurons. In addition, two subunits of the NMDA receptor, the NMDA2A and
NMDA2B were increased. The NMDA2A receptor is the subunit for which Glu
binds to open the calcium pore (Furukawa et al., 2005). Finally, the gene for an
intracellular calcium binding protein, Calbindin-28K, was also upregulated.
Calbindin-28K buffers high levels of intracellular calcium, but Calbindin-28K is
found in low levels in motor neurons and is non-existent in spinal motor neurons
(Van Den Bosch et al., 2006). While the microarray study did not correlate gene
copy number to actual protein levels, it seemed evident that the GLUD1
transgenic mice were attempting to compensate for the increased amount of
stimulus-evoked Glu release and the possibility of slow, indirect excitotoxicity.
Upon completion of the study with the GLUD1 transgenic C57BL/6 mouse,
it was decided to let a small group of the transgenic mice age to determine if any
phenotypic traits developed. At 16 months of age, we noticed that the mice
developed lower limb abnormalities that affected their movement, gait, and
righting behavior.
characteristics.

As of yet, BALB/C mice have not displayed such
Upon further histological examination conducted at the

University of Kansas, it was determined that the GLUD1 transgenic mice had
severe atrophy of Betz cells in layer IV of the motor cortex (figure 3.16) as well as
atrophy of the lower motor neuron in the ventral horn of the spinal cord (figure
3.17). These two areas were associated with motoric movement and helped to
explain the motor deficits seen in the GLUD1 transgenic mice at 16 months of
age.
The histology from the University of Kansas was not easily explained by
itself, however, taken as a whole with our in vivo amperometric data we have
proposed a working hypothesis as outlined in figure 3.18.

Upregulation of

GLUD1 genes leads to production of more GLUD1 protein. This in turn lead to
the synthesis of Glu from α-ketoglutarate and subsequent increased vesicle
packaging of Glu in glutamatergic neurons. With increased amounts of Glu in

94

Figure 3.16: C57BL/6 GLUD1 Transgenic Mouse Motor Cortex Histology
The motor cortex of WT (left) and GLUD1 transgenic (right) C57BL/6 mice were stained for
neurons. GLUD1 transgenic mice showed severe atrophy of the large pyramidal neurons in
Layer IV of the motor cortex associated with motor movement. Staining and figures courtesy of
the University of Kansas, Dr. Elias K. Michaelis’ laboratory.
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Figure 3.17: C57BL/6 GLUD1 Transgenic Mouse Spinal Cord Histopathology
The ventral horn of the spinal cord in WT (left) and GLUD1 transgenic (right) C57BL/6 mice were
stained for neurons. GLUD1 transgenic mice showed severe atrophy of the large lower motor
neurons in the ventral horn of the spinal cord associated with motor movement. Staining and
figures courtesy of the University of Kansas, Dr. Elias K. Michaelis’ laboratory.
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vesicles, the GLUD1 transgenic mice release more Glu into the extracellular
space upon stimulus-evoked Glu release as compared to WT mice as shown
with our amperometry data.

Recent data have shown that pre-synaptic

cytoplasmic Glu availability affects the mean quantal amplitude, which implies
increased vesicular filling of Glu and more Glu released upon depolarization.
(Ishikawa et al., 2002; Wilson et al., 2005; Wu et al., 2007).

Our amperometry

data also showed that Glu uptake was the same rate in the GLUD1 transgenic
mice compared to WT mice.

This means that more Glu is available in the

synaptic cleft to activate iGluRs and mGluRs; in particular the NMDA receptor,
whose Glu binding domain has been shown by DNA microarray data to be
upregulated in GLUD1 transgenic mice. Since motor neurons have little to no
calcium sequestering proteins (Van Den Bosch et al., 2005) mitochondria are
forced to buffer the intracellular calcium. Over time, if the mitochondria become
damaged by excessive intracellular calcium, proteases, oxygenases, and
reactive oxygen species (ROS) form, which are key mediators of excitotoxic cell
death (Nicholls and Budd, 2001).

This may explain the severe motor

impairments and histological motor neuron atrophy staining seen in GLUD1
transgenic mice at 16 months of age.
Using in vivo amperometry with our Glu selective MEAs, we demonstrated
that upregulation of GLUD1 led to a significant increase in stimulus-evoked Glu
release in both the C57BL/6 and BALB/C mouse strains. Stimulus-evoked Glu
release was also significantly higher in the C57BL/6 mouse strain compared to
the BALB/C strain possibly due to the higher endogenous activity of GLUD1 in
C57BL/6 mice. We hypothesize that this increased stimulus-evoked Glu release
caused excitotoxicity over time (16 months) that selectively damaged motor
neurons in both the motor cortex and spinal cord leading to severe motoric
deficits in the GLUD1 transgenic mice. Despite the fact that stimulus-evoked Glu
release was elevated in the BALB/C mice, it was not sufficient to cause
excitotoxicity since the same phenotypic traits were not observed in this strain of
mouse. To our knowledge, the GLUD1 transgenic C57BL/6 mouse model was
the first animal model that showed spontaneous motor neurodegeneration.
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Figure 3.18: Proposed Excitotoxic Mechanism for GLUD1 C57BL/6 Mice
Our proposed hypothesis of the excitotoxic mechanism underlying the motor deficits seen in
GLUD1 C57BL/6 trangenic mice. The above figure depicted two synapses, one from a healthy,
WT mouse (left) and the other synapse from GLUD1 transgenic C57BL/6 mice (right).
Upregulation of GLUD1 genes led to production of more GLUD1 protein. This in turn led to the
synthesis of Glu from α-ketoglutarate and subsequent increased vesicle packaging of Glu in
glutamatergic neurons. With increased amounts of Glu in vesicles, the GLUD1 transgenic mice
released more Glu into the extracellular space after stimulus compared to WT.

Glu uptake was

similar between GLUD1 transgenic mice and WT mice. More Glu was available in the synaptic
cleft of GLUD1 trangsenic mice to activate iGluRs and mGluRs; in particular the NMDA receptor,
whose gene for the Glu binding domain was upregulated in GLUD1 transgenic mice. Since motor
neurons had little to no calcium sequestering proteins, mitochondria were forced to buffer the
intracellular calcium. Over time, if the mitochondria became damaged by excessive intracellular
calcium, proteases, oxygenases, and reactive oxygen species (ROS) formed, which were key
mediators of excitotoxic cell death.
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Chapter Four: Glutamate Dynamics in Glutamate Pyruvate
Transaminase Transgenic and Knockout C57BL/6 Mice
Introduction
The glutamate-glutamine cycle is a well understood mechanism that is
essential for glutamatergic neurotransmission.

Upon depolarization and

vesicular release of Glu, the neurotransmitter is taken up into astrocytes by high
affinity transporters (Danbolt, 2001). Once in the astrocytes, Glu is degraded into
glutamine by glutamine synthetase that is localized only in astrocytes. Glutamine
is not neurotoxic and therefore it can be safely transported out of the astrocytes
through System N located on astroglial cells. In the extracellular space,
glutamine is transported into neurons through System A (Bak et al., 2006).
When returned to the neuron, glutamine is converted back into Glu by PAG,
which is located on the inner mitochondrial membrane (Kvamme et al., 2000).
This Glu formed is returned to the cytosol and subsequently packaged into
vesicles for future neurotransmitter signaling.
Since neurons are incapable of net synthesis of Glu from glucose
(Waagepetersen et al., 2005), the Glutamate-glutamine cycle was previously
thought to provide neurons with all the Glu necessary for neurotransmitter
signaling. Because of this theory, the glutamate-glutamine cycle was originally
thought to operate in a stoichiometric one-to-one ratio. For every Glu released,
one glutamine was transported into neurons to replenish the neurotransmitter
pool of Glu. However, recent evidence suggests this theory is simplistic (Broman
et al., 2000; Fonnum, 1993; Peng et al., 1993; Danbolt, 2001; Waagepetersen et
al., 2000; Hertz, 2004; Waagepetersen et al., 2005) due to recent

13

C NMR data

that suggests one-third of the Glu in the Glutamate-glutamine cycle is newly
synthesized from glucose (Gruetter et al., 2001; Hertz, 2004). This indicates that
other enzymes must be responsible for synthesis and degradation of Glu for the
neurotransmitter pool.

Glu is closely related metabolically to the TCA cycle

(Hertz, 2004; Waagepetersen et al., 2005).

For example, when Glu is

transported into astrocytes, it can be metabolized into glutamine by glutamine

100

synthetase or transaminated into α-ketoglutarate.

Alpha-ketoglutarate can

then enter the TCA cycle where it eventually metabolizes into malate, which
decarboxylates into pyruvate and reduces to lactate. Lactate can be transported
out of astrocytes and into neurons by monocarboxylate transporters (Gladden,
2004). Once in the neurons, lactate can oxidize to pyruvate and either re-enter
the TCA cycle or transaminates back into Glu for neurotransmitter packaging and
signaling (Refer to figure 1.2). This example demonstrates one of the many
possible fates of Glu and is used to show the complicated competition for Glu
between cellular energy demands and neurotransmitter signaling. Furthermore,
Hassel and Bråthe (2000) demonstrate that it is possible to obtain Glu formation
independent of glutamine.

This implies that enzymes other than PAG and

glutamine synthetase are responsible for de novo synthesis or degradation of
Glu.

Two such Glu metabolizing enzymes found in neurons are GPT and

GLUD1. Chapter Three highlighted the effects of upregulation of GLUD1 on
increasing Glu for neurotransmitter release.

We wanted to characterize how

upregulation or knockout of the GPT gene affects the neurotransmitter pool of
Glu in the mouse Str.
GPT exists as a dimmer with a molecular mass of approximately 100 kDa
in most species (Saier and Jenkins, 1967). The enzyme catalyzes a reversible
transaminase reaction using pyruvate as a co-substrate to form alanine and αketoglutarate (Figure 1.3A). Biochemical studies show GPT activity in both the
cytosol and mitochondria of astrocytes and neurons (Balazs and Haslam, 1965;
Erecińska et al., 1994), but the greatest activity is found in astrocytes of the
cerebral cortex (Westergaard et al., 1993). It is debated throughout the literature
whether GPT favors Glu degradation (Saier Jr. and Jenkins, 1967; Ruščák et al.,
1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993; Schousboe et
al.,

2003).

This

process

most

likely

depends

on

the

amount

of

substrates/products available. However, Matthews and colleagues (2000, 2003)
demonstrated that GPT is an active Glu degrading enzyme that acts as an
effective neuroprotectant in cell culture models of exogenous and endogenous
Glu excitotoxicity. Unfortunately, GPT does not exist in the extracellular space
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and, due to its large size, is unable to cross the blood-brain barrier. This makes
it an unsuitable candidate for excitotoxicity thereapeutics; nevertheless these
studies demonstrate the propensity for GPT to metabolize Glu.
Due to the broad spectrum of transaminase molecules found in the brain,
there are no specific modulators for this enzyme. To determine the role GPT
plays on the neurotransmitter pool of Glu, two different mouse models were
created.

The first model has upregulated activity of GPT, while the second

model has removed this gene altogether. In the present study we examined the
differences in stimulus-evoked Glu release and reuptake (using an isotonic
solution of 70 mM KCl and 5 mM Glu; pH 7.4) in the Str of GPT transgenic as
well as knockout (KO) C57BL/6 mice. Stimulus-evoked Glu release provides an
indication as to any differences upregulation or KO of GPT causes in the amount
of Glu available for neuronal release. Examining reuptake of stimulus-evoked
Glu release and clearance of exogenously applied Glu provides information
regarding Glu transporter availability or function in the transgenic and KO mice
compared to WT controls.
Methods
All transgenic mice were developed at the University of Kansas by Dr.
Elias K. Michaelis’s laboratory.

A rat GPT transgene was inserted into the

mouse genome under the control of the Neuronal specific enolase (NSE)
promoter. The NSE promoter has been shown to be expressed only in neurons
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997). Transgenic
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with
vectors containing cDNA of rat GPT placed under the control of the NSE
promoter.

This promoter was excised from the pNSE-LacZ vector by first

digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.
The NSE promoter was also excised and cloned into the modified pGEM-7Z.
Finally, a GPT open reading frame was cloned into the pNSE-GEM-7Z to create
the pNSE-GPT vector for the GPT transgenic mice. To create the GPT KO line,
a nonfunctional rat GPT open reading frame was cloned into the pNSE-GEM-7Z
vector. The vector was digested, the DNA recovered, and microinjected into the
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nucleus of fertilized mouse ooctyes to generate either the GPT transgenic or KO
mice. Oocytes were transferred to surrogate C57BL/6 mice. Pups carrying the
transgene were identified by PCR and Southern Blot Analysis. Progeny were
eventually backcrossed into a C57BL/6 mouse strain. Gene copy number was
assayed by Southern Blot analysis and determined to be upregulated three to
four-fold in the transgenic mouse strains compared to WT littermates through the
first four generations of breeding.
GPT transgenic and KO C57BL/6 mice were transported to the University
of Kentucky and housed as described in Chapter Two. For the GPT C57BL/6
mice, males between the ages of 8 and 12 months were used at the time of
recordings. For the GPT KO study, both male and female mice were studied.
Only the results from the female analysis were included in this chapter. Breeding
prevented sufficient numbers of male homozygous mice for complete analysis.
All data regarding male GPT KO mice are found in Appendix A. Mice were given
3 i.p. injections of 12.5% urethane for a total dose of 1.25 g/kg. All studies were
conducted in the Str.

Glu recordings were conducted using enzyme-based

MEAs with a sampling rate of 1 Hz as previously described in Chapter Two. At
the time of our studies in the C57BL/6 GPT transgenic mice, self-referencing
techniques were not utilized.

As our MEA technology progressed, self-

referencing was routinely utilized including the study with GPT KO mice.

A

craniotomy was performed over both striatal hemispheres and MEAs were
stereotaxically placed using the coordinates from Paxinos and Franklin (2004)
(AP: +0.9 mm; ML ± 1.5, ±1.7 mm; DV: -2.25, -2.75, -3.25, -3.75 mm vs bregma)
in order to create a depth profile of the Str. A glass micropipette with an internal
diameter of 10-12 µm was attached to the PCB and positioned among the four Pt
recording sites, resting 50-100 µm above the recording surface. Through this
glass micropipette isotonic solutions of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5
mM CaCl2; pH 7.4) and 5 mM Glu (in 0.9% saline; pH 7.4) were locally applied to
the surrounding brain tissue to study glutamatergic neurotransmission. Upon
initial MEA placement, a stable baseline recording was obtained for at least 30
minutes prior to local application of solutions. When self-referencing MEAs were
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used, resting Glu levels were calculated during this initial baseline time period.
After the initial baseline recording, solutions were locally applied at regular 30
second intervals (for a total of 20 signals; 10 signals from each Pt recording site)
to assess Glu dynamics at each dorsal ventral position. Due to the reproducibility
of Glu signals in vivo (figure 4.1), all signals for a particular depth were averaged
into a single data set for that depth. Data analysis involved a two-tailed student’s
t-test comparing GPT transgenic to WT mice. An ANOVA with a Tukey’s post
hoc test was used to analyze the GPT KO data to compare heterozygous and
homozygous to control. All data was reported as mean ± standard error of the
mean and significance was defined as p < 0.05.
Results
In the C57BL/6 GPT transgenic and WT mice, local application of 70 mM
KCl resulted in robust, reproducible Glu signals compared to baseline (figure
4.2).

We did not observe any significant difference in the amount of Glu

released between transgenic and WT mice.

To quantitate this finding, we

volume matched the amount of stimulus locally applied to both mouse groups.
Only Glu signals that were elicited by 100 to 200 nl of 70 mM KCl were used for
this analysis, therefore, no significant difference in the amount of stimulus applied
was observed between the GPT transgenic (131 ± 7 nl) and WT (140 ± 6 nl) mice
(figure 4.3A).

When the average maximal amplitude of Glu release was

quantitated, there was no significant difference in the amount of Glu released
between WT (6.3 ± 0.7 µM) and GPT transgenic (6.1 ± 0.9 µM) mice (figure
4.3B). Using the same subset of signals, any striatal, depth-related alterations in
stimulus-evoked Glu release were also examined (figure 4.4). The average Glu
release was calculated at each depth (DV -2.25 to -3.75 mm) and compared
amongst groups. No significant differences were seen within groups of mice
across the different depths. On average, GPT transgenic mice released slightly
more Glu compared to WT mice at depth -2.25, 3.25, and 3.75 mm; however, it
was not a significant difference.
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Figure 4.1: Reproducibility of Glu Signals from 70 mM KCl Depolarization
The above trace demonstrated the reproducibility of Glu signals elicited due to stimulus-evoked
release by 70 mM KCl. Signals were from a GPT KO homozygous C57BL/6 mouse and taken at
approximately 30 second intervals. The reproducibility of the Glu signals allowed us to average
the individual signals for a given depth into a single data set. Arrows indicated time point of local
application of an isotonic solution of 70 mM KCl.
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Figure 4.2: 70 mM KCl-Evoked Glu Release Traces in the GPT Transgenic Mice
Series of amperometric Glu recordings showing differences in volume matched stimulus-evoked
Glu release in WT (red) and GPT (blue) transgenic mice. Note the reproducibility of the signal in
both WT and GPT transgenic mice. Arrows indicate time points for local application of an isotonic
solution of 70 mM KCl (pH 7.4).
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Figure 4.3: Stimulus-Evoked Glu Release in GPT Transgenic Mice
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 100 and
200 nl were analyzed for the GPT transgenic (n=4) and WT (n=9) mice. Since the volumes were
matched, no significant difference in the amount of stimulus locally applied was observed
between WT (140 ± 6 nl) and transgenic mice (131 ± 7 nl). B) The average maximal amplitude of
Glu released upon local application of 70 mM KCl was not significantly different in the GPT
transgenic (6.1 ± 0.9 µM) compared to WT littermates (6.3 ± 0.7 µM).
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Figure 4.4: Stimulus-Evoked Glu Release Depth Profile in the GPT Transgenic Mouse
Average stimulus-evoked Glu release at different recording depths within the Str of GPT
transgenic (n=4) and WT (n=9) mice. No significant differences were observed within groups of
mice across the different depths. On average, GPT transgenic mice released slightly more Glu
compared to WT mice at depths -2.25, 3.25, and 3.75 mm; however, it was not a significant
difference. A two-tailed t-test was conducted at each depth for statistical analysis.
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Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics
(Nicholson, 1995) and was affected by the amount of available substrate, Glu
uptake was analyzed by selecting a subset of signals with maximum release
values were in the range of 3-13 µM. This range was chosen, because these
peak Glu values were easily obtainable in both groups. Within this subset of
signals, no significant difference in average maximum release of Glu was
observed in WT (6.3 ± 0.4 µM) and GPT transgenic (6.3 ± 0.6 µM) mice (figure
4.5A). We did observe a significant decrease in the uptake rate of stimulusevoked Glu seen between WT (1.8 ± 0.2 µM/sec) and GPT transgenic (0.7 ± 0.1
µM/sec) mice (figure 4.5B). Using the same subset of signals, we wanted to
examine if there was any depth related alterations in the uptake rate of stimulusevoked Glu release (figure 4.6).

No significant differences were seen within

groups of mice across the different depths. On average, GPT transgenic mice
had slower uptake of Glu compared to WT mice over all depths. This decrease
was only significant (**p<0.01) at DV -3.25 mm between WT (2.0 ± 0.3 µM/sec)
and GPT transgenic (0.6 ± 0.2 µM/sec) mice.
Because Glu transporters are electrogenic (Takahashi et al., 1997; Doble,
1997) and the introduction of potassium ions and subsequent membrane
depolarization changed their function, we wanted to determine transporter
function without membrane depolarization.

To do this, we locally applied an

isotonic solution of 5 mM Glu (pH 7.4) and used a subset of Glu signals that were
in the range of 3-13 µM, which was the same range used to analyze the uptake
of stimulus-evoked Glu. Since we amplitude matched, there was no significant
difference in the maximal amplitude of exogenously applied 5 mM Glu in the GPT
transgenic (8.3 ± 0.6 µM) and WT (9.5 ± 0.4 µM) mice (figure 4.7A). Similar to
the stimulus-evoked Glu uptake data, there was a significant decrease (**p<0.01)
in the clearance rate for locally applied 5 mM Glu for the GPT transgenic (1.7 ±
0.2 µM/sec) mice compared to WT (2.9 ± 0.2 µM/sec) mice (figure 4.7B). Using
the same subset of signals, we wanted to examine if there was any depth related
alterations in the clearance of exogenously applied Glu (figure 4.8).

No

significant differences were seen within groups of mice across the different

109

Figure 4.5: Stimulus-Evoked Glu Uptake in the GPT Transgenic Mouse Groups
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for both the GPT transgenic (n=4) and WT (n=9) mice. No significant difference was
observed between WT (6.3 ± 0.4 µM) and GPT transgenic (6.3 ± 0.6 µM) mice. B) When the
uptake rate of stimulus-evoked Glu was examined, GPT transgenic (0.7 ± 0.2 µM/sec) mice
cleared Glu significantly (***p <0.001) slower compared to WT (1.8 ± 0.2 µM/sec) mice.
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Figure 4.6: Stimulus-Evoked Glu Uptake Depth Profile in the GPT Transgenic Mouse
Average stimulus-evoked Glu release at different recording depths within the Str of GPT
transgenic (n=4) and WT (n=9) mice. No significant differences were observed within groups of
mice across the different depths. On average, GPT transgenic mice had slower uptake of Glu
compared to WT mice across all depths. This decrease was only significant (**p<0.01) at DV
-3.25 mm between WT (2.0 ± 0.3 µM/sec) and GPT transgenic (0.6 ± 0.2 µM/sec) mice. A twotailed t-test was conducted at each depth for statistical analysis.
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Figure 4.7: 5 mM Glu Clearance in the GPT Transgenic Mouse Groups
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for both the GPT transgenic (n=4) and WT (n=9) mice. No significant difference was
observed between WT (9.5 ± 0.4 µM) and GPT transgenic (8.3 ± 0.6 µM) mice. B) When the
clearance of exogenously applied Glu was examined, GPT transgenic (1.7 ± 0.2 µM/sec) mice
cleared Glu significantly (**p <0.01) slower than WT (2.9 ± 0.2 µM/sec) mice.
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Figure 4.8: Exogenously Applied 5 mM Glu Clearance Depth Analysis
Average uptake rate of exogenously applied 5 mM Glu at different recording depths within the Str
of GPT transgenic (n=4) and WT (n=9) mice. No significant differences were observed within
groups of mice across the different depths. GPT transgenic mice had significantly (*p<0.05)
slower uptake than WT mice at depths -2.75 mm (1.5 ± 0.4 µM/sec and 2.8 ± 0.4 µM/sec,
respectively) and -3.25 mm (1.8 ± 0.5 µM/sec and 3.4 ± 0.4 µM/sec, respectively). A two-tailed ttest was conducted at each depth for statistical analysis.
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depths.

We observed that GPT transgenic mice had a significantly (p<0.05)

slower uptake rate of exogenously applied 5mM Glu compared to WT mice at
depths -2.75 mm (1.5 ± 0.4 µM/sec and 2.8 ± 0.4 µM/sec, respectively) and -3.25
mm (1.8 ± 0.5 µM/sec and 3.4 ± 0.4 µM/sec, respectively).
Next, we wanted to perform the same series of recordings in the GPT KO
mouse groups. Local application of 70 mM KCl resulted in robust, reproducible
Glu signals compared to baseline similar to what was observed in the GPT
transgenic mouse groups.

From these traces we noticed that the GPT

heterozygous and WT mice released similar amounts of Glu upon depolarization,
however, the homozygous mice released significantly more Glu than either group
(figure 4.9).

To quantitate this finding, we volume matched the amount of

stimulus locally applied to both mouse groups.

Only Glu signals that were

elicited by 50 to 150 nl of 70 mM KCl were used for this analysis, therefore, no
significant difference in the amount of stimulus used was observed between the
GPT WT (101 ± 4 nl), heterozygous (93 ± 8 nl) and homozygous (107 ± 5 nl)
mice (figure 4.10A). When the average maximal amplitude of Glu release was
quantitated, GPT homozygous mice (5.9 ± 0.8 µM) released significantly more
Glu (p < 0.05) compared to WT (4.1 ± 0.3 µM) and heterozygous (4.0 ± 0.7 µM)
littermates (figure 4.10B).

Using the same subset of signals, striatal, depth-

related alterations in stimulus-evoked Glu release were also examined (figure
4.11). The average Glu release was calculated at each depth (DV -2.25 to -3.75
mm) and compared amongst the GPT KO mouse groups. No significant
differences were seen within groups of mice across all depths. On average, the
GPT homozygous mice released more Glu compared to WT and heterozygous
mice at each recording depth, however, it was not a significant difference at any
recording depth.
Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics
(Nicholson, 1995) and was affected by the amount of available substrate, Glu
uptake was analyzed by selecting a subset of signals with maximum release
values were in the range of 3-13 µM. This range was chosen, because these
peak Glu values were easily obtainable in both groups. Within this subset of
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Figure 4.9: 70 mM KCl-Evoked Glu Release Traces in the Female GPT KO Mice
Series of amperometric Glu recordings showed differences in volume matched stimulus-evoked
Glu release in WT (+/+; red), heterozygous (+/-; blue) and homozygous (-/-; yellow) mice. Note
the reproducibility of the signal in all three groups. The heterozygous mice had similar amounts
of stimulus-evoked Glu release compared to WT mice, while the homozygous mice had increased
release compared to either group. Arrows indicated time points for local application of an isotonic
solution of 70 mM KCl (pH 7.4).
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Figure 4.10: Stimulus-Evoked Glu Release in the Female GPT KO Mice
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150
nl were analyzed for the GPT WT (n=5; +/+; red), heterozygous (n=4; +/-; blue) and homozygous
(n=4; -/-; yellow) mice. Since the volumes were matched, no significant difference in the amount
of stimulus locally applied was observed between WT (101 ± 4 nl), heterozygous (93 ± 8 nl),
homozygous (107 ± 5 nl) mice. B) The average maximal amplitude of Glu released upon local
application of 70 mM KCl was significantly increased (*p < 0.05) in the GPT homozygous mice
(5.9 ± 0.8 µM) compared to WT (4.1 ± 0.3 µM) and heterozygous (4.0 ± 0.7 µM) littermates.
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Figure 4.11: Stimulus-Evoked Glu Release Depth Profile in the Female GPT KO Mice
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT
(n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4; -/-; yellow) mice.

No

significant differences were observed within groups of mice across the different depths. On
average, GPT homozygous mice released slightly more Glu compared to WT and heterozygous
mice at all recording depths; however, it was not a significant difference. A one-way ANOVA
with Tukey’s post hoc was conducted at each depth for statistical analysis.
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signals, no significant difference in average maximum release of Glu was
observed in WT (4.8 ± 0.3 µM), heterozygous (6.0 ± 0.5 µM) and homozygous
(6.1 ± 0.4 µM) mice, nor was a significant difference in the uptake rate of
stimulus-evoked Glu release observed between WT (1.5 ± 0.1 µM/sec),
heterozygous (1.8 ± 0.2 µM/sec), and homozygous (1.6 ± 0.2 µM/sec) mice
(figure 4.12).
Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997;
Doble, 1997), we wanted to determine transporter function without membrane
depolarization. To do this, we locally applied an isotonic solution of 5 mM Glu
(pH 7.4) and examined a subset of Glu signals that were in the range of 3-13 µM,
which was the same range as those used for our stimulus-evoked Glu uptake
analysis.

There was no significant difference in the maximal amplitude of

exogenously applied 5 mM Glu in the GPT WT (8.6 ± 0.3 µM), heterozygous (8.4
± 0.4 µM), and homozygous (7.8 ± 0.3 µM) mice (figure 4.13A).

Unlike the

stimulus-evoked Glu uptake, we observed slower clearance in the heterozygous
(2.5 ± 0.3 µM/sec) mice compared to the WT (3.1 ± 0.2 µM/sec) mice. The
homozygous mice (2.3 ± 0.2 µM/sec) had a significantly (p<0.05) slower
clearance of exogenously applied Glu compared to WT mice (figure 4.13B).
Using the same subset of signals, striatal depth-related alterations in
exogenously applied 5 mM Glu clearance was examined (figure 4.14).

The

average clearance rate was calculated at each recording depth (DV -2.25 to 3.75 mm) and compared amongst the GPT KO mouse groups. No significant
differences were seen within groups of mice across all depths. On average, the
GPT homozygous mice had slower clearance of exogenously applied 5 mM Glu
compared to WT mice at each recording depth, however, it was not a significant
difference at any recording depth.
Since self-referencing MEAs were used to study the GPT KO mice, we
were able to determine resting Glu levels in the Str. Thirty second baseline
measures were taken prior to local application of 70 mM KCl. Resting Glu levels
were only measured when 70 mM KCl was in the barrel of the glass micropipette.
Possible diffusion of 5 mM Glu out of the barrel caused unphysiologically
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Figure 4.12: Stimulus-Evoked Glu Uptake in the Female GPT KO Mice
A) Subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-13
µM for both the GPT WT (n=5; +/+; red), heterozgyous (n=4; +/-; blue), and homozygous (n=4;
-/-; yellow) mice.

No significant difference was observed between WT (4.8 ± 0.3 µM),

heterozygous (6.0 ± 0.5 µM) and homozygous (6.1 ± 0.4 µM) mice. B) When the uptake rate of
stimulus-evoked Glu was examined, no significant differences were seen between WT (1.5 ± 0.1
µM/sec), heterozygous (1.8 ± 0.2 µM/sec), and homozygous (1.6 ± 0.2 µM/sec) mice.
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Figure 4.13: 5 mM Glu Clearance in the Female GPT KO Mice
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 313 µM for the GPT WT (n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4;
-/-; yellow) mice. There was no significant difference in the maximal amplitude of exogenously
applied 5 mM Glu in the GPT WT (8.6 ± 0.3 µM), heterozygous (8.4 ± 0.4 µM), homozygous (7.8
± 0.3 µM) mice. B) We observed slower clearance in the heterozygous (2.5 ± 0.3 µM/sec) mice
compared to the WT (3.1 ± 0.2 µM/sec) mice. The homozygous mice (2.3 ± 0.2 µM/sec) had a
significantly (*p<0.05) slower clearance rate of exogenously applied Glu compared to WT mice.
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Figure 4.14: 5 mM Glu Clearance Depth Profile in the Female GPT KO Mice
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT
(n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4; -/-; yellow) mice.

No

significant differences were observed within groups of mice across the different depths. On
average, GPT homozygous mice had slower clearance of exogenously applied 5 mM Glu
compared to WT mice at all recording depths; however, it was not a significant difference. A oneway ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis.
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elevated levels of resting Glu. Using our self-referencing recording techniques,
resting Glu levels were similar in the Str of WT (0.9 ± 0.1 µM), heterozygous
(1.4 ± 0.4 µM) and homozygous (1.0 ± 0.1 µM) mice (figure 4.15A). Additionally,
a depth analysis profile revealed resting Glu levels were similar at all recording
depth within mouse groups. On average, GPT heterozygous mice had elevated
resting Glu levels at all recording depths, but this was not significant (figure
4.15B).
Discussion
GPT catalyzes a reversible transaminase reaction using pyruvate as a cosubstrate to form alanine and α-ketoglutarate.

It is debated throughout the

literature whether GPT favors Glu degradation (Saier Jr. and Jenkins, 1967;
Ruščák et al., 1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993;
Schousboe et al., 2003). This process most likely depends on the amount of
substrates/products available.

Matthews and colleagues (2000, 2003)

demonstrated that GPT was an active Glu degrading enzyme that acted as an
effective neuroprotectant in cell culture models of exogenous and endogenous
Glu excitotoxicity. The broad spectrum of transaminase molecules in the brain
made it difficult to develop specific modulators for this enzyme. To determine the
role GPT played in glutamatergic neurotransmission, two different mouse models
were created. The first model had upregulated activity of GPT while the second
model had removed this gene altogether.
Local application of 70 mM KCl resulted in robust, reproducible Glu
signals in both the GPT transgenic and GPT KO mouse groups.

When the

average maximal amplitude of Glu release was quantitated we saw no significant
differences between the GPT transgenic and WT littermates nor any significant
depth related differences in stimulus-evoked Glu release between the two
groups. We observed that the GPT transgenic mice had significantly slower
uptake rates of stimulus-evoked Glu as well as clearance of exogenously applied
5 mM Glu. A depth profile revealed GPT transgenic mice, on average, had a
slower rate of Glu uptake compared to WT mice, which became significant at
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Figure 4.15: Resting Glu Levels in the Female GPT KO Mice
A) Resting Glu levels were averaged through the entire Str and no significant (p=0.16) differences
were found between WT (0.9 ± 0.1 µM), heterozygous (1.4 ± 0.4 µM) and homozygous (1.0 ± 0.1
µM) mice. B) Average resting Glu levels were determined for each depth within the Str of WT
(+/+; red), heterozygous (+/-; blue), and homozygous (-/-; yellow). No significant difference was
observed within mouse groups over the different recording depths.

On average, GPT

heterozygous mice had elevated resting Glu levels at all recording depths, but this was not
significant.

A one-way ANOVA with a Tukey’s post hoc was conducted at each depth for

statistical analysis.
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recording depths -2.75 mm and -3.25 mm. In the GPT KO, homozygous mice
had a significantly increased release of Glu compared to WT after local
application of 70 mM KCl. A depth profile revealed that GPT homozygous KO
mice, on average, released more Glu at all recording depths compared to WT
mice. These values were not significant at any recording depth. We observed
no significant difference in the uptake rate of stimulus-evoked Glu release, but
found that the clearance rate after local application of 5 mM Glu in the
homozygous mice was significantly slower compared to WT. A depth profile
showed no significant difference at any of the recording depths.

Since self-

referencing MEAs were used for the GPT KO study, we were able to record
resting Glu levels in these mice. We saw no significant difference in Glu resting
levels among the mouse groups, but GPT heterozygous mice, on average, had
nonsignificantly (p=0.16) higher Glu resting levels compared to WT and
homozygous mice. This was also observed at all recording depths.
We observed no significant difference in stimulus-evoked Glu release in
the GPT transgenic mouse groups. The same experiment in the GPT KO mice
revealed that homozygous mice released significantly more Glu compared to WT
littermates. Depth profiles of the Str showed no significant differences among the
GPT transgenic as well as the GPT KO mice.

The GPT homozygous mice

showed a trend of higher stimulus-evoked Glu release.

Our depth profile

analysis demonstrated the advantage of our recording capability to measure
discrete regions within a large brain structure.

Other in vivo recording

techniques, such as microdialysis, were too large to perform this type of analysis.
Because of this advantage we showed that the Str was not a homogenous
structure for Glu release and regional differences exist. More importantly, we
demonstrated that knockout of a Glu metabolizing enzyme is responsible for
increased neuronal release of Glu. Since cell culture studies have demonstrated
the propensity for GPT to metabolize Glu (Matthews et al., 2000, 2003) it was
reasonable to hypothesize that dysfunction of this gene led to an increase in Glu
availability for vesicular release from neurons. What was more difficult to explain
was the fact that upregulation of the same gene showed no decrease in stimulus-
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evoked Glu release.

Increasing the gene copy number did not necessarily

correlate to an increase in enzyme production.

Also, since Glu is the

predominant excitatory pathway throughout the mammalian CNS, a minimum
amount of Glu must be made available for neurotransmission to maintain normal
brain function (Wojcik et al., 2004; Takamori, 2006). Other Glu metabolizing
enzymes (such as GLUD1, PAG and/or aspartate aminotransferase) may
compensate for the increased activity of GPT and return Glu to those levels seen
for normal neurotransmission as in WT mice.

A quantitative western blot

analysis of Glu metabolizing enzymes must be run to test this hypothesis.
The uptake rate for stimulus-evoked Glu release as well as clearance of
exogenously applied Glu was determined for both GPT transgenic and KO
groups.

We determined that Glu uptake of stimulus-evoked Glu as well as

clearance of exogenously applied Glu was significantly decreased in the GPT
transgenic mice. In the GPT KO mice we saw now significant change in uptake
of stimulus-evoked Glu, but did see a significant decrease in the clearance rate
of exogenously applied 5 mM in the homozygous mouse group.

Since Glu

uptake was driven by electrochemical gradients across the cell membrane to
produce a negative membrane potential (Takahashi et al., 1997; Doble, 1999),
depolarization of glial membranes by the local application of 70 mM KCl may be
responsible for the differences in the uptake rates when compared to clearance
rates of exogenously applied 5 mM Glu in the GPT KO mice. This may also
explain why the uptake rate in both the GPT transgenic and GPT KO was faster
for exogenously applied 5 mM Glu compared to stimulus-evoked Glu uptake.
What was more difficult to explain was how a Glu metabolizing enzyme affected
Glu transporter function. Investigation of the mouse genome revealed that the
mouse GPT and EAAT1 gene are both located on chromosome 15.

We

hypothesize that insertion or disruption of the GPT gene had downstream affects
on the EAAT1 gene. If production of the EAAT1 protein was compromised, this
may explain the significantly decreased uptake rate compared to WT littermates.
Further studies on transporter number or function need to be completed to
address these issues.
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Using our self-referencing recording techniques, we were able to record
resting Glu levels in the Str of GPT KO mice. Resting Glu levels were similar in
the WT, heterozygous, and homozygous mouse groups, despite the differences
seen in stimulus-evoked Glu release as well as decreases in the clearance rate
of exogenously applied Glu in the homozygous mice. These two factors led one
to hypothesize that resting Glu levels were elevated in the homozygous mice
compared to WT littermates. One possible explanation for this finding was that
resting Glu levels were analyzed in anesthetized mice.

Anesthetics such as

urethane exert their effects by enhancing inhibitory synaptic neurotransmission
as well as inhibiting excitatory neurotransmission (Hara and Harris, 2002). Our
laboratory has also demonstrated that urethane significantly decreased resting
Glu levels by 58 percent (Rutherford et al., 2007). Because of these two factors,
anesthetized mouse models may not provide accurate measures of resting Glu.
Using in vivo amperometry with our Glu selective MEAs, we demonstrated
that upregulation of GPT did not change stimulus-evoked Glu release, but
significantly decreased the rate at which Glu was cleared from the extracellular
space. Stimulus-evoked Glu release was significantly higher in the homozygous
GPT KO mice. The GPT homozygous mice also showed a significantly slower
ability to clear exogenously applied 5 mM Glu from the extracellular space.
Despite these alterations on glutamatergic neurotransmission, we have not
observed any phenotypic changes in either the GPT transgenic or the GPT KO
mice. The significantly decreased uptake rate seen in GPT transgenic as well as
the GPT homozygous mice was an interesting finding. Studies have found that
EAAT expression or uptake of Glu was decreased in several neurological
disorders including ALS, Huntington’s disease (HD), and AD (Beart and O’Shea
2007).

One would hypothesize to observe similar characteristics as the

aforementioned neurological disorders in these transgenic and KO mice due to
decreased Glu uptake.
Copyright © Kevin Nicholas Hascup
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Chapter Five: Understanding L-Glutamate Dynamics in the
Awake, Freely Moving C57BL/6 Mouse
Introduction
Previous sections have focused on Glu neurotransmission in ethyl
carbamate (urethane) anesthetized transgenic mouse models. Urethane is an
injectible anesthetic widely used in animal research (Hara and Harris, 2002;
Sabeti et al., 2003) that modulates ligand-gated ion channels to mediate
anesthesia-induced CNS depression (Yamakura et al., 2001). It has already
been shown that urethane has minimal affects on dopamine clearance (Sabeti et
al., 2003), which is the reasoning for using this anesthetic by our laboratory for
non-survival surgeries. However, data indicates that urethane inhibits responses
of NMDA and AMPA receptors (Hara and Harris, 2002).

Rutherford and

colleagues (2007) have also demonstrated that urethane can lower resting Glu
levels by 58 percent. In addition, general anesthetics such as isoflurane, can
inhibit NMDA and AMPA receptors (Yamakura et al., 2001; Mellon et al., 2007)
as well as inhibiting potassium-evoked release (Larsen and Langmoen, 1998;
Liachenko et al., 1999) and re-uptake (Liachenko et al., 1999) of Glu. These are
just two examples of commonly used anesthetics in animal laboratories. Many
other general anesthetics affect iGluRs (Perouansky et al., 1998; Yamakura et
al., 2001; Mellon et al., 2007). These studies indicate that most anesthetics exert
some action or affect on the glutamatergic system.

In an attempt to better

understand Glu neurotransmission without the effects of anesthesia, our
laboratory has begun to use the MEA technology in awake, freely moving
animals.
Currently, in vivo microdialysis is the most commonly used technique to
study extracellular Glu in freely moving mice (Olive et al., 2000; Uezono et al.,
2001; Wang et al., 2005; Holmer et al., 2005; Zuo et al., 2006; Hao et al., 2007;
Win-Shwe et al., 2007). Microdialysis utilizes semipermeable membranes to
restrict the diffusion of extracellular molecules or neurotransmitters along their
concentration gradients (Ungerstedt, 1984; Di Chiara et al., 1996). With
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microdialysis, several analytes can be measured simultaneously allowing for
studies of multiple neurotransmitter systems. However, the temporal and spatial
resolution of this technique may be inadequate to properly measure the fast
dynamics of Glu neurotransmission. Strides are being made to increase the
temporal resolution into several second intervals by coupling microdialysis with
capillary electrophoresis (Tucci et al., 1997; Kennedy et al., 2002; Rossell et al.,
2003). Even with these recent improvements, it is unlikely that microdialysis can
achieve the sub-second response time necessary for studying in vivo Glu
dynamics due to diffusion processes required for molecules to cross the dialysis
membrane.

While

collection

and

analyzing

of

microdialysis

samples

corresponding to one second intervals is possible (Rossell et al., 2003), work by
Kennedy’s group shows that band broadening of the sample within the tubing
prevents this technique from achieving response times faster than ten seconds
(Lada et al., 1997). Since Glu neurotransmission occurs on a sub-second to
second time scale (Kinney et al., 1997), faster recording techniques are
necessary to understand its release and uptake dynamics. Furthermore, several
microdialysis studies report that the Glu overflow measured with microdialysis is
not TTX – dependent (Timmerman and Westerink, 1997; Baker et al., 2002;
Melendez et al., 2005). This suggests that Glu signals measured from
microdialysis are not neuronally derived, which does not fulfill the classical
criteria for exocytotic release and questions the source of resting Glu levels
To make matters worse, the large size of the microdialysis probe causes
substantial short- and long-term trauma, which is evidenced by histological,
physiological, and biochemical changes in nearby CNS tissue (Bungay et al.,
2003).

During the first hours after implantation the blood-brain barrier is

disrupted, blood flow to the tissue surrounding the probe is decreased and
release of neurotransmitters is altered (Westerink, 1995).

Positron emission

tomography (PET) imaging has revealed that glucose metabolism is drastically
and irreversibly altered by chronic implantation of a microdialysis cannula/probe
(Schiffer et al., 2006). Three days after implantation a glial barrier is observed
and may account for probe blockage (Benveniste and Diemer, 1987). This glial
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barrier is markedly increased if nonfunctional microdialysis probes are removed
and functional probes are reinserted in an attempt to continue freely moving
studies within the same animal (Georgieva et al., 1992). Clapp-Lilly and
colleagues (1999) demonstrate that ultrastructural damage occurs up to 1.4 mm
away from a microdialysis probe implant site.

In addition, normal dialysate

perfusion and removal of material by the probe may produce concentration
gradients that damage tissue up to several millimeters away from the implant site
(Bungay et al., 1990). The implantation damage caused by microdialysis probes
has

drastic

effects

on

local

neurotransmitter

dynamics.

Carbon

fiber

microelectrodes coupled with voltammetric techniques were used to show that
stimulus-evoked dopamine release is attenuated up to 220-250 µm from the
probe implant site (Yang et al., 1998; Borland et al., 2005). If this probe-induced
trauma along with glial barrier formation is not taken into account for
microdialysis analysis, the estimation of extracellular concentrations and
clearance of neurotransmitters such as DA and Glu can be underestimated (Lu et
al., 1998; Yang et al., 1998; Bungay et al., 2003). Furthermore, Frumberg and
colleagues (2007) demonstrated that rats implanted with microdialysis probes in
the right Str performed significantly worse in object recognition tasks despite no
change in locomotor activity. These studies demonstrate the excessive damage
caused by a dialysis probe as well as question the physiological validity of
dialysis samples.
Within the past decade, several groups have developed Glu selective
microelectrodes to address the above inconsistencies with microdialysis studies
on glutamatergic physiology (Hu et al., 1994; Rahman et al., 2005) and some
studies utilizing these microelectrodes show that Glu is TTX-dependent (Kulagina
et al., 1999; Day et al., 2006; Oldenziel et al., 2006).

Our laboratory has

developed an enzyme-based MEA that is capable of detecting low levels of Glu
on a sub-second time scale (500-800 msec) that is free from CNS interferents
such as DOPAC and AA (Burmeister and Gerhardt, 2001; Burmeister et al.,
2002). These MEAs have been successfully used by our laboratory to measure
Glu dynamics in aged Fischer 344 rats (Nickell et al., 2004; Nickell et al., 2007)
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as well as resting Glu levels in Fischer 344 rats (Day et al., 2006). Even more
recently, our laboratory has successfully modified these MEAs for chronic
recordings in awake, freely moving rats (Rutherford et al., 2007). The present
study concerns the adaptation and validation of these MEAs for selective Glu
recordings in the awake, freely moving mouse model. First, we have adapted
our methodology for chronic recordings of resting and phasic (rapid) changes in
Glu in awake mice. Next, we investigated the reproducibility of such methods for
measures in the C57BL/6 PFC and Str. Finally, we studied the pharmacological
effects TTX and THA have on resting Glu levels in the mouse Str.
Methods
All materials and methods for freely moving recording were thoroughly
outlined in Chapter Two. Male C57BL/6 between the ages of 5 and 6 months
were used at the time of recordings. Glu recordings were conducted using selfreferencing, enzyme-based MEAs with a sampling rate of 1 Hz. A craniotomy
was performed over the Str (AP: +0.9 mm; ML: -1.5 mm; DV: -3.85 mm vs.
bregma) or PFC (AP: +1.54 mm, ML: 0.3 mm, DV: -2.45 mm vs. bregma) and
MEAs were implanted using the coordinates from Paxinos and Franklin (2004).
A stainless steel guide cannula was attached to the PCB and positioned so an
internal, acute stainless steel cannula was positioned among the 4 Pt recording
sites, resting 50-100 µm above the recording surface.

Through this internal

cannula isotonic solutions of 1 mM Glu (in 0.9% saline; pH 7.4); 0.9%
physiological saline, citrate, 100 µM THA, and 1 µM TTX (all pH 7.4) were locally
applied to the surrounding brain tissue to study glutamatergic neurotransmission.
Prior to connecting the mouse pedestal with the FAST 16 Mark II recording
system, mice were allowed to freely roam around the recording chamber for at
least 30 minutes to acclimate to their environment. Once connected to the FAST
16 Mark II recording system, the mice underwent a minimum 60 minute
acclimation period to establish a stable baseline recording.

Following this

acclimation period, the dummy cannula was removed and the internal, acute
cannula (connected to a 10 µl Hamilton Syringe) was inserted into the guide
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cannula on recording sessions when chemicals were locally applied. After the
internal cannula was inserted, another acclimation period of 30 minutes was
allowed to reestablish baseline. Following this period, resting Glu, the effects of
locally applied Glu, TTX or THA were studied for up to three additional hours.
The volumes of locally applied Glu were kept constant at 0.5 µl while the volumes
for locally applied TTX, THA, and appropriate controls, saline (THA) and citrate
(TTX), were kept at 1.0 µl.
Following completion of all recording sessions (after multiple days of
recording), mice were anesthetized with isoflurane and transcardially perfused
with 0.9% saline followed by 4% paraformaldehyde. The brain was removed and
stored in 4% paraformaldehyde for three days followed by storage in 0.1 M
phosphate buffer (10% sucrose) for sectioning and staining to confirm MEA
placement.
Data analysis involved a one-way ANOVA with Tukey’s post hoc to
examine any differences in resting Glu levels, maximal amplitude, t80 and uptake
rate of Glu over multiple days post-implantation. A two-tailed student’s t-test was
used to compare different brain regions on similar days as well as differences in
resting Glu after local application of THA or TTX compared to appropriate
controls (0.9% saline and citrate, respectively). All data were reported as mean ±
standard error of the mean and significance was defined as p < 0.05.
Results
The FAST 16 Mark II recording system along with our modified MEA
allowed for reliable second-by-second recordings of Glu in the Str and PFC of
awake, freely moving mice. We consistently implanted the pedestal assemblies
and recorded Glu for as long as 2 weeks in awake mice. Local application of an
isotonic solution of Glu (1 mM; 0.5 µl; pH 7.4) through the internal cannula was
used to verify Glu recordings in vivo.

Figure 5.1 shows representative Glu

signals in the Str (A) and PFC (B) of awake, freely moving mice. Glu measures
were robust and reproducible within brain regions, and over multiple days (figure
5.2).
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Figure 5.1: Representative Glu Traces After Local Application of 1 mM Glu
Representative traces of locally applied Glu (1 mM; 0.5 µl) in the Str (A) and PFC (B) of male
C57BL/6 mice. Glu was locally applied at the time points indicated by the arrows. A rapid,
reproducible spike was recorded in both brain regions using self-referencing MEAs. Maximal
peak height suggests in vivo Glu signal from local application of Glu (arrows), while baseline
measures suggest resting Glu levels.
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Figure 5.2: Local Application of Glu in the PFC and Str
Locally applied Glu data for days 3, 5, and 7 post-implantation in the Str (A, n=8) and PFC (B,
n=6) of C57BL/6 mice. Glu (0.5 µl, 1 mM) was locally applied in both brain regions over multiple
days and recorded using a self-referencing MEA. Substantial and stable Glu recordings were
observed over all days measured indicating reliable, in vivo Glu measurements for at least 7 days
post-implantation.

Average maximum amplitude over days within brain regions as well as

between the PFC (30.5 ± 7.8) and the Str (35.6 ± 9.9) was not significantly different.
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An isotonic solution of Glu (1 mM; 0.5 µl; pH 7.4) was locally applied in the
PFC and Str of male, C57BL/6 mice on days 3, 5, and 7 post-implantation. As
shown in figure 5.2, Glu signals were reproducible over multiple days within the
Str (figure 5.2A) and PFC (figure 5.2B) as well as similar between the two brain
regions. Table 5.1 provides a list of the average maximum amplitude values on
days 3, 5 and 7 post-implantation for both brain regions.
No significant difference in maximal Glu response was observed between
brain regions after local application of 1 mM Glu. We observed differences in the
clearance of locally applied Glu as shown by the traces in figure 5.3. When we
examined the uptake rate of locally applied 1 mM Glu (figure 5.4) we found that
both the Str (figure 5.4A) and PFC (figure 5.4B) cleared exogenously applied Glu
slower over days, however, this was not significant. We also observed that the
Str (13.4 ± 4.2 µM/sec), on average, had a faster clearance of Glu compared to
the PFC (5.8 ± 1.9 µM/sec), but this was not significant (p=0.17) between brain
regions on either day 3, 5, or 7 post implantation (figure 5.4C).

Table 5.2

provides a list of the average uptake rate values on days 3, 5 and 7 postimplantation. Due to the long duration of decay signals coupled with the fact that
our uptake rate analysis only factors the first 5 seconds of signal decay, we
wanted to examine the time period it takes to clear 80% of the Glu signal (t80)
(figure 5.5). We did not observe any significant difference in the t80 of locally
applied Glu over days in the Str (figure 5.5A) and PFC (figure 5.5B) of C57BL/6
mice. We noticed a nonsignificant increase in t80 over days in both brain regions.
Also, the average t80 was increased in the PFC compared to the Str, which
became significant (p<0.05) on day 7 post-implantation (17.2 ± 2.9 sec and 10.0
± 1.6 sec, respectively). Table 5.2 provides a list of the average t80 values for
days 3, 5 and 7 post-implantation for both brain regions.
Resting Glu measures in the awake mice were measured in the PFC and
Str of male, C57BL/6 mice on days 3 through 7 post-implantation using the selfreferencing technique described in Chapter Two. Briefly, the self-referencing site
current was subtracted from the Glu recording site current, and divided by the
Glu recording site slope obtained from in vitro calibration. We observed no
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Table 5.1: Local Application and Resting Glu Measures on Days 3 through 7 PostImplantation
Days Post-Implantation
3

4

5

6

7

Average

Locally Applied
Glu (μM)

PFC
(n=6)

31.4 ± 7.2

n/a

31.7 ± 7.7

n/a

28.4 ± 8.6

30.5 ± 7.8

Str
(n=8)

35.6 ± 11.3

n/a

36.4 ± 8.7

n/a

34.7 ± 9.7

35.6 ± 9.9

Resting Glu (μM)

Brain
Region

PFC
(n=8)

3.3 ± 1.3

3.2 ± 1.1

4.0 ± 0.9

3.0 ± 0.9

3.0 ± 1.0

3.3 ± 1.0

5.5 ± 1.3

5.0 ± 1.0

5.1 ± 1.1

4.4 ± 1.1

4.9 ± 1.2

5.0 ± 1.2

Str
(n=10)

The extracellular Glu concentrations in the PFC and Str from local application of 1 mM Glu (0.5
µl) and resting Glu levels on days 3 through 7 post-implantation.
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Figure 5.3: Representative Traces of Glu Clearance in the Str and PFC
Local application of 1 mM Glu (0.5 µl; pH 7.4) resulted in similar maximal amplitude between
MEAs implanted in the Str and PFC of C57BL/6 mice. We observed that clearance kinetics were
different between the two brain regions. Traces were from day 3 post-implantation for both brain
regions.
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Figure 5.4: Clearance Rate of Locally Applied 1 mM Glu
Clearance rate of locally applied 1 mM Glu in the Str (A, n=8) and PFC (B, n=6) of C57BL/6 mice
on days 3, 5, and 7 post-implantation. There was non significant decrease in the clearance of
Glu over days within a brain region (p=0.17, Str; p=0.37, PFC). C) Comparison of clearance rate
between brain regions over days. When a two-tailed t-test was used to compare brain regions
over days there was no significant difference in the clearance of exogenously applied 1 mM Glu
on either day 3 (p=0.16), 5 (p=0.28), or 7 (p=0.12).
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Figure 5.5: t80 of Locally Applied 1 mM Glu
The time period for 80 percent of the Glu signal to decay (t80) in the Str (A, n=8) and PFC (B, n=6)
of C57BL/6 mice. There was a nonsignificant trend towards increasing t80 over increasing days
post-implantation (p=0.35, Str; p=0.32, PFC). The PFC of C57BL/6 mice cleared exogenously
applied 1 mM Glu slower compared to the Str of C57BL/6 mice, which was significant (*p<0.05)
on day 7 post-implantation, but not on days 3 (p=0.08) or 5 (p=0.22) post implantation (two-tailed
t-test between Str and PFC on day 7 post-implantation).
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Table 5.2: Clearance Kinetics of Exogenously Applied 1 mM Glu
Days Post-Implantation

Uptake
Rate
(µM/sec)

Brain
Region

3

5

7

Average

PFC (n=6)

7.5 ± 2.1

6.1 ± 2.2

3.7 ± 1.3

5.8 ± 1.9

Str (n=8)

20.7 ± 7.0

10.7 ± 3.2

8.8 ± 2.3

13.4 ± 4.2

PFC (n=6)

7.5 ± 2.1

13.2 ± 2.8

17.2 ± 2.9

12.6 ± 2.6

Str (n=8)

6.9 ± 1.3

8.7 ± 1.5

10.0 ± 1.6

8.5 ± 1.5

t80

(sec)

The clearance of extracellular Glu concentrations after local application of 1 mM Glu (0.5 µl) in
the PFC and Str on days 3 through 7 post-implantation.
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significant difference in resting Glu over days in the Str (figure 5.6A) and the PFC
(figure 5.6B). However, the average resting Glu levels were decreased in the
PFC compared to the Str although not significantly (p=0.31). Table 5.1 provides
a list of the average resting Glu levels for days 3 through 7 post-implantation for
both brain regions.
We wanted to determine how blocking the high-affinity transporters
located on glial cells (Danbolt, 2001) affected resting Glu levels in the Str. To test
this we locally applied 100 µM of THA, a transportable, competitive inhibitor for
all excitatory amino acid transporters (EAAT) (Anderson et al., 2001; Chatton et
al., 2001; Gaillet et al., 2001), in the Str of C57BL/6 mice. Figure 5.7A shows Glu
tracings after local application of 100 µM THA (1.0 µl) in 0.9% saline (pH 7.4) and
0.9% saline control (1.0 µl, pH 7.4). Local application of 100 µM THA in saline
caused a significant increase (p < 0.05) in resting Glu levels (2.9 ± 1.2 µM; n=7)
compared to saline control (0.3 ± 0.1 µM; n=7) (figure 5.7B).

This was

approximately a 60% increase in resting Glu levels in the Str when compared to
our study in table 5.1.
We further investigated the source of resting Glu by determining the extent
of exocytotic release from neurons.

To test this, we locally applied TTX, a

sodium channel blocker that prevented depolarization and subsequently
terminated the action potential-dependent vesicular release of Glu.

Local

application of 1 µM TTX (1.0 µl, pH 7.4), in an isotonic solution of citrate, in the
Str of C57BL/6 mice caused a significant decrease (*p < 0.05) in resting Glu
levels (-1.0 ± 0.2 µM; n=6) compared to an isotonic solution of citrate control (1.0
µl, pH 7.4) (-0.3 ± 0.1 µM; n=6) (figure 5.8). This was approximately a 20%
decrease in resting Glu in the Str when compared to our study in table 5.1.
Finally, we wanted to study the affects of a stressor on resting Glu levels.
To do this, we applied fox urine on a cotton ball and introduced it into the
recording chamber for 5 minutes. The Glu trace in figure 5.9 shows that the fox
urine stressor caused a robust increase (~7 µM) in Glu levels in the Str of
C57BL/6 mice throughout the duration of the stressor (black line). Glu levels
returned to baseline approximately 15 minutes after the stressor was removed.
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Figure 5.6: Resting Glu Levels in the Str and PFC
Resting Glu levels were assessed on days 3 through 7 post-implantation in the Str (A, n=10) and
PFC (B, n=8) of C57BL/6 mice. Self-referencing MEAs were used to determine resting Glu
levels. The self-referencing site current was subtracted from the GluOx coated site current, and
divided by the GluOx slope, to yield resting Glu levels. Average resting Glu over days between
the PFC (3.3 ± 1.0) and the Str (5.0 ± 1.2) of male C57BL/6 mice was not significantly (p=0.31)
different.
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Figure 5.7: Local Application of 100 µM THA
Effects of local application of THA. A) Representative tracings of local application of THA (1.0 µl;
100 µM) and 0.9% saline control (1.0 µl) in the Str of C57BL/6 mice. Local application of THA
resulted in a robust, sustained increase in extracellular Glu compared to saline control.

B)

Change in resting Glu levels were significantly increased with local application of THA (2.9 ± 1.2
µM; n=7) compared to saline control (0.3 ± 0.1 µM; n=7) (*p < 0.05).
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Figure 5.8: Local Application of 1 µM TTX
Effects of local application of TTX. A) Representative tracings of local application of TTX (1.0 µl;
1 µM) and citrate control (1.0 µl) in the Str of C57BL/6 mice. Local application of TTX resulted in
a robust, sustained decrease in extracellular Glu compared to citrate control. B) Change in
resting Glu levels were significantly decreased with local application of TTX (-1.0 ± 0.2 µM; n=6)
compared to citrate control (-0.3 ± 0.1 µM; n=6) (*p <0.05).
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Figure 5.9: Fox Urine Affects Resting Glu Levels
A fox urine soaked cotton ball was introduced into the recording chamber for 5 minutes (black
line). During this time period Glu levels rose to approximately 7 µM above baseline until the fox
urine soaked cotton ball was removed. Glu levels returned to baseline approximately 15 minutes
after removal of the cotton ball.
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Discussion
The objective of this study was to adapt our current method for enzymebased second-by-second Glu detection used in anesthetized animals or isolated
preparations, to a system that can be used in awake, freely moving mice over
multiple days. The small size and lightweight design of the pedestal allowed for
chronic recordings with limited effects on the mouse’s behavior and ability to
perform everyday activities. We also wanted to develop a technology that was
able to record second-by-second measures of Glu over multiple days, unlike
microdialysis studies in freely moving mice, or other animals, that are normally
performed in a single day over minute time scales (Olive et al., 2000; Uezono et
al., 2001; Wang et al., 2005; Holmer et al., 2005 a,b; Zuo et al., 2006; Hao et al.,
2007; Win-Shwe et al., 2007). Similar to the work conducted by Rutherford and
colleagues (2007) this study demonstrated the ability of our enzyme-based MEAs
to reliably measure Glu for at least 7 days post-implantation. In addition, the
small size of the ceramic tip of our MEA produced less damage than a
chronically implanted microdialysis probe (Clapp-Lilly et al., 1999; Borland et al.,
2005; Rutherford et al., 2007), which allowed us to sample physiologically
relevant Glu (Drew et al., 2004). The small size of our MEAs, in conjunction with
our self-referencing capability (Burmeister and Gerhardt, 2001), allowed us to
measure resting levels of Glu and determine that a portion was TTX-dependent
and not from reversal of the high-affinity transporters for Glu as demonstrated
using THA to block the EAATs.
When using in vivo amperometry, the ability to selectively identify the
molecule of interest was questioned; however, our laboratory overcame these
issues.

First, the enzyme-based MEAs differentially recorded a specific

molecule, in this case Glu, due to the high selectivity of GluOx for its substrate
(Glu) (Kusakabe et al., 1983). Varying the applied potential to the Pt recording
surface is another way we identify the molecule of interest.

The reporter

molecule, H2O2 that was produced from the metabolism of Glu by GluOx was
predominantly oxidizable at +0.7 V vs. a Ag/AgCl reference electrode. When the
applied potential is dropped to +0.2 V vs. a Ag/AgCl reference electrode, much of
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the H2O2 was no longer oxidized at the Pt recording surface resulting in a
decrease in signal (Day et al., 2006; Rutherford et al., 2007). Finally, the ability
to perform self-referencing and subtract off interferents from the Glu signal
enhanced the selectivity of our MEA. Since the sentinel sites were not coated
with GluOx, they did not respond to changes in extracellular concentrations of
Glu, thereby allowing us to qualitatively visualize responses that were solely from
a Glu source. Furthermore, the offline subtraction method allowed us to remove
any possible interferents or noise artifacts that quantitatively added to the
extracellular Glu concentration.

Self-referencing methods were employed

throughout this study to ensure that resting and peak responses (maximum
amplitude) were due primarily to changes in extracellular Glu levels.
We locally applied an isotonic solution of Glu (0.5 µl, 1mM) in the PFC and
Str of the C57BL/6 mouse on days 3, 5 and 7 post-implantation to determine the
longevity of the enzyme-based MEA in vivo. We saw no significant change in
MEA sensitivity for Glu in either brain region on days 3 - 7 post-implantation.
Both brain regions had similar responses to local application (0.5 µl) of 1 mM Glu
with the Str (35.6 ± 9.9 µM) having slightly higher responses (p=0.71), on
average, compared to the PFC (30.5 ± 7.8 µM) as shown in table 5.1. Rutherford
and colleagues (2007) observed similar in vivo MEA longevity to Glu in the PFC
and Str of Fischer 344 and Long Evans rat strains. Since there was no decline in
MEA response for Glu we concluded that the enzyme activity of GluOx, when
adhered to our Pt recordings sites of our MEA, was viable for at least 7 days in
vivo. This had important implications as we progress this technology to study
behavior related changes in extracellular Glu over days in the awake, freely
moving mouse.
To better understand the clearance of exogenously applied 1 mM Glu we
examined the uptake rate and time for 80% decay (t80) of the Glu signals on days
3, 5 and 7 post-implantation. We found that in both the PFC and Str there was a
nonsignificant decrease in uptake rate over days.

We also noticed that the

average Glu uptake rate in the Str (13.4 ± 4.2 µM/sec) was increased compared
to the PFC (5.8 ± 1.9 µM/sec), but not significantly (p=0.17). Due to the long
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duration of Glu uptake after local application of 1 mM Glu in the freely moving
mice we also decided to look at the time period for 80 percent of the signal to
decay (t80).

Both the Str (p=0.35) and PFC (p=0.32) had a nonsignificant

increase in t80 over days, which was to be expected since the uptake rate
decreased over days. On average, the PFC (12.6 ± 2.6 sec) had a longer t80
compared to the Str (8.5 ± 1.5 sec), which was significant (p<0.05) on day 7 postimplantation. Since we saw a slower uptake rate in the PFC compared to the Str,
it was expected that the duration of clearance was longer in the PFC. These
differences indicate several possibilities. Clearance differences between brain
regions could indicate that there was a variation in Glu transporter number
between the two brain regions, with the Str having a higher density of
transporters resulting in faster clearance. Addressing changes in Glu clearance
over days within a brain region was more difficult to explain.

Differences in

cellular density and number of synapses between brain regions (and even within
the neocortex) could affect diffusion of neurotransmitters as well as transporter
numbers (DeFelipe et al., 2002). We know that our MEAs caused only limited
damage to the surrounding brain tissue (Rutherford, et al., 2007); however, we
were uncertain on the extent of damage caused by the guide cannula; especially,
when factoring in removal/insertion of the dummy and internal cannula over
multiple days. If we were damaging the surrounding glia, it would go to reason
there would be less transporters available thus slowing Glu uptake over days in
both brain regions (Yi and Hazell, 2006; Beschorner et al., 2007). We were also
unsure of what local application of 1 mM Glu does to the surrounding CNS
tissue.

This could induce transporter trafficking to and from the plasma

membrane thus affecting clearance kinetics over days (Fournier, et al., 2004).
Our MEA self-referencing recording techniques were also used to
effectively and reliably measure resting Glu levels (Day et al., 2006; Rutherford et
al., 2007). As shown in table 5.1 our data indicated that there was no significant
(p=0.31) change in resting Glu levels over days within the PFC and the Str nor
averaged across brain regions (3.3 ± 1.0 µM; 5.0 ± 1.2 µM, respectively). The
limited number of publications using microdialysis in freely moving C57BL/6 mice
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to study resting Glu levels made it difficult to compare the techniques. We were
unaware of any studies using microdialysis in the PFC of freely moving C57BL/6
mice, but Meshul’s group had three separate studies with probe placement in the
Str (Holmer et al., 2005 a,b; Shakil et al., 2005). In table 5.3, our resting Glu
values utilizing our enzyme-based MEA technology coupled with in vivo
amperometry in the Str of freely moving C57BL/6 mice were higher (at least
double in two studies) compared to what Meshul’s group observed using
microdialysis.

These discrepancies may be explained by the difference in

sampling time and method as well as the origin of the Glu pool being sampled.
The small size of our MEA tips caused less damage compared to a microdialysis
probe (Clapp-Lilly et al., 1999; Peters et al., 2004; Borland et al., 2005;
Rutherford et al., 2007) which helped to improve the spatial resolution of the
sampling method (Drew et al., 2004).

Furthermore, our considerably faster

sampling rate allowed us to measure Glu closer to the synapse and subsequently
the neuronal pool of Glu (Drew et al., 2004).
Our laboratory was also interested in determining how resting Glu levels in
the Str were affected by blocking all EAATs using the transportable competitive
inhibitor, THA (Figure 7). Local application of an isotonic solution of 100 µM THA
(1.0 µl, pH 7.4) caused a significant (p<0.05) increase (2.9 ± 1.2 µM) in resting
Glu levels when compared to 0.9% saline control (0.3 ± 0.1 µM). This was an
approximate 60% increase in resting Glu levels in the Str when compared to
averaged resting Glu Str values from table 5.1. Furthermore, local application of
THA resulted in sustained Glu elevation when compared to our data from local
application of exogenous Glu. This was expected since resting Glu was now
competing for uptake with THA whereas exogenously applied Glu induced an
immediate effect without competition for uptake present. When blocking the high
affinity transporters, resting Glu levels were from diffusion from the synapse and
essentially neuronal sources.

Unfortunately, heteroexchange of Glu from

astrocytes cannot be ruled out with transportable inhibitors, however, even nontransportable inhibitors such as D,L-threo-β-benzyloxyaspartate (TBOA) were
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Table 5.3: Comparison of Resting Glu Levels in the Str of C57BL/6 Mice

Author

Technique

Sampling
Interval

Location

Resting Glu (µM)

Hascup, K.N. et al.

amperometry

1 sec

Striatum

5.0 ± 1.2

Holmer, H.K. et al.

microdialysis

15 min

Striatum

3.5 ± 0.1 to 4.2 ± 0.1

Holmer, H.K. et al.

microdialysis

15 min

Striatum

~ 2.75

Shakil, S.S. et al.

microdialysis

15 min

Striatum

1.2 ± 0.1 to 1.8 ± 0.1

Resting Glu levels in the Str of C57BL/6 mice when measured using MEAs compared to studies
using microdialysis probes.
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shown to induce heteroexchange at similar concentrations (Anderson et al.,
2001).
To determine the neuronal contribution to resting Glu levels in the Str, the
sodium channel blocker, TTX, was locally applied adjacent to the MEA. Local
application of an isotonic solution of 1 µM TTX (1.0 µl; pH 7.4) (-1.0 ± 0.2 µM)
caused a significant decrease (p < 0.05) in resting Glu levels compared to citrate
control (1.0 µl; pH 7.4) (-0.3 ± 0.1 µM). This was an approximate 20% decrease
in resting Glu levels in the Str when compared to averaged resting Glu levels
from table 5.1.

This observation was in contrast with several microdialysis

studies examining TTX-dependency in rats (Timmerman and Westerink, 1997)
and further supported findings conducted by our laboratory in rats (Day et al.,
2006) and others using microelectrodes (Kulagina et al., 1999; Oldenziel et al.,
2006).

Unlike other TTX studies using Glu selective microelectrodes in

anesthetized rats, our freely moving mouse studies did not completely attenuate
resting Glu levels for two possible reasons. First, our laboratory demonstrated
that the use of anesthetic significantly decreased resting Glu levels (Rutherford,
et al., 2007) in rats. Anesthetics such as chloral hydrate and urethane exert their
effects by enhancing inhibitory synaptic neurotransmission as well as inhibiting
excitatory neurotransmission (Hara and Harris, 2002); possibly making the
glutamatergic system more susceptible to blockade of sodium channels by TTX.
Second, our concentration of TTX (1 μM) used was 100 fold lower compared to
those used in the anesthetized rat studies (Kulagina et al., 1999; Day et al.,
2006; Oldenziel et al., 2006). It should be noted that TTX concentrations of 5 µM
and higher were locally applied and resulted in severe lower limb paralysis
forcing us to immediately euthanize these mice according to our approved
protocols.
Finally, we wanted to study the effects of a stressor on resting Glu levels.
To do this, we applied fox urine on a cotton ball and introduced it into the
recording chamber for 5 minutes, which resulted in a ~7 µM increase in Glu
levels. Glu levels rose throughout the 5 minute stressor and took approximately
15 minutes to return to baseline after removal. Since this was an odor stressor, it
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took time for the smell to diffuse out of the recording chamber once the cotton
ball was removed, which may explain the prolonged time period for levels to
return to baseline. This experiment demonstrated our ability to record changes in
Glu due to behaviorally related stimuli.
In summary, the present studies using MEAs configured for second-bysecond Glu measurements were viable for at least 7 days post-implantation in
the awake, freely moving mouse. This increased recording time span has helped
us to better understand resting Glu levels.

We observed a nonsignificant

difference in resting Glu levels between the PFC and Str of awake C57BL/6
mice. We also observed that local application of pharmacological agents such
THA and TTX altered resting Glu levels. We saw a significant increase in resting
Glu levels with the addition of THA and a significant decrease in resting Glu
levels with the addition of TTX, which indicated that resting Glu levels were
neuronally derived. These findings provided evidence that the high spatial and
low temporal resolution provided by our MEA technology was necessary to better
understand resting Glu levels. Furthermore the ability to monitor Glu without
anesthesia allowed us to study Glu dynamics for at least 7 days postimplantation. When we couple this finding with our changes in Glu from a
stressor such as fox urine we can design behavioral paradigms to better
understand physiological release and uptake of Glu.

Copyright © Kevin Nicholas Hascup
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Chapter Six: Conclusion
Introduction
The most important findings from our GLUD1 transgenic mouse studies is
their increased stimulus-evoked Glu release as well as their spontaneous motor
neuron degeneration. It is well known that excessive Glu release and activation
of post-synaptic receptors can kill neurons (Olney, 1978). This has undoubtedly
led us to the model excitotoxicity proposed in Chapter III.

Upregulation of

GLUD1 gene leads to production of more GLUD1 protein. This in turn leads to
the synthesis of Glu from α-ketoglutarate and subsequent increased vesicle
packaging of Glu in glutamatergic neurons. With increased amounts of Glu in
vesicles, the GLUD1 transgenic mice released more Glu into the extracellular
space after stimulus compared to WT.

Since there is not a compensatory

increase in Glu uptake in the GLUD1 transgenic mice, more Glu is available in
the synaptic cleft of GLUD1 trangsenic mice to activate iGluRs and mGluRs. In
particular the NMDA receptor, whose gene for the Glu binding domain was
upregulated in GLUD1 transgenic mice. Since motor neurons have little to no
calcium sequestering proteins (Van Den Bosch et al., 2005), mitochondria are
forced to buffer the intracellular calcium. Over time, if the mitochondria become
damaged by excessive intracellular calcium, proteases, oxygenases, and
reactive oxygen species (ROS) form, which are key mediators of excitotoxic cell
death. Despite this model, it doesn’t explain what neurological disease state
these mice most closely represent.

Unfortunately, there is not a simple

relationship between high extracellular levels of glutamate and neuronal death
(Obrenovitch and Urenjak, 1997), which makes narrowing this transgenic mouse
down to a specific disease state a daunting task.
Alzheimer’s Disease
AD is a chronic degenerative neurological disorder characterized by
progressive loss of memory and cognition (Katzman and Saitoh, 1991).
Pathologically, AD is characterized by three major hallmarks: senile plaques
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consisting of amyloid β-peptide (Aβ), neurofibrillary tangles consisting of
hyperphosphorylated tau protein, and loss of synapses (Katzman and Saitoh,
1991).

Since Glu is involved in cognition, it goes to reason that this

neurotransmitter plays a key role in the progression of AD.

Recent studies

suggest that glutamate-induced NMDA receptor activation stimulates amyloid
precursor protein to produce Aβ (Gordon-Krajcer et al., 2002). Burbaeva and
colleagues (2005) determined that GLUD1 was increased in brain tissue
homogenate from the prefrontal cortex (PFC) of Alzheimer’s disease (AD)
patients compared to control patients. This group concludes that alterations in
Glu metabolizing enzymes may be responsible for changes in the extracellular
concentration of Glu.

If an increase in GLUD1 is causing an increase in

extracellular concentrations of Glu, this may lead to over stimulation of NMDA
receptors and excess Aβ production with consequent oxidative stress-induced
neuroexcitotoxicity.

Studies have also shown that the EAAT2 activity is

significantly reduced in the brains of AD patients (Masliah, et al., 1996). Other
studies have found a correlation between loss of glutamine synthetase and
cognitive and functional status of AD patients (Antuono et al., 2001). Inhibition of
Glu transport, coupled with decreased activity of glutamine synthetase or
increased activity of GLUD1, may lead to increased extracellular levels of Glu.
These increased levels of extracellular Glu can cause excessive stimulation of
NMDA receptors and excitotoxic processes involving excess intraneuronal
Calcium accumulation and eventual neuronal death.
The information provided above presents some potential similarities
between the GLUD1 transgenic mice as a model of AD. Our studies have not
directly examined the GLUD1 transgenic mouse brains for formation of senile
plaques or tauopathies.

Staining at the University of Kansas has shown

ubiquitinated protein aggregates in the hippocampus of 16-20 month old GLUD1
mice. These results suggested the appearance of aggresome-like structures in
vulnerable neurons of GLUD1 transgenic mice, indicating neuronal stress. AD
patients show that CA1 neurons are selectively damaged at an early stage of the
disease and the same neurons show accumulations of ubiquitinated-proteins.
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We cannot make definitive conclusions regarding the levels of EAAT2
transporters in the GLUD1 transgenic mice because the appropriate experiments
to examine this have not been conducted. However, no difference in Glu uptake
was observed with our MEA studies. In addition, no studies were conducted to
determine activity of glutamine synthetase. The oxidative stress due to Aβ may
explain EAAT2 and glutamine synthetase dysfunction, but this has not been
elucidated in the GLUD1 motor deficient mice.

The biggest drawback to

elucidating this mouse as a model of AD is the fact that the mice show no
cognitive impairment in behavioral memory studies, a hallmark of AD in humans.
More studies are needed to examine these factors to provide additional
information to better characterize these mice as a model of AD.
Amyotrophic Lateral Sclerosis
ALS is a chronic progressive disorder characterized by the selective
degeneration of motor neurons in the cerebral cortex, brainstem, and spinal cord
(Danbolt, 2001). Symptoms normally are muscular weakness and atrophy which
leads to extensive paralysis and death due to respiratory failure generally within
2-5 years from diagnosis (McGeer and McGeer, 2005). There is a growing body
of evidence implicating excitotoxicity as a contributing factor to motor neuron
injury either as a primary or secondary mechanisms (Heath and Shaw, 2002). A
study conducted by Malessa and colleagues (1991) have shown that GLUD1 is
upregulated in the ventral horn of the spinal cord of ALS patients. It is well
documented that Glu levels are increased in the CSF of ALS patients (Rothstein
et. al, 1990; Doble, 1999; Heath and Shaw, 2002; Spreux-Varoquaux et al.,
2002). Since the GLUD1 reaction favors Glu formation, this finding by Malessa
and colleagues, suggests a causative relation for the increased levels of Glu.
These CSF Glu levels may be high enough to cause excitotoxicity and damage
motor neurons—a hallmark of ALS. Other studies have shown that EAAT2 levels
are lower resulting in reduced uptake of extracellular Glu (Rothstein et al., 1992).
Currently, it is not clear if the reduced EAAT2 expression is the primary event
leading to motor neuron death and ALS or if the reduced expression is secondary
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to the neuron loss; however, available data suggests it to be the later (Danbolt,
2001).
The information presented above provides a strong case for categorizing
the GLUD1 transgenic mice as a model of ALS.

We know from our

electrochemical studies that increased gene copy number leads to an increase of
stimulus-evoked Glu release. At 16 months of age, these mice have obvious
movement and righting impairments. Histological data provided by the University
of Kansas clearly show upper and lower motor neuron atrophy and necrosis in
the GLUD1 transgenic mice. The only piece of evidence not supporting a model
of ALS is a decrease in the EAAT2 levels.

We cannot make definitive

conclusions regarding the levels of EAAT2 transporters in the GLUD1 transgenic
mice because the appropriate experiments to examine this have not been
conducted. However, no difference in Glu uptake was observed with our MEA
studies. If transporter levels are decreased as a secondary mechanism, it might
go to reason that we should not have seen differences in Glu clearance since all
our electrochemical studies were conducted in GLUD1 mice that were 8-12
months of age.

Similar studies in the 16 month motor deficient GLUD1

transgenic mice might help elucidate this question as well as provide us with
more information to better characterize these mice as a model of ALS.
Epilepsy
Epilepsy is a chronic neurological disorder characterized by recurring
seizures. As the principal excitatory neurotransmitter, Glu inevitably plays a role
in the initation and spreading of seizure activity (Danbolt, 2001). Studies have
shown that Glu levels are elevated in patients with various epilepsies and it has
been shown that Glu is elevated patients just prior to the onset of seizures
(Danbolt, 2001). It is not known if defective uptake plays a role in epilepsy in
humans, but reduced expression of transporters has been shown to cause or be
associated with seizures in animal models (Danbolt, 2001). For example, mice
lacking EAAT2 develop spontaneous seizures.
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The motor deficient GLUD1 mice would not be categorized well as a
model of epilepsy. Despite the fact that force plate actometer studies conducted
at the Unversity of Kansas have noted seizure like activity during behavioral
studies in some of the GLUD1 motor deficient mice. However, this does not
explain the motor deficits observed in these mice.

Also, we cannot make

definitive conclusions regarding the levels of EAAT2 transporters in the GLUD1
transgenic mice because the appropriate experiments to examine this have not
been conducted. However, no difference in Glu uptake was observed with our
MEA studies. Based on these findings the GLUD1 motor deficient mice are not a
good model of epilepsy.
Huntington’s Disease
Huntington’s disease (HD) is a neurodegenerative disorder characterized
by adult onset with choreic movements combined with mental impairments. The
gene responsible for HD is localised on chromosome 4 that encodes the protein
huntingtin. The disease is caused by the presence of strings of CAG repeats in
the DNA that introduce polyglutamine sequences into the protein that endows the
protein with neurotoxic properties (Doble, 1999). Initial observations showed that
the NMDA agonist, quinolinic acid, reproduce the lesions seen in HD. Additional
studies suggest that selective neurodegeneration can be produced by energy
impairment, which sensitizes striatal neurons to the excitotoxic effects of Glu,
which is a classic case of slow excitotoxicity.
The motor deficient GLUD1 mice would not be categorized well as a
potential model of HD. The main similarities are centered on the movement
disorders.

Histological studies show that the large upper and lower motor

neurons are deteriorating in the GLUD1 mice. This is unlike HD where the larger
neurons are spared and the medium sized neurons atrophy. Also, there is no
indication that the huntingtin protein is altered in these mice, but a direct
examination of this protein in the GLUD1 mice is needed before anything
definitive can claimed. But based on these early observations, the GLUD1 motor
deficient mice is not a good model of HD.
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Parkinsons Disease
PD is a progressive degenerative neurological disorder pathologically
characterized by motor symptoms that include rigidity, hypokinesia and tremor,
which is a result of massive and selective loss of dopaminergic neurons in the
nigrostriatal pathway (Doble, 1999). This causes imbalance in the motor circuits
in the basal ganglia, which leads to a net increase in inhibitory output from the
basal ganglia to the thalamus (Doble, 1999).

This results in profound

modifications of glutamatergic firing throughout the basal ganglia.

Some

experimental evidence suggests that neurodegeneration of dopaminergic
neurons in substantia nigra involves a toxic action exerted by Glu on the NMDA
receptor.
The motor deficient GLUD1 mice would not be categorized well as a
potential model of HD. The main similarities are centered around the movement
disorders. The main difference is the fact that there appears to be no loss of
dopaminergic neurons in the GLUD1 motor deficient mice. Preliminary studies
conducted in Dr. Don Gash’s laboratory showed no loss of dopaminergic neurons
as well as tyrosine hydroxylase staining for catecholamines.

Since loss of

dopaminergic neurons is a hallmark sign of PD in humans, based on these
preliminary studies, it would be impossible to use the GLUD1 motor deficient
mice as a model of PD.
Final Notes
Based on the data presented for the predominant neurological disorders
described in this chapter, the most likely candidate that the GLUD1 motor
deficient mice would model is ALS.

The GLUD1 mice show spontaneous

motorneuron degeneration around 16 months of age, which is slightly past the
half-way time point of a mouse’s lifespan. This is similar age of onset for people
who develop ALS. The histopathology is similar between ALS and the GLUD1
mice. In both, the spontaneous degeneration is limited to the large upper and
lower pyramidal neurons. More studies are needed to provide a stronger case.
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For example, we have not studied the role of Calcium ions, which is speculated
to lead to formation of reactive oxygen species, which is implicated in models of
excitotoxicity. A long term goal of this project is to provide evidence that shows
the increased levels stimulus-evoked Glu release due to upregulation of the
GLUD1 gene leads to overstimulation of the NMDA receptor and subsequent
Calcium influx and eventual reactive oxygen species formation leading to motor
neuron degeneration. But these early studies indicate something not normally
studied when it comes to neurological disorders.

Dysregulation of Glu

metabolizing enzymes may be the initial event that leads to a cascade of
problems that overtime causes the severe memory or motor impairments. More
studies throughout the scientific community need to be conducted in animal
models of neurological diseases to address this issue.
Copyright © Kevin Nicholas Hascup
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Appendix A: L-Glutamate Dynamics in Male Glutamate Pyruvate
Transaminase Knock Out Mice
Introduction
The development of the GPT KO mouse line was one of several
transgenic mouse lines bred in Dr. Elias Michaelis’s research laboratory at the
University of Kansas. Unfortunately, their laboratory was not equipped or funded
to maintain a large breeding colony for each transgenic model being studied. For
this reason, litters were kept small, which forced our early studies to examine
both male and female GPT KO mice. Our preliminary studies indicated several
gender differences in Glu regulation when examining this first set of GPT KO
mice. This was expected since the limited data examining hormonal regulation
on Glu neurotransmission indicates that female hormones act as antagonists on
iGluRs (Bergeron et al., 1996). Because of its antagonistic effects on iGluRs,
progesterone has been shown to be a successful post-injury treatment for stroke
and traumatic brain injury in both males and females (Stein, 2001). In addition,
recent work suggests that the estrogen receptor alpha (ERα) is found at
extranuclear sites on neurons where they directly modulate excitation or
inhibition (Stein, 2001 and Toran-Allerand, 1996).

Since females, not males

maintain circulating blood plasma levels of progesterone and occasionally
estrogen, we hypothesized that male and female GPT KO mice would differ in
Glu neurotransmission.
These differences we observed in our preliminary studies warranted
further examination with a larger number of animals for both male and female
GPT KO mice. However, due to the age range used in these studies, the small
litters, and the fact that the University of Kansas was performing behavioral and
histological studies on these mice, few male GPT homozygous mice were
available for study. This made it difficult to statistically compare the male and
female GPT KO groups. All data regarding the male GPT KO mice are given
below and general comparisons between genders are discussed.
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Methods
All transgenic mice were developed at the University of Kansas by Dr.
Elias K. Michaelis’s laboratory. A nonfunctional rat GPT transgene was inserted
into the mouse genome under the control of the Neuronal specific enolase (NSE)
promoter. The NSE promoter has been shown to be expressed only in neurons
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997). Transgenic
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with
vectors containing cDNA of nonfunctional rat GPT placed under the control of the
NSE promoter. This promoter was excised from the pNSE-LacZ vector by first
digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.
The NSE promoter was also excised and cloned into the modified pGEM-7Z.
Finally, a nonfunctional GPT open reading frame was cloned into the pNSEGEM-7Z to create the pNSE-GPT vector for the GPT transgenic mice.

The

vector was digested, the DNA recovered, and microinjected into the nucleus of
fertilized mouse ooctyes to generate the GPT KO mice.
transferred to surrogate C57BL/6 mice.

Oocytes were

Pups carrying the transgene were

identified by PCR and Southern Blot Analysis.

Progeny were eventually

backcrossed into a C57BL/6 mouse strain.
GPT KO C57BL/6 mice were transported to the University of Kentucky
and housed as described in Chapter Two. For the GPT KO study, both male and
female mice were studied. Only the results from the male analysis are included
in this Appendix; the female analysis is found in Chapter Four. Breeding limited
sufficient numbers of male homozygous mice (n=2) for complete analysis and
comparison between genders
Mice were given 3 i.p. injections of 12.5% urethane for a total dose of 1.25
g/kg. All studies were conducted in the Str. Glu recordings were conducted
using enzyme-based MEAs with a sampling rate of 1 Hz as previously described
in Chapter Two. A craniotomy was performed over both striatal hemispheres and
MEAs were stereotaxically placed using the coordinates from Paxinos and
Franklin (2004) (AP: +0.9 mm; ML: ± 1.5, ±1.7 mm; DV: -2.25, -2.75, -3.25, -3.75
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mm vs bregma) in order to create a depth profile of the Str in transgenic and WT
mice. A glass micropipette with an internal diameter of 10-12 µm was attached
to the PCB and positioned among the four Pt recording sites, resting 50-100 µm
above the recording surface. Through this glass micropipette isotonic solutions
of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2; pH 7.4) and 5 mM Glu
(in 0.9% saline; pH 7.4) were locally applied to the surrounding brain tissue to
study glutamatergic neurotransmission. Upon initial MEA placement, a stable
baseline recording was obtained for at least 30 minutes prior to local application
of solutions. Since self-referencing MEAs were used, resting Glu levels were
calculated during this initial baseline time period.

After the initial baseline

recording, solutions were locally applied at regular 30 second intervals (for a total
of 20 signals; 10 signals from each Pt recording site) to assess Glu dynamics at
each recording depth. Due to the reproducibility of Glu signals in vivo, all signals
for a particular depth were averaged into a single data set for that depth. Data
analysis involved an ANOVA with a Tukey’s post hoc test to compare GPT KO
groups.

All data was reported as mean ± standard error of the mean and

significance was defined as p < 0.05.
Results
Local application of 70 mM KCl resulted in robust, reproducible Glu
signals compared to baseline. To quantitate the amount of Glu released, we
volume matched the amount of stimulus locally applied to all three mouse
groups. Only Glu signals that were elicited by 50 to 150 nl of 70 mM KCl were
used for this analysis, therefore, no significant difference in the amount of
stimulus used was observed between the GPT WT (107 ± 4 nl), heterozygous
(97 ± 4 nl) and homozygous (109 ± 9 nl) mice (figure A.1A). When the average
maximal amplitude of Glu release was quantitated, GPT heterozygous mice (10.9
± 1.3 µM) released significantly more Glu (p < 0.001) compared to WT (2.9 ± 0.5
µM) and (p < 0.05) homozygous (3.9 ± 1.2 µM) littermates (figure A.1B). Using
the same subset of signals, striatal, depth-related alterations in stimulus-evoked
Glu release were also examined (figure A.2). The average Glu release was

161

Figure A.1: Stimulus-Evoked Glu Release in the Male GPT KO Mice
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150
nl were analyzed for the GPT WT (n=4; +/+; red), heterozygous (n=7; +/-; blue) and homozygous
(n=2; -/-; yellow) mice. Since the volumes were matched, no significant difference in the amount
of stimulus locally applied was observed between WT (107 ± 4 nl), heterozygous (97 ± 4 nl),
homozygous (109 ± 9 nl) mice. B) The average maximal amplitude of Glu released upon local
application of 70 mM KCl was significantly increased (***p < 0.001) in the GPT heterozygous
mice (10.9 ± 1.3 µM; blue) compared to WT (2.9 ± 0.5 µM; red) and homozygous (3.9 ± 1.2 µM;
yellow) littermates. Male GPT heterozygous mice also released significantly (# p < 0.05) more
Glu compared to homozygous mice.
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Figure A.2: Stimulus-Evoked Glu Release Depth Profile in the Male GPT KO Mice
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT
(n=4; red; +/+), heterozygous (n=7; blue; +/-), and homozygous (n=2; yellow; -/-) mice. GPT
heterozygous (15.1 ± 3.6 µM) mice released significantly (p < 0.05) more Glu compared to WT
(2.9 ± 0.9 µM) and homozygous (4.7 ± 2.4 µM) mice at recording depth -2.25 mm. A trend was
also observed for increased Glu release at recording depth -2.75 and -3.75 mm. A one-way
ANOVA with Tukey’s post hoc was conducted at each depth for statistical analysis.
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calculated at each depth (DV -2.25 to -3.75 mm) and compared amongst the
GPT KO mouse groups. GPT KO heterozygous mice released significantly (p <
0.05) more Glu at depth -2.25 mm compared to WT and homozygous mice.
Also, at recording depths -2.75 mm and -3.75 mm the average maximal Glu
released for GPT KO heterozygous mice approached significance (p = 0.07 and
p = 0.06, respectively).
Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics
(Nicholson, 1995) and was affected by the amount of available substrate, Glu
uptake was analyzed by selecting a subset of signals with maximum release
values were in the range of 3-13 µM. This range was chosen, because these
peak Glu values were easily obtainable in both groups. Within this subset of
signals, no significant difference in average maximum release of Glu was
observed in WT (4.8 ± 0.4 µM), heterozygous (5.9 ± 0.3 µM) and homozygous
(6.0 ± 0.4 µM) mice (figure A.3A). We did observe significantly faster Glu uptake
in the GPT KO heterozygous (p < 0.05; 1.8 ± 0.2 µM/sec) and homozygous (p <
0.001; 2.8 ± 0.4 µM/sec) mice compared to WT (1.2 ± 0.1 µM/sec). We also
observed that the GPT homozygous mice had significantly (p < 0.05) faster Glu
uptake compared to heterozygous mice (figure A.3B).

Examining the same

subset of signals, a striatal depth analysis was performed for Glu uptake (figure
A.4). At recording depth -3.75 mm, GPT homozygous mice had a significantly (p
< 0.05) faster Glu uptake rate (2.6 ± 0.4 µM/sec) compared to WT (1.0 ± 0.2
µM/sec) mice. Stimulus-evoked Glu uptake in the GPT heterozygous (3.3 ± 1.2
µM/sec) mice approached significance (p = 0.0513) compared to WT (1.0 ± 0.1
µM/sec) mice at the recording depth -3.25 mm.
Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997;
Doble, 1999), we wanted to determine transporter function without membrane
depolarization. We locally applied an isotonic solution of 5 mM Glu (pH 7.4) and
examined a subset of Glu signals. Unfortunately, the low number of animals
studied for the GPT homozygous group limited the number of signals. For this
reason, we had to analyze signals that were in the range of 8-13 µM, which was
a higher range as those used for our stimulus-evoked Glu uptake analysis.
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Figure A.3: Stimulus-Evoked Glu Uptake in the Male GPT KO Mouse Groups
A) Subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-13
µM for both the GPT WT (n=4; +/+; red), heterozgyous (n=7; +/-; blue), and homozygous (n=2;
-/-; yellow) mice.

No significant difference was observed between WT (4.8 ± 0.3 µM),

heterozygous (6.0 ± 0.5 µM) and homozygous (6.1 ± 0.4 µM) mice. B) When the uptake rate of
stimulus-evoked Glu was examined, both heterozygous (1.8 ± 0.2 µM/sec; blue), and
homozygous (2.8 ± 0.4 µM/sec; yellow) mice had significantly faster Glu uptake (*p < 0.05, ***p <
0.001; respectively) compared to WT (1.2 ± 0.1 µM/sec; red) mice. Also, GPT homozygous mice
had a significantly (#p < 0.05) faster Glu uptake compared to heterozygous mice.

165

Figure A.4: Stimulus-evoked Glu Uptake Depth Profile in the Male GPT KO Mice
Average stimulus-evoked Glu release at different recording depths within the Str of GPT KO WT
(n=4; +/+; red), heterozygous (n=7; +/-; blue), and homozygous (n=2; -/-; yellow) mice.

On

average, GPT homozygous mice had faster uptake of stimulus-evoked Glu compared to WT and
heterozygous mice at all recording depths. This became significant (*p < 0.05) at recording depth
-3.75 mm and approached significance at depth -3.25 mm when compared to WT mice. A oneway ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis.
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When examining this range of signals, there was no significant difference in the
maximal amplitude of exogenously applied 5 mM Glu in the GPT WT (9.4 ± 0.4
µM), heterozygous (9.9 ± 0.4 µM), and homozygous (10.5 ± 0.4 µM) mice (figure
A.5A).

Similar to the stimulus-evoked Glu uptake study, we observed

significantly (p < 0.001) faster uptake in the homozygous (6.1 ± 0.3 µM/sec) mice
compared to the WT (3.0 ± 0.4 µM/sec) and heterozygous (3.6 ± 0.3 µM/sec)
mice (figure A.5B). Using the same subset of signals, striatal depth-related
alterations in clearance of exogenously applied 5 mM Glu was examined (figure
A.6). The average clearance rate was calculated at each recording depth (DV
-2.25 to -3.75 mm) and compared amongst the GPT KO mouse groups. The
clearance of exogenously applied 5 mM Glu was significantly (p < 0.05) faster in
the GPT homozygous mice compared to controls at recording depths -2.75 mm
(6.0 ± 0.5 µM/sec and 2.9 ± 0.8 µM/sec, respectively) and -3.75 mm (6.2 ± 0.7
µM/sec and 2.3 ± 0.4 µM/sec, respectively). At recording depth -3.25 mm, we
observed a nonsignificant increase (p = 0.1) in the clearance of exogenously
applied 5 mM Glu compared to WT littermates. The limited range of amplitudes
chosen for this study made it difficult to obtain enough values to perform
statistical analysis at recording depth -2.25 mm.
Since self-referencing MEAs were used to study the GPT KO mice, we
were able to determine resting Glu levels in the Str. Thirty second baseline
measures were taken prior to local application of 70 mM KCl. Resting Glu levels
were only measured when 70 mM KCl was in the barrel of the glass micropipette.
Possible diffusion of 5 mM Glu out of the barrel caused unphysiologically
elevated levels of resting Glu. Using our self-referencing recording techniques,
resting Glu levels showed a nonsignificant (p=0.09) decreasing trend in
heterozygous (0.9 ± 0.1 µM) and homozygous (0.4 ± 0.1 µM) mice when
compared to control (1.1 ± 0.3 µM) mice (figure A.7A). Additionally, a depth
analysis profile revealed a similar trend at all recording depths to what was
observed when the recording depths were averaged.

GPT control mice had

elevated resting Glu levels at all recording depths, but this was not significant
(figure A.7B).
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Figure A.5: 5 mM Glu Clearance in the Male GPT KO Mouse Groups
A) A subset of Glu signals were examined whose average maximal amplitude fell in a range of 813 µM for the GPT WT (n=3; +/+; red), heterozygous (n=5; +/-; blue), and homozygous (n=2; -/-;
yellow) mice.

There was no significant difference in the maximal amplitude of exogenously

applied 5 mM Glu in the GPT WT (9.4 ± 0.3 µM), heterozygous (9.9 ± 0.3 µM), and homozygous
(10.5 ± 0.4 µM) mice. B) We observed significantly (***p < 0.001;

###

p < 0.001) faster Glu

clearance in the homozygous (6.1 ± 0.3 µM/sec; yellow) mice compared to the WT (3.0 ± 0.4
µM/sec; red) and heterozygous (3.6 ± 0.3 µM/sec; blue) mice.
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Figure A.6: 5 mM Glu Clearance Depth Profile in the Male GPT KO Mice
Average clearance rates of exogenously applied 5 mM Glu at different recording depths within the
Str of GPT WT (n=3; +/+; red), heterozygous (n=5; +/-; blue), and homozygous (n=2; -/-; yellow)
mice. On average, Glu clearance was faster in the GPT homozygous mice compared to controls
at all recording depths. This was significant (*p < 0.05) at recording depths -2.75 and -3.75 mm
and approached significance at recording depth -3.25 mm. A one-way ANOVA with a Tukey’s
post hoc was conducted at each depth for statistical analysis.
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Figure A.7: Resting Glu Levels in the Male GPT KO Mice
A) Resting Glu levels were averaged through the entire Str and no significant (p=0.09) differences
were found between WT (1.1 ± 0.3 µM; n=4; red), heterozygous (0.9 ± 0.1 µM; n=6; blue) and
homozygous (0.4 ± 0.1 µM; n=2; yellow) mice. B) Average resting Glu levels were determined for
each depth within the Str of WT (+/+; red), heterozygous (+/-; blue), and homozygous (-/-; yellow)
mice. No significant difference was observed within mouse groups over the different recording
depths. The slower clearance trend in (A) was observed at each recording depth.
ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis.

170

A one-way

Discussion
The low number of male GPT homozygous mice (n=2) studied made it
difficult to statistically compare groups of male mice as well as compare groups
of mice across gender.

We did, however, observe some drastic differences

between the two genders.

Stimulus-evoked Glu release was significantly

increased in the male GPT heterozygous mice compared to both control and
homozygous mice.

In the female groups only the GPT homozygous mice

showed significantly increased Glu levels compared to WT mice.

When the

uptake of stimulus-evoked Glu release was examined, both heterozygous and
homozygous male mice displayed faster uptake kinetics compared to controls.
The female mice exhibited no differences in uptake kinetics across all three
groups.
Comparing the clearance rates of exogenously applied 5 mM Glu is
difficult. The small number of available homozygous mice studied limited the
range of maximal amplitude to 8-13 µM for analysis. A maximal amplitude range
of 3-13 µM was used to study stimulus-evoked Glu uptake in male and female
mice as well as clearance of exogenously applied 5 mM Glu in female mice.
Because of the different maximal amplitude ranges examined, direct comparison
of uptake or clearance values is skewed.

We observed that male GPT

homozygous mice cleared exogenously applied Glu significantly faster than WT
and heterozygous mice, which was also seen in the uptake analysis of stimulusevoked Glu release in the male GPT KO mice. When comparing gender, female
GPT homozygous mice cleared exogenously applied 5 mM Glu significantly
slower compared to controls.
Using our self-referencing recording techniques, we were able to record
resting Glu levels in the Str of GPT KO male mice. Resting Glu levels were
similar in the WT, heterozygous, and homozygous mouse groups, despite the
differences seen in stimulus-evoked Glu release as well as increases in the
uptake and clearance rates of Glu in the homozygous mice. We did observe a
nonsignificant decrease in resting Glu in the homozygous male mice.
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The

decrease in resting Glu may be due to the significantly increased Glu clearance
in the male homozygous mice. If Glu is cleared from the extracellular space
faster, that may indicate an increased transporter density, which would lower
resting Glu levels. Further studies are needed to determine the validity of this
hypothesis.

In the GPT KO female mice, we did not see any significant

differences in resting Glu levels, but a nonsignificant increase was observed in
the GPT heterozygous female mice. Resting Glu values were similar between
male and female GPT KO mouse groups.
Despite the low number of male homozygous mice studied, there are
obvious differences in Glu regulation between the male and female GPT KO
mice, especially when examining the uptake of stimulus-evoked Glu release and
clearance of exogenously applied Glu.

These comparisons indicate extreme

differences in either the number or function of EAATs in the mouse striatum. By
increasing the number of male GPT homozygous mice in our studies, we can
make some direct comparisons between genders.
Copyright © Kevin Nicholas Hascup
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Appendix B: Understanding L-Glutamate Dynamics in the
Awake, Freely Moving BALB/C Mouse Model.
Introduction
The

C57BL/6

mouse

line

was

used

for

feasibility

and

initial

characterization of the freely moving recording because we anticipated studying
the GLUD1 motor deficient mice. However, as we progress this technology for
behavioral research, it will be important to characterize the BALB/C mouse strain
as well in order to provide a comparative assessment of behavior between
different inbred strains.

Inbred strains of mice differ in their behavioral and

neurochemical responses to stimuli. For example, the BALB/C strain exhibits
neophobia, especially when compared to other inbred strains, which makes them
suitable candidates for anxiety research (Belzung and Griebel, 2001, Belzung et
al., 2001). This increased anxiety reduces their social behavior and increases
aggressive behaviors, which may indicate that the BALB/C mice are a useful
model for identifying gene and neurobiological pathways in autism-related
diseases (Brodkin, 2007).

Studies have also shown that electric footshock

induces a higher increase in dopamine in the PFC of BALB/C mice compared to
C57BL/6 mice (Herve et al., 1979). However, predator stressors such as fox
urine elicit larger DOPAC increases in the PFC of C57BL/6 mice as compared to
BALB/C mice further indicating that neurochemical changes due to stress or
behavior may be situation-specific (Hayley, et al., 2001). For these reasons it is
useful to compare different strains of inbred mice when conducting behavioral
research.
Methods
All materials and methods for freely moving recording were thoroughly
outlined in Chapter Two.

Male BALB/C mice between the ages of 5 and 6

months at the time of recordings were used in these experiments.

Glu

recordings were conducted using self-referencing, enzyme-based MEAs with a
sampling rate of 1 Hz. A craniotomy was performed over the PFC (AP: +1.54
mm; ML: 0.3 mm; DV: -2.45 mm vs. bregma) and MEAs were implanted using
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the coordinates from Paxinos and Franklin (2004).

A stainless steel guide

cannula was attached to the PCB and positioned so an internal, acute stainless
steel cannula was positioned among the 4 Pt recording sites, resting 50-100 µm
above the recording surface. Through this internal cannula isotonic solutions of 1
mM Glu (in 0.9% saline; pH 7.4) or 50 µM (S)-4-Carboxyphenylglycine (CPG)
were locally applied to the surrounding brain tissue to study glutamatergic
neurotransmission. Prior to connecting the mouse pedestal with the mouse hat,
mice were allowed to freely roam around the recording chamber for at least 30
minutes to acclimate to their environment. Once connected to the mouse hat,
the mice underwent a minimum 60 minute acclimation period to establish a
stable baseline recording. Following this acclimation period, the dummy cannula
was removed and the internal, acute cannula (connected to a 10 µl Hamilton
Syringe) was inserted into the guide cannula on recording sessions when
chemicals were locally applied. After the internal cannula was inserted, another
acclimation period of 30 minutes was allowed to reestablish baseline. Following
this period, resting Glu, and the effects of locally applied Glu or CPG were
studied for up to three additional hours. The volumes of locally applied Glu were
kept constant at 0.5 µl while the volume for 50 µM CPG was kept at 1.0 µl.
Following completion of all recording sessions (after multiple days of
recording), mice were anesthetized with isoflurane and transcardially perfused
with 0.9% saline followed by 4% paraformaldehyde. The brain was removed and
stored in 4% paraformaldehyde for three days followed by storage in 0.1 M
phosphate buffer (10% sucrose) for sectioning and staining to confirm MEA
placement.
Data analysis involved a one-way ANOVA with Tukey’s post hoc to
examine any differences in resting Glu levels and maximal amplitude over
multiple days post-implantation. Since only two mice were studied, all data was
reported as mean ± standard deviation and significance was defined as p < 0.05.
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Results
Similar to our studies in the freely moving C57BL/6 mice, the FAST 16
Mark II recording system along with our modified MEA allowed for reliable
second-by-second recordings of Glu in the PFC of awake, freely moving BALB/C
mice. We implanted the pedestal assemblies and recorded Glu for one week in
the awake BALB/C mice. Local application of an isotonic solution of Glu (1 mM;
0.5 µl) through the internal cannula was used to verify Glu recordings in vivo.
Figure B.1 shows representative Glu signals in the PFC of awake, freely moving
BALB/C mice.

Glu measures were robust and reproducible within and over

multiple days. Figure B.2A shows the mean maximal Glu response on days 3, 5
and 7 post-implantation.
Resting Glu measures were studied in the PFC of BALB/C mice on days 3
through 7 post-implantation using the self-referencing technique described in
Chapter Two. Briefly, the self-referencing site current was subtracted from the
Glu recording site current, and divided by the Glu recording site slope obtained
from in vitro calibration. We observed no significant difference in resting Glu over
days in the PFC (figure B.2B).
Local application of 50 µM CPG in the PFC of BALB/C mice resulted in a
bi-phasic affect on glutamatergic neurotransmission. Immediately following local
application there was a rapid, robust spike (~4 µM) in extracellular Glu that
returned to baseline after several seconds (figure B.3). Resting Glu levels then
decreased (~0.5 µM) for approximately 15 minutes. The inset in figure B.3 shows
the average change in resting Glu due to administration of 50 µM CPG.
Discussion
Similar to our freely moving studies in the C57BL/6 mice, we successfully
adapted our enzyme-based MEAs to record Glu in the awake, freely moving
BALB/C mouse for at least 7 days post-implantation.

We locally applied an

isotonic solution of Glu (0.5 µl, 1mM) in the PFC of BALB/C mice on days 3, 5
and 7 post-implantation to determine the longevity of the enzyme-based MEA in
vivo. We saw no significant change in MEA sensitivity for Glu on days 3 - 7 post-
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Figure B.1: Representative Glu Traces From Local Application of 1 mM Glu
Representative traces of locally applied Glu (1 mM; 0.5 µl) in the PFC of male BALB/C mice. Glu
was locally applied at the time points indicated by the arrows. A rapid, reproducible spike was
recorded in the PFC using self-referencing MEAs. Maximal peak height shows in vivo Glu signal
from local application of Glu (arrows), while baseline measures show resting Glu levels.
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Figure B.2: Local Application and Resting Glu Levels in the PFC of BALB/C Mice
A. Locally applied Glu data for days 3, 5, and 7 post-implantation in the PFC (n=2). Glu (0.5 µl, 1
mM) was locally applied over multiple days and recorded using a self-referencing MEA. Stable
Glu recordings were observed over all days measured indicating reliable in vivo Glu
measurements for at least 7 days post-implantation. B. Resting Glu levels were assessed on
days 3 through 7 post-implantation in the PFC (n=2) of BALB/C mice. Self-referencing MEAs
were used to determine resting Glu levels.
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Figure B.3: Local Application of CPG in the PFC of BALB/C Mice
Local application of 50 µM CPG (1.0 µl; pH 7.4) resulted in a rapid increase in Glu followed by a
prolonged decrease in resting Glu levels as shown in the trace. The inset shows the average
change in Glu from unstimulated resting Glu.
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implantation. The average maximum amplitude from local application of 1 mM
Glu in the BALB/C mouse strain (30.8 ± 7.6 µM) was similar to what was
observed in the PFC of freely moving C57BL/6 mice (30.5 ± 7.8). Also, our selfreferencing recording technique allowed us to measure resting Glu levels in the
PFC of BALB/C mice on days 3 through 7 post-implantation.

We saw a

nonsignificant increase in resting Glu levels over days; however, the large
variance made it difficult to compare these values to what was observed in the
PFC of C57BL/6 mice. Additional studies need to be conducted before definitive
comparisons can be determined.
The cystine-Glu exchanger has been a proposed mechanism for
regulating resting Glu levels (Baker et al., 2002; Melendez et al., 2005).

The

cystine-Glu exchanger is located on glia cells (figure 1.1) and acts by uptake of
cystine into glia coupled with the export of Glu into the extracellular space.
Microdialysis studies examining the cystine-Glu exchanger has shown that
blockade of this transporter by CPG results in a decrease in resting Glu levels
(Baker et al., 2002; Melendez et al., 2005). In addition, CPG has also been
reported as a group I mGluR competitive antagonist (Brabet et al., 1995; Doherty
et al., 1999). Group I mGluRs are excitatory autoreceptors located on both preand post-synaptic glutamatergic neurons. Blockade of the pre-synaptic group I
mGluR should also cause a decrease in resting Glu levels.

Unexpectedly,

immediately following local application of 50 µM CPG we observed a fast spike in
Glu levels, which lasted only seconds.

This immediate increase in Glu was

reproducible both within and between animals. Following the spike we observed
an expected, prolonged decrease in resting Glu levels that lasted approximately
15 minutes. A separate study using 50 µM CPG was conducted in the PFC of
the Long Evans rat by our laboratory (manuscript in preparation) and a similar
immediate increase followed by a decrease in resting Glu levels was observed.
This initial spike in resting Glu levels has not been previously reported and was
an unexpected finding. The fact that the initial spike in Glu lasted on the order of
seconds makes it difficult for microdialysis to observe this phenomenon due to
the low temporal resolution of the technique. Based on current literature, there is
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no definitive explanation for this rapid increase in Glu, and may be due to an
unknown interaction with a pre-synaptic Glu autoreceptor.
This study demonstrates the ability to successfully use the MEA freely
moving technology in more than one strain of mice. The present studies using
MEAs configured for second-by-second Glu measurements were viable for at
least 7 days post-implantation in the awake, freely moving BALB/C mouse. We
observed a nonsignificant increase in resting Glu levels in the PFC of awake,
freely moving BALB/C mice over days. Further studies are needed to decrease
the variance across days and make comparisons between Glu regulation in the
BALB/C PFC and the C57BL/6 PFC. Local application of 50 µM CPG resulted in
a currently unreported rapid spike in Glu followed by an expected decrease in
resting Glu levels. These findings provided evidence that the high spatial and
low temporal resolution provided by our MEA technology was necessary to better
understand the effects CPG has on resting Glu levels. These studies have set
the foundation to study behavioral differences in Glu regulation between the
BALB/C and C57BL/6 mouse strains.
Copyright © Kevin Nicholas Hascup
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Appendix C: Development of a Self-Referencing Microelectrode
Array for Detection of Hydrogen Peroxide
Introduction
The first generation of MEAs (despite a multitude of PCB, ceramic tips,
and recording site layout designs) all had four or five Pt recording sites
(Burmeister and Gerhardt, 2005). While this was revolutionary at the time, our
lab prides itself in pushing technology further. We have developed several new
MEA designs with 8 and 16 Pt recording sites and eventually one with 32
recording sites.

The advantage of additional recording sites allows us to

simultaneously measure neurochemicals from multiple brain regions or even
measure multiple neurochemicals within a single brain region. With additional
recording sites placed in a confined geometrical area, the reporter molecule,
H2O2, can diffuse to sites other than those from which it forms leading to false
detection of analyte on those sites.

Consider a MEA with both GluOx and

choline oxidase enzymes placed on neighboring sites.

Some of the H2O2

generated from a GluOx site may diffuse to the choline oxidase coated site thus
falsely contributing to the detection of choline. In an attempt to prevent this, we
considered placing a layer of catalase overtop the enzyme and sentinel sites.
This would prevent any H2O2 from being detected on sites other than those that
enzymatically produced the reporter molecule.
Catalase is a tetrameric, diffusion controlled enzyme that catalyzes the
decomposition of H2O2 into H2O and ½O2 (Eventoff et al., 1976; Dringen et al.,
2005).

We were interested in using catalase for several important reasons.

First, catalase is endogenously expressed in peroxisomes that are located in all
brain cells in vivo (Schad et al., 2003) so introduction of this enzyme would not
be foreign to the microenvironment.

Second, catalase has a slightly larger

molecular weight (250 kilodaltons) compared to that of GluOx (140 kilodaltons)
so incorporation of this enzyme into our BSA / Glut mixture is not difficult.
Finally, catalase requires no substrates and is considered to be “catalytically
perfect”, with reaction rates approaching that of diffusion speeds. This means a
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molecule of catalase catalyzes a reaction almost every time it encounters a
molecule of H2O2, so even large concentrations of this reporter molecule can be
decomposed quickly. This makes catalase a great enzyme to prevent H2O2 from
reaching adjacent recording sites on our MEAs.
The interest in developing a self-referencing catalase MEA for detection of
H2O2 is two-fold. The first is to advance our MEA technology for measurements
of multiple analytes. The second has a more neurochemical basis. Interest in
detection of H2O2 in living brain tissues is growing. The production of H2O2 and
other reactive oxygen species is implicated in the etiology of neurodegenerative
disorders such as PD (Kulagina and Michael, 2003).

Second, the laboratory of

Dr. Margaret Rice has demonstrated that H2O2, similar to nitric oxide, plays an
important role as a diffusible neuromodulator (Avshalumov et al., 2003; Kulagina
and Michael, 2003; Avshalumov et al., 2007). Dr. Rice’s group contends that
complex I of the electron transport chain found on the inner mitochondrial
membrane is responsible for the majority of H2O2 found in the Str (figure C.1).
To determine if it was even possible for H2O2 to diffuse out of mitochondria, we
enlisted the help of Dr. Patrick G. Sullivan’s laboratory to collect mitochondrial
preparations for study. Various electron transport chain complex inhibitors were
added in vitro to determine if H2O2 could be generated and subsequently leave
the mitochondria where it can be detected by our MEA. These studies would
help determine the factors that control the rate and concentration of H2O2 that
can be produced in the brain.
To conduct these studies, we developed a self-referencing MEA for H2O2
determination. The concept of this MEA is similar to that of the GluOx selfreferencing MEA. The sites coated with a mixture of BSA/Glut and Catalase was
applied on two of the Pt recording sites to act as a sentinel sites while the other
pair of recording sites were coated with just the BSA/Glut mixture and
subsequently detected H2O2.

Several feasibility studies were conducted to

determine if catalase could block exogenously applied H2O2 from being detected
by our MEA both in vitro and in vivo.

The following section outlines the

development

of

and

application
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our

catalase

MEA.

Figure C.1: Mitochondrial Electron Transport Chain
The electron transport chain builds up a proton electrochemical gradient across the inner
mitochondrial membrane. For simplicity, electron flow is not shown but is transported between
Complexes I, II, and III by the membrane soluble Coenzyme Q and between complexes III and IV
by the membrane protein cytochrome c. H+ is pumped out of the mitochondrion during electron
transport (Complexes I, III, and IV) and its exergonic return powers the synthesis of ATP from
ADP through the ATP synthase (Complex V). Figure adapted from Mattiasson and Sullivan,
2006).

183

Materials and Methods
Bovine liver catalase (aqueous solution >40,000 units/mg protein) was
obtained from Sigma-Aldrich (Catalog #C3155). Preparation for enzyme coating
was similar to that of GluOx. All proteins and enzymes were brought to room
temperature and 0.010 g of BSA Fraction V, 99% (Sigma-Aldrich, Catalog #A3059) was dissolved in a 1.5 mL microcentrifuge tube containing 985 μl ddH2O
by manual agitation. Once dissolved, 5 μl of Glut solution, Grade I, 25% (SigmaAldrich Catalog #G-6257) was added to the BSA mixture and manually mixed by
inversion five times. The solution was then set aside for five minutes until it
turned a faint yellow color. Glut crosslinked proteins that adhered to the MEA
surface when cured. The BSA served as a matrix to protect catalase activity
during immobilization.

Next, 9 μl of the BSA/Glut mixture was removed and

added to a 300 μl microcentrifuge tube. Lastly, 1 μl of the catalase stock solution
was added and mixed by pipette agitation.
All MEAs were tested for their response to H2O2 to ensure Pt site
functionality prior to enzyme coatings.

After testing, MEAs were rinsed with

ddH2O and dried in an oven (105 – 115 ºC) for 10 minutes to remove residual
H2O prior to coating. Catalase solutions and the inactive protein matrix of BSA/
Glut were applied to the Pt recording sites by hand. Solutions were drawn up
into a 10 μl Gastight® Hamilton microsyringe (Hamilton Co. Catalog #80065) and
slowly dispensed to form a small droplet of solution at the tip of the microsyringe.
Using a dissecting microscope, the droplet was briefly applied to the Pt recording
sites.

The solution quickly dried, leaving behind a thin, translucent layer of

enzyme that was visible underneath a dissecting microscope. Two additional
coats of catalase were applied in the same manner with one minute dry times in
between each coat. This procedure was complete once a visible film remained
following coating. The advantage of using multisite MEAs was that a pair of
recording sites was coated with the catalase mixture and the adjacent sites were
coated with the inactive protein matrix in the same manner as applying the
catalase mixture to create the self-referencing catalase MEA.
allowed to cure at room temperature for 48-72 hours.
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MEAs were

Adult, male Sprague-Dawley rat (~250g) mitochondria were isolated in the
laboratory of Dr. Patrick Sullivan using previously published protocols (Nukula et
al., 2006).

Rats were anesthetized using a carbon dioxide chamber and

decapitated.

Their brains were quickly removed and the cortices dissected.

Cortex tissue was placed in ice cold isolation buffer with 1 mM ethylene glycol
tetraacetic acid (EGTA) (75 mM sucrose, 215 mM mannitol, 0.1% BSA, 1 mM
EGTA, 20 mM HEPES, pH 7.2).

Tissue was put into an all glass dounce

homogenizer with 3 mLs of isolation buffer with EGTA, homogenized, split into
four 2 mL tubes, topped off with isolation buffer and spun at 1,300 x g for 5
minutes at 4°C. The supernatant was taken off and saved in separate tubes.
The pellet was resuspended in isolation buffer and spun at 1,300 x for 5 minutes
at 4°C.

Supernatant was discarded (by slinging off) and the pellets were

resuspended in 500 µl of isolation buffer. A nitrogen bomb was used to rupture
the cell membrane in order to release the mitochondria from cells. The samples
were placed in a cold nitrogen bomb for 10 minutes at 1000 psi to burst
synaptoneurosomes formed by homogenization. After bombing, the sample was
spun on a Percoll gradient, with fresh stocks of 30%, 24%, and 40% Percoll
made with isolation buffer. The gradient was made by first adding 3.5 mLs of the
24% stock to the ultracentrifuge tube and then, using a 5 mL syringe, injecting
3.5 mLs of the 40% stock to the bottom of the tube. Using equal amounts of the
30% Percoll stock and sample, a 15% Percoll solution was made and 3 mLs
were added to the top of the gradient. The gradient was spun in a high speed
Sorval centrifuge for 10 minutes at 30,400 x g. The third fraction containing the
purified mitochondria was removed, put into clean tubes, and topped off with
isolation buffer without EGTA. The samples were spun at 16,700 x g for 15
minutes.

The supernatant was removed and the pellet was resuspended in

isolation buffer without EGTA and spun at 13,000 x g for 10 minutes. After the
supernatant was removed and discarded, the pellet was resuspended in 500 µl
isolation buffer without EGTA and transferred to a microcentrifuge tube, which
was then spun at 10,000 x g for 10 minutes. The supernatant was removed and
the pellet was resuspended in enough isolation buffer without EGTA to get a
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concentration of 10-15 µg/µl. A BCA protein assay kit was used to determine
protein concentration by measuring absorbance at 560 nm with a BioTek
Synergy HT treated plate (Winooskin, Vermont).
Results
The catalase MEA was tested first in vitro to determine its ability to block
exogenously applied H2O2.

Figure C.2 shows a representative tracing of a

catalase coated MEA calibration. The MEA tip was placed into a 40 mL solution
of 0.05 M PBS. 500 µl of 20 mM AA (final beaker concentration of 250 µM) and
3 additions of 40 µl of 8.8 mM H2O2 (final beaker concentration of 8.8, 17.6, and
26.4 µM) were added to the beaker. As seen in figure C.2, the sites coated with
catalase showed minimal response to additions of H2O2, while those coated with
just BSA and Glut showed a large change in current from baseline.
Next, we wanted to determine if the catalase could decompose H2O2
before it was detected on our Pt recording sites in vivo.

To do this we

anesthetized a C57BL/6 mouse with three subcutaneous injections of 12.5%
urethane for a final dose of 1.25 g/kg.

100 µM H2O2 was added to the glass

micropipette and locally applied in 30 second intervals in the mouse Str. Figure
C.3A shows a trace of the responses to 100 µM H2O2 (25 nl) on the catalase
coated and inactive protein matrix coated sites.

As shown in figure, local

application 100 µM H2O2 resulted in robust, reproducible peaks that quickly
returned to baseline on the BSA/Glut coated sites. The catalase coated sites
showed minimal response to additions of H2O2. Figure C.3B shows the trace
after subtracting the concentration on the catalase coated sites from the
concentration on the BSA/Glut coated sites. This figure also indicates resting
H2O2 levels in the extracellular space of the mouse Str, which were
approximately 0.3 µM.
Since we observed a small response to H2O2 on the catalase coated sites
in vivo we wanted to determine if this was due to H2O2 reaching the Pt recording
sites or if this was due to pressure artifact from locally applying a solution close
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Figure C.2: Calibration Trace of a Catalase MEA
A self-referencing catalase coated MEA for detection of H2O2. The red trace represents a site
coated with BSA/Glut and catalase while the blue trace represents a site coated with just the
inactive protein matrix of BSA and Glut. All four sites of the MEA were electroplated with 5 mM
mPD prior to calibration. 500 µl of 20 mM AA (final beaker concentration of 250 µM) was first
added (arrow head) and allowed to come to baseline. Minimal change in baseline current was
observed indicating good selectivity of the MEA. Next, 3 additions of 40 µl of 8.8 mM (final
beaker concentration of 8.8, 17.6, and 26.4 µM H2O2) were added. Only the site coated with the
inactive protein matrix showed a measurable response to H2O2 indicating the effectiveness of
catalase degrading H2O2 before it could be detected on the Pt recording sites.
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Figure C.3: Local Application of 100 µM H2O2
A) Local application of 100 μM H2O2 (25 nl, arrow heads) resulted in robust, reproducible peaks
compared to baseline on the BSA/Glut (blue) coated sites. A minimal response on the catalase
coated site was observed. B) The concentration on the catalase coated site was subtracted from
the concentration on the BSA/Glut coated site to obtain the self-referencing trace.

Baseline

values indicate resting H2O2 levels, while peak heights indicate maximal amplitude of response.
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to the MEA. To do this we performed a series of recordings at two different
potentials in the mouse Str.

The first series of recordings was taken at an

applied potential of +0.7 V vs. a Ag/AgCl reference electrode; a potential where
H2O2 was readily oxidizable. Next, we dropped the potential to +0.2 V vs. a
Ag/AgCl reference electrode; a potential where H2O2 was not as readily oxidized.
Figure C.4 shows the responses on the catalase and BSA/Glut coated sites to
local application of 100 µM H2O2 at an applied potential of +0.7 and +0.2 V vs. a
Ag/AgCl reference electrode. As shown by the graphs, the BSA/Glut coated site
(figure C.4A) had a robust response to local application of 100 µM H2O2 that was
attenuated when the potential was dropped to +0.2 V. The catalase coated sites
showed a much lower response to local application of 100 µM H2O2 at +0.7 V.
When the potential was dropped to +0.2 V on the catalase coated sites, there
was no longer a response, but rather a dilution artifact. This indicates that the
catalase was not completely degrading the locally applied H2O2, so a small
portion was detected on the Pt recording sites.
Next, we wanted to determine the linearity of the catalase MEAs
response to local application of increasing volumes of 100 µM H2O2. To do this,
a catalase MEA was positioned in the Str of a Fisher 344 rat and a dose
response test was performed by increasing the volume of 100 µM H2O2 locally
applied. Peak responses were determined from three ejections, in thirty second
intervals of 25, 50, 75, 125, 175, and 250 nl of 100 µM H2O2. Figure C.5A shows
the series of self-referenced recordings from increasing the volume of 100 µM
H2O2 locally applied adjacent to the catalase MEA.

As shown by the trace,

increasing the volume led to an increase in peak response. To quantitate this,
the three ejections at each volume were averaged as shown in figures C.5B and
C.5C. Peak responses were reproducible for each volume as indicated by the
tight error bars. Also, we reported an r2 = 0.85 for the six series of volumes
ejected. Finally, we noticed that resting H2O2 levels in the Fisher 344 rat Str
were similar (~ 0.3 µM) to what was observed in the C57BL/6 mouse Str.
We wanted to incorporate catalase with our GluOx coated MEAs to
determine the feasibility of coating multiple enzymes onto a single MEA. To do
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Figure C.4: Potential Change for H2O2 Determination
A.) A BSA/Glut coated site showing a large response to local application of 100 µM H2O2 (arrows)
at an applied potential of +0.7 V vs a Ag/AgCl reference electrode.

When the potential was

dropped to +0.2 V, much of the H2O2 was not oxidized resulting in smaller peaks. The y-axis was
split in order to see the peak response at +0.2 V

B) A BSA/Glut and catalase coated site

showing a small response to local application of 100 µM H2O2 at +0.7 V and a dilution effect at
+0.2 V. Arrows indicate time points for local application.
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Figure C.5: Increasing Volume of Locally Applied 100 µM H2O2
A) A self-referenced trace from local application of 100 μM H2O2 in the Str of Fischer 344 rats. A
series of three ejections were performed for each volume ejected (25, 50, 75, 125, 175, and 250
nl), which are shown above the peaks. Within each series of volumes, peaks heights were robust
and reproducible. Baseline values indicate resting H2O2 levels.

B and C) For each group of

similar ejection volumes, peak heights were averaged into a single data set and the linear
regression was determined with a fit of r2 = 0.85.
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this, we applied 3 layers (as previously described in Chapter 2) of BSA/Glut and
GluOx onto recording sites 1 and 2. Next, we applied 3 layers of BSA/Glut and
Catalase onto recording sites 3 and 4. This dual enzyme MEA was allowed to
cure for 72 hours and then mPD was electropolymerized onto all four recording
sites. The MEA was then calibrated as shown in figure C.6 and showed good
response to additions of Glu on sites 1 and 2, no response to H2O2 on sites 3 and
4, and no response to interferents such as AA and DA.
Our last catalase design included a self-referencing GluOx with a
BSA/Glut and Catalase mixture placed over top of this layer.

This was an

experiment to test whether or not catalase could be used to prevent diffusion of
GluOx generated H2O2 to additional recording sites. Two different MEAs were
tested prior to coating to ensure all four sites responded to H2O2. Sites 1 and 2
were coated with 3 layers of BSA/Glut and GluOx while sites 3 and 4 were
coated with just the inactive protein matrix of BSA/Glut. This was allowed to cure
for 48 hours. Next, 3 layers of a mixture of BSA/Glut and catalase was applied
onto all 4 Pt recording sites and cured for 48 hours.

A second MEA was

prepared in the similar fashion except only 1 layer of the BSA/Glut and catalase
mixture was applied on all four sites. No exclusion layer was applied to either
MEA. Calibration consisted of final beaker concentrations of 20, 40, and 60 µM
Glu and 8.8 and 17.6 µM H2O2. Both MEAs showed very small responses to Glu
(< 1 pA/ µM). The first MEA with 3 layers of catalase showed a smaller response
to Glu than the second MEA with 1 layer of catalase. When examining the
response to H2O2, the first MEA, with 3 coats of catalase, showed no response,
but the second MEA, with 1 coat of catalase, had a small response (Data not
shown).
Mitochondria were isolated as described above and 50 µg/250 µl was
placed in a sterile 48 well cell culture plate (Corning Incorporated, Corning, NY)
filled with 1 mL of respiration buffer. A waterpad connected to a circulating water
bath was placed underneath to maintain a 37°C temperature.

A miniature stir

bar (10 mm X 3 mm) was placed in the well for faster diffusion and was
controlled by a battery operated stirrer that was placed underneath the water
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Figure C.6: Calibration of a Glutamate Oxidase and Catalase Coated MEA.
This dual enzyme MEA was coated with BSA/Glut and GluOx on sites 1 and 2 (blue trace) and
BSA/Glut and Catalase on sites 3 and 4 (red trace). Final beaker concentrations of 250 µM AA;
20, 40, and 60 µM Glu; 2 µM DA; and 8.8 and 17.6 µM H2O2 were added (arrow heads) for the
calibration. A trace from site 1 shows the response to both Glu and H2O2. A trace from site 3
shows no response to either Glu or H2O2. Neither site responded to additions of AA or DA. The
MEA was tested prior to enzyme coating to ensure all sites responded to H2O2.
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pad. A Ag/AgCl reference electrode and a catalase coated MEA was placed into
the well and allowed to reach baseline. 10.0 µl of pyruvate malate (PM) was
added to start the Kreb’s Cycle and buildup the membrane potential. This was
allowed to reach baseline for 1 minute and then 5.0 µl of adenosine diphosphate
(ADP) was added. This provides the substrate for Complex V and, along with the
membrane potential, drives the synthesis of ATP. A byproduct of respiration was
superoxide, however, addition of ADP did not result in formation of measurable
levels of H2O2 as shown in figure C.7. This reaction was allowed to occur for 2
minutes and then 4.0 µl of oligomycin was added, which blocks Complex V
thereby stopping respiration. Blocking Complex V allows production of reactive
oxygen species. During in vitro calibration of the catalase MEA, Oligomycin was
added as a test substance and found to be electrochemically active at an applied
potential of +0.7 V vs a Ag/AgCl reference electrode.

This explains the

immediate increase in baseline after its addition rather than the formation of
H2O2. After 1 minute a new baseline was reached and, 1 µl of Antimycin-A was
added, which is a Complex III inhibitor. This prevents electrons from moving
along the electron transport chain, stops oxygen consumption to water, and
forms large levels of superoxide. After addition of Antimycin-A, we observed a
sustained, elevated increase in H2O2 production (~4 µM) that reached baseline
after ~8 minutes as shown in figure C.7.

Two separate additions of 4 µl of

carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) were added once
H2O2 production had baselined. FCCP is a chemical uncoupler that translocates
H+ down its concentration gradient across the inner mitochondrial membrane
thus shutting down respiration. Additions of FCCP resulted in a decrease in
H2O2 concentration that had built up from Antimycin-A (figure C.7).
Discussion
Catalase was successful at blocking H2O2 detection both in vitro and in
vivo indicating that this enzyme could be used for self-referencing, amperometric
detection of H2O2. A pair or recording sites were coated with the BSA/Glut and
catalase while the other pair of recording sites were coated with just the
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Figure C.7: Amperometric Traces of H2O2 Produced from Mitochondria Preparations
A.)A self-referencing catalase MEA was used to measure H2O2 formation (blue trace) due to
blocking specific complexes of the electron transport chain in mitochondria.

B) The self-

referenced trace of the data shown in A. ATP synthesis was begun by adding PM and ADP.
Respiration results in superoxide formation, but this did not cause measurable H2O2 formation.
Next, oligomycin (O) was added, which was electrochemically active, resulting in the fast increase
in baseline. Antimycin-A (Anti) was added and inhibits Complex III thus driving formation of ~ 4
µM H2O2. After ~8 minutes when H2O2 production had reached baseline, two additions of FCCP
were added and a decrease in H2O2 levels were seen.
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BSA/Glut mixture. Without this protein coating, the H2O2 detecting sites would
respond more quickly to analyte. Protein layers are necessary on both recording
sites to minimize difference between the recording properties of the different
MEA recording sites.
In vivo, local application of 100 µM H2O2 (25 nl) resulted in robust,
reproducible peaks compared to baseline in both the C57BL/6 mouse and a
Fisher 344 rat.

Local application of 100 µM H2O2 (25 nl) in the mouse Str

resulted in responses that were ~ 20 µM in peak height while a small (~ 1 µM)
response was observed on the catalase coated sites. To determine if this was
due to pressure artifact or incomplete decomposition of H2O2 by catalase, the
potential was dropped from +0.7 V to +0.2 V vs a Ag/AgCl reference electrode.
At an applied potential of +0.2 V, where H2O2 is not as readily oxidized, the
catalase coated sites showed dilution artifact after local application of 100 µM
H2O2. This indicates that the responses seen on the catalase coated site was
due to incomplete decomposition of H2O2 by catalase. It should be noted that the
concentration of H2O2 locally applied adjacent to the recording site was
significantly larger than the concentration of H2O2 released from the
mitochondrial preparations. This helps to justify that the catalase coated MEA
works well at physiologically relevant concentrations of H2O2 in vivo.
Unfortunately, addition of the BSA/Glut and Catalase coating over top of
the already cured GluOx layer resulted in minimal Glu detection during
calibration. When only 1 catalase layer was applied rather than 3, we observed a
better response to Glu during calibration; however, the catalase was not capable
of fully degrading the exogenously applied H2O2. This indicates that the layers of
GluOx and catalase are too thick thus preventing diffusion of molecules to the Pt
recording sites. It should be noted that this experiment was conducted without
any exclusion layers. An additional layer of either Nafion® or mPD would likely
prevent detection of any analyte by the MEA.

This test has pushed the

laboratory towards other MEA designs with additional Pt recording sites
positioned among the analyte detecting sites. These additional sites would be
raised above the surface of the MEA to act as a physical barrier to prevent
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diffusion of H2O2 to other recording sites. Also, a current can be applied to these
sites to treat them as a H2O2 scrubber, oxidizing the molecule into H2O and ½ O2.
With our self-referencing capabilities we were able to examine resting
levels of extracellular H2O2. The few studies we conducted in the Str of an
anesthetized C57BL/6 mouse and Fisher 344 rat indicated that resting H2O2
were ~0.3-0.4 µM. This is slightly less than the 1-2 µM resting levels reported
using microdialysis in the gerbil hippocampus (Lei et al., 1998) as well as the 1-3
µM levels reported using carbon fiber amperometric microsensors in the Str of
Sprague-Dawley rats (Kulagina and Michael, 2003). The levels we reported may
be lower for several reasons. First, the damage caused by microdialysis probes
has been thoroughly discussed already in this thesis (refer to Chapters 1 and 5).
The damage may produce elevated levels of H2O2 and other reactive oxygen
species which are known to form due to brain injury. Also, the fact that the
microdialysis study was conducted in a different rodent model (gerbil) as well as
a different brain area may account for the differences. But, this does not explain
the differences in resting levels seen with our MEA and a similar dimension
carbon fiber microsensor. The carbon fiber microsensor does not have multiple
recording sites which prevents the removal of interferents from the analyte signal.
If good exclusion layers were not applied, interferents may account for the
elevated resting levels of H2O2 observed in this study.
Finally, we used the self-referencing catalase MEA to measure H2O2
formation from mitochondrial preparations in vitro. In order to induce H2O2 we
needed to provide substrates (PM and ADP) to start respiration. Superoxide
formation is a byproduct of respiration and is used to synthesize H2O2.
Respiration did not result in measurable levels of H2O2 formation in vitro. Next,
we added an inhibitor of Complex V, oligomycin, which stops respiration, thus
backing up the electron transport chain creating high levels of reactive oxygen
species.

Oligomycin is electrochemically active, which causes the response

seen on both sets of recording sites. The response is much too quick to be
attributed to the formation of H2O2, therefore blocking Complex V does not
resulted in detectable levels of H2O2 formation. We did observe that blocking
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Complex III with Antimycin-A resulted in steady formation of H2O2 (~4 µM) over
an 8 minute time period. Blocking Complex III prevents consumption of O2 so
none is converted to water. This leads to formation of high levels of superoxide
that is shown to be synthesized into H2O2. FCCP is a chemical uncoupler that
can carry H+ across the inner mitochondrial membrane, shutting down the
electron transport chain and thus formation of superoxide.

Additions of this

resulted in a decrease in the H2O2 already formed from blocking Complex III.
This phenomenon is difficult to explain since FCCP itself should not induce
degradation of already formed H2O2, but rather prevent additional formation of
H2O2. Prior to additions of FCCP, H2O2 production probably reached baseline,
because the amount of available substrates may have been fully utilized for
respiration. Without available substrates, the electron transport chain would halt.
Furthermore, adding FCCP would diminish the proton gradient and prevent
respiration. With no more superoxide production to generate H2O2, endogenous
catalase present in mitochondria may begin to degrade the H2O2 formed. This
may explain the decrease in H2O2 observed after additions of FCCP.
As mentioned in the introduction, we were interested in determining if
H2O2 was generated in the mitochondria from blocking certain electron transport
complexes. Dr. Margaret Rice’s group has data demonstrating that Rotenone, a
compound that blocks electron transfer from Complex I to ubiquinone, can lead
to H2O2 formation and release from the mitochondria. Our laboratory performed
several studies in vitro with the mitochondrial preparations that were similar to
those conducted using Antimycin-A. Substituting Rotenone for Antimycin-A we
did not observe any H2O2 formation (data not shown).

We did however,

determine that blocking Complex III causes a large accumulation of H2O2, most
likely through the generation of superoxide. We determined that this H2O2 is
capable of leaving the mitochondria since we detected increased H2O2 levels in
the respiration buffer using our self-referencing catalase MEA. Additional studies
need to be conducted to determine if any of this H2O2 can escape the
intracellular space in vivo prior to degradation by endogenous catalase as well as
determine if H2O2 can act as a diffusible neuromodulator.
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